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Abstract of Thesis 
Introduction: 
The research undertaken m this thesis was to inform OPTIMISE, a randomised 
controlled trial of goal directed haemodynamic therapy (GDHT) versus usual care in 
high-risk patients undergoing gastrointestinal surgery. The trial involved a complex 
intervention of cardiac output monitored administration of fluids and inotropic drugs 
during the perioperative period. Uncertainty exists regarding: 
1. Whether the choice of fluid therapy could have influenced the outcome of the trial. 
6% hydroxyl-ethyl starch (HES) bas been associated with risk of death and acute 
kidney injury (AKI) in critically ill patients. 
2. Whether he availability or provision of critical care beds is associated with 
improved surgical outcome and thus could have influenced the outcome of the trial. 
The trial intervention has trad itionally been administered in a critical care setting, 
and this may have a bearing on outcome. 
3. The trial intervention itself could have been associated with increased cardiac 
complications. Concerns remain regarding the administration of inotropic agents 
outwith traditional indications. 
Methods: 
1. A meta-analysis was undertaken comparing perioperative use of 6% HES 
solutions to any comparator. 
2. Surgical activity, population demographics and critical care provision in the UK 
were examined using large administrative databases. 3. A UK-wide cohort of non-
cardiac high-risk surgical patients admitted to intensive care was generated by 
combining data held by the Scottish Intensive Care Audit Group (SICSAG) and the 
Intensive Care National Research and Audit Centre (ICNARC) for the calendar year 
2009. 4. Using this data, advanced statistical modelling techniques were used to test 
the association between critical care bed provision and outcome after high-risk 
surgery. 5. Measurement of postoperative 5th generation highly sensitive troponin 
(HST) release was undertaken in a subgroup of trial participants, in order to 
determine if the intervention was assoc iated with increased myocardial necrosis. 
Logistic regression was undertaken to test if preoperative measurement of HST was 
associated with risk of death or major adverse cardiac events (MACE). 
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Results: The principal findings of this thesis were: 
I. In a meta-analysis of 1567 patients from 19 clinical trials comparing perioperative 
administration of 6% HES solutions versus any comparator no difference was 
observed in 30-day mortality arms (p=0.91, 12=0%; FEM: RD 0.00, 95% CI -0.02, 
0.02) or AKI (p=0.62, 12=0%; FEM: RD -0.01, 95% CI -0.04, 0.02) was observed. 2. 
Significant variation exists in ICU bed provision within the UK. 3. In an 
epidemiological study of 16 I 47 patients admitted to ICU following surgery in the 
UK, significant variation in acute hospital mortality was observed (OR 1.42; 95% Cl : 
1.29, 1.62). This did not appear to be accounted for by severity of illness, other 
patient-level factors or ICU bed provision. 4. Using HST we were unable to detect 
any difference in myocardial injury or infarction between GDHT and usual care 
groups. Preoperative HST measurement did not predict those at risk of perioperative 
death or MACE. 
Conclusion: 
Use of 6% HES in the trial intervention was unlikely to have affected trial outcome. 
Significant regional variation exists in outcome after surgery in the UK, which 
cannot be account for by patient level-factors or ICU bed provision. The trial 
intervention in OPTIMISE was unlikely to have caused increased incidence of 
myocardial infarction or necrosis. In this study preoperative measurement of 5th 
generation HST did not appear to predict those at risk of death at 30 or 180 days or 
MACE. 
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Chapter 1. Introduction - High Risk Surgery 
1.1 Introduction 
Surgery remains an effective treatment for a wide range of pathologies and is an 
essential component of healthcare systems worldwide. In the developed world 
surgical science is expanding and becoming increasingly complex. Moreover, 
complex surgery is being offered to an increasingly aged and co-morbid population. 
In the developing world it may be the only treatment option for a range of diseases 
and injuries. It has been estimated that as many as 40 million surgical procedures are 
performed in the USA and Europe every year 1 and as many as 236 mWion 
procedures worldwide. 2 
As with many medical therapies, surgery has risks as well as benefits and there is 
often a failure to balance these. 3 Delivery of adequate perioperative care is a major 
challenge for modern healthcare at every stage of the process, from patient selection 
and preoperative assessment, through delivery of anaesthesia and surgery to 
postoperative care. 
The largest dataset on postoperative care available anywhere in the world is the 
National Surgical Quality Improvement Program (NSQIP). NSQIP is a large 
database of over a million patients, administered by The Department of Veterans 
Affairs in the USA. A recent study by Kburi et al 4 utilised the NSQIP database and 
the authors followed up over 100 000 patients undergoing eight surgical procedures 
up to 8 years. Specifically, they looked for incidence of any of 22 pre-defined types 
of complication within 30 days of surgery. Approximately 15% of these patients 
went on to develop complications within 30 days of surgery (Table I). 
A key finding of this study was that the development of short term morbidity 
("complications") within the first 30 days after surgery was associated with a 
substantially increased long-term mortality rate compared with those patients who 
did not develop a compl.ication within a similar time period (28.1 % vs. 6.9%, 
p<0.001), even following adjustment for co-morbidities (Table 2). 
Undergoing even relatively minor surgery may cause physiological disturbance and a 
pro-inflammatory state, which can have consequences extending beyond the 
immediate postoperative period. For example, Sweetland et al prospectively 
examined the incidence of thromboembolic events using the "Million Women" 
database in the UK. This database collected demographic data on 1.3 million women 
who took part in a breast cancer-screening programme between 1996 and 2001 . 5 
Using data linkage techniques, he looked for an association between day case or 
inpatient surgery (the exposure of interest) and the first diagnosis of thromboembolic 
disease as a day case or hospital admiss ion or as a cause of death. He found that 
women were 70 times more likely to be admitted with venous thromboembolism in 
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the first six weeks after inpatient surgery and that frequency of a thromboembolic 
event peaked at 3 weeks. The risks were lower but still substantially increased 7- I 2 
weeks after surgery. A persistent inflammatory response, proportionate to the 
severity and duration of the surgery and continuing beyond the operative period has 
been suggested as a cause of thromboembolic and other complications. 4 
Comparison can be made with cardiac surgical patients, who in some senses 
epitomise "high risk surgery": undergoing major thoracic procedures, often with co-
existing cardiac disease, poor functional reserve and in many cases the additional 
insult of cardiopulmonary bypass. Moreover, as interventiooal cardiology advances, 
surgery is being increasingly offered to patients of advanced age and who are 
undergoing complicated surgery or reoperation. Here routine admission to an 
intensive care unit and protocolised management are the norm. European Association 
of Cardiothoracic Surgery data reports a mortality of 2.2% (0.8% excluding 
reoperation) for isolated coronary artery bypass grafting (CABG) and 3.4% for an 
isolated valve procedure. 6 This is a much lower mortality quoted for say, an 
emergency laparotomy, for which a mortality of 15-30% has been quoted in some 
studies. 7•8 Examples of some of the higher risk non-cardiac procedures carried out in 
the UK i.e. with a mottality of greater than 5% are outlined in Table 3. 
This thesis will consider in detail means of identifying the bjgb risk, non-cardiac 
surgical group using clinical and epidemiological means and also other novel 
methods e.g. biomarkers. In addition it will investigate whether other interventions 
for example critical care utilisation, choice of fluid therapy or goal directed 
haemodynamic therapy could improve outcomes in this group. 
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Urinary Tract Occurences 
Progressive Renal Insufficiency 
Acute Renal Failure 




Peripheral Nerve Injury 
Cardiac Occurrences 
Cardiac Arrest Requiring CPR 
Myocardial Infarction 
Other Occurrences 
Bleeding> 4 units Blood 
Graft/Prosthesis/Flap Failure 




(adapted from "Complications in Surgery," MW Mulholland and GR Docherty) 
Table 2 List of NSQIP complications in order of prognostic significance. 
Complication 
1. Cardiac Arrest 9.Pulmonary Embolism 
2. Failure to Wean I 0. Urinary Tract Infection 
3. Systemic Sepsis II. Pneumonia 
4. Cerebrovascular Accident 12. Superficial Infection 
5. Renal Failure 13. Deep Wound Infection 
6. Myocardial Infarction 14. Graft failure 
7. Renal Insufficiency 15. Peripheral Nerve Injury 
8. Coma 16. Ileus 
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Table 3 Selected hospital resource groups with mortality greater than 5% (from 
Pearse et al, 2006). 




QO I: Emergency aortic surgery 6,598 Emergency 2,72 1 41.24 
F33: Large intestine; major procedures with 5,765 Emergency 1,290 22.38 
complicating coodition(s) 
F41: General abdominal; very major or major 11 ,648 Emergency 1,843 15.82 
procedures aged over 69 
H05: Complex hip or knee revisions 1,667 Elective 186 ll.l 6 
H33: Neck of femur fracture; aged over 69 years 170,804 Emergency 15,780 9.24 
or with complicatjng condition(s) 
Fll: Stomach or duodenum; complex procedures 3,714 Elective 312 8.4 
1.2 High Risk Non-Cardiac Surgery as a Global Health Issue 
Little is known about the volume of surgery undertaken globally. Weiser and co-
workers gathered health, demographic and economic data from 192 member states of 
the WHO in an attempt to estimate the global volume of major surgery. 2 The 
authors considered major surgery to be "any intervention occurring in a hospital 
operating theatre involving the incision, excision, manipulation, or suturing of 
tissue", however the authors acknowledge that using administrative databases to 
estimate thi s can be problematic. 
For the purposes of this study, countries were pre-divided into four groups based on 
their annual per capita healthcare spend: high-expenditure countries spending in 
excess of $1000 per day; middle-expenditure countries spending $401-$1000; low-
expenditure countries spending $101-400 and poor-expenditure countries spending 
less than $100. The investigators used data from countries where surgical volume 
was known and extrapolated this to countries where data did not exist, based on 
annual per capita healthcare spend. The investigators estimated the total global 
volume of surgery to be 234.2 million (95% CI 187.2-281 .2million) which equated 
to a surgical rate of 4016 per 100 000 population or one operation per 25 people per 
year. A summary of surgical activity from this study divided according to healthcare 
expenditure is found in Table 4. 2 
Average surgical rates for selected developed nations are summarised in Table 5. 
The UK had an average surgical rate of 13,365 per l 00 000 population in 2004. This 
is higher than the average for "High Expenditure" nations (11 , 110 per 100 000). 
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Death and complication rates are even more difficult to estimate, although many 
commentators use studie by Gawande et al 9 to quote an overall 30-day mortality 
rate of 0.4-0.8% and studies by Kable et al 10 and Khuri et al 4 quote a major 
morbidity rate of 3-16%. Caution must be exercised in interpreting these figures and 
using them to extrapolate to other populations, as definitions of operative morbidity 
and mortality are arbitrary and hugely variab le . This issue is considered later in the 
chapter. However even by conservative estimates, 7 million patie nts may suffer a 
major complication and I million may die every year in the perioperative period 
worldwide, which constitutes a major global healthcare issue. Thus predicting which 
patients are at risk of death and complications (the so-called " high-risk "surgical 
group) may allow beller utilisation of resources and potentially therapeutic 
interventions to improve outcomes for many patients. 
Table 4 Surgical activity by healthcare expenditure (Weiser eta!). 
Expenditure Mean Estimated Estimated Volume Share of Global 
Surgical rate per of Surgery m Population (%) 
I 00,000 (SE*) millions (95% CI) 
Poor (n=47) 295 (53) 8. 1 (3 .4-12.8) 34.8 
Low (n=60) 2,255 (342) 53.8 (9.8-97.4) 35.0 
Middle (n=47) 4,248 (524) 34.3 (23.6-43.3) 14.6 
High (n=38) I J , 110 ( l ,300) 138 ( 132.5- 143.9) 15.6 
*standard error 
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Table 5. Surgical activity for selected nations (Weiser et al). 
Country Population Annual Number of Surgical 
(2004) Procedures 100,000) 
Australia 20,155,129 1,823,123 9,049 
Belgium 10,419,049 1,085,065 10,414 
France 60,495,537 8,268,114 13,667 
Germany 82,689,21 0 7,715,478 9,331 
Hungary 10,097,731 2,359,746 23,369 
Spain 43,064,189 3,026,060 7,027 
United Kingdom 59,667,844 8,135,609 13,365 
United States 298,212,895 63,808,613 21,397 
1.3 Geographical Variations in Surgical Outcome in the USA and Western 
Europe 
Rate 
Evidence exists that the UK performs poorly compared to other developed nations. 
Bennett-Guerrero et al prospectively followed two large cohorts undergoing high 
risk non -cardiac surgery from the UK (n=1056) and from the US (n=1539) to 
determine the applicability of the Portsmouth Physiological and Operative Severity 
Score for the Enumeration of Mortality and Morbidity (P-POSSUM) scoring system. 
I 
Patients were stratified according to risk level and in this study, for any given risk 
level, mortality rates were over four-fold higher in the UK cohort than in the US 
cohort (OR 4·50; CI 2.81-7.49; p < 0·001). In the patients at the highest risk of death 
in hospi tal, i.e. a predicted mortality of greater than 20%, the observed mortality in 
the US cohort was 9.7% compared with 35.9% in the UK cohort. Differences in 
provision of and access to critical care facilities between the UK and USA were 
postulated as a potential cause of these findings and this issue is considered in more 
detail in this thesis. 
A more recent study of surgical outcome was the "EuSOS" Study, a 7 day-cohort 
study conducted across Europe in April 2011. Data from 46,539 patients from 498 
hospitals across 28 nations was included in this study and patients were followed up 
to a maximum of 60 days. ·11 Wide differences in crude mortality were observed; the 
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(per 
lowest mortality was in Iceland (1.2%) and the highest in Latvia (21.5%). Nations 
were compared against the UK, which bad the largest dataset. A logistic regression 
model using patient and surgical factors associated with hospital mortality (e.g. age, 
co-morbid disorder, emergency surgery) was constructed and used to adjust for 
possible confounding between countTies. After correction for confounding variables, 
significant differences in surgical outcome remained. Ireland (OR 2.61 (1.3-5.27)), 
Latvia (OR 4.98(1.22-20.29)) and Poland (OR 6.92 (2.37-20.27)) were among 
countries where significantly worse outcomes after surgery were observed when 
compared with the UK. Finland (OR 0.44 (0.19-1.05)), Sweden (OR 0.58 (0.23-
1.49)), Germany (OR 0.85 (0.5-1.43)) and Iceland (OR 0.47 (0.07-3.4 1 )) were 
among countries with a trend towards improved survival, but this failed to reach 
statistical significance. 
A recent study of outcomes after surgery for ruptured Abdominal Aortic Aneurysm 
(AAA) repair suggests that marked differences in outcome between the USA and UK 
remain. 12 
1.4 High Risk Non-Cardiac Surgery in the UK 
Exact figures regarding volume of surgery in the UK and associated outcomes are 
difficult to find. In the year 2000 the NHS Executive estimated the number of 
surgical procedures carried out in the NHS as approx imately 2.3 million 13 with an 
estimated mortality of 1.4%. 
The Whitehall II study, a large prospective cohort study of 6478 British civil servants 
aged 35-55 years and published in 2008 found that certified sickness associated with 
a surgical procedure was associated with a greater than two fold increase in 
mortality. 14 
Pearse et al used 2 large UK databases to attempt to identify and characterise the 
hlgh-risk surgical population in the UK. 15 The first was Hospital Episodes Statistics 
(HES), the English national statistical data warehouse for care provided by NHS 
hospitals. The second was the case mix programme (CMP) maintained by the 
Intensive Care National Audit and Research Centre (ICNARC), which collect 
admission and outcome data on patients admitted to ICU in England, Wales and 
Northern Ireland. At the time this paper was published the ICNARC collected data 
on ICU admissions for 94 NHS trusts. Data was extracted on all adult surgical 
admissions to both hospital and ICU in these 94 NHS trusts. Surgical procedures 
were categorised into hospital resource groups (HRGs). HRGs are groups of 
procedures classified together by hospital coders (for activity, funding or audit 
purposes) based on clinical similarity and resource requirement. HRGs with a 
mortality of 5% or more were classified as "high risk" in tills study. Examples were: 
emergency aortic surgery; large bowel surgery; major general abdominal surgery 
with complicating condition; surgery for neck of femur fracture. All the remaining 
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procedures were classified as "standard risk". Of the 4 117 727 procedures studied in 
a 70 month period approximately 2.9 million were elective and 1.2 million were 
emergencies with a mortality rate of 0.44% and 5.4% respectively. This high-risk 
group (i.e. patients having a procedure with a greater than 5% mortality) made up 
only 12.5% of total procedures but approximately 80% of perioperative deaths were 
in this group. However fewer than 15% of these "high risk" patients were admitted 
directly to critical care following surgery and in tbis study patients admitted to ICU 
after initial care on a standard ward had a mortality of 37%. 
Two reports published in the UK in 2011 highlighted the growing disparity in 
postoperative care between the UK and other developed countries (e.g. the USA) and 
the high rate of complications and mortality suffered by high risk patients 
undergoing major surgery. 
The first, a report entitled "Knowing the Risk - A Review of the Perioperative Care 
of Surgical Patients" published by the National Enquiry into Perioperative Deaths 
(NCEPOD) highlighted failure to adequately assess high-risk patients before surgery 
and lack postoperative care in an intensive care unit for a significant number of these 
patients. A key recommendation of this report was to introduce a UK-wide system 
allowing rapid and easy identification of patients who are at high risk of 
postoperative mortaJity and morbidity. The report also recommended "to aid 
planning for provision of facilities for high risk patients, each Trust should analyse 
the volume of work considered to be high risk and quantify the critical care 
requirements of this cohort". 3 
The second report by the Department of Health and Royal College of Surgeons in 
England entitled "The Higher Risk General Surgical Patient: Towards Improved 
Care for a Forgotten Group" found that the mortality for higher-risk general surgery 
(which includes most major abdominal and vascular procedures), exceeded that for 
cardiac surgery by three-fold and that complication rates of over 50% are common. 
Poorly designed hospital services (including intensive care provision) and lack of 
appreciation of risk were blamed for the alarmingly high death rates of which "15 to 
20 per cent are typical, and can be as high as 40 per cent in the most elderly 
patients". 16 Thus estimating the scale of the problem in the UK, predicting the 
patients at risk of dying or developing complications in the postoperative period, and 
finding strategies to reduce this is a major challenge. 
Recent studies suggest that this problem continues to be a major issue in the UK. The 
UK Emergency Laparotomy Network studied 1853 patients undergoing emergency 
laparotomy in 35 NBS trusts in England and found an overall mortality of 14.9% 
rising to 24.4% in patients aged 80 or over. In addition this study described huge 
vari ability in standards of perioperative care including monitoring, consultant 
presence in the operating theatre and use of critical care resources. 8 In a more recent 
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study published in 2013, Symonds et al used the "Hospital Episodes Statistics" 
(HES) database to examine 367,796 high-risk (defined as a 30 day mortality of 
greater than 5%) emergency admissions in 145 NHS Hospital Trusts in England. He 
found an overall mortality of 15.6% in this group but found evidence of significant 
variabi lity between hospitals. The authors speculated that access to emergency 
hospital services such as specialist radiological imaging (e.g. CT scanning of 
abdomen), surgical and critical care services may explain this finding. 17 
In conclusion, mortality rates after emergency and high-risk non-cardiac surgery are 
high and standards of care in the UK remain highly variable. This problem is not 
unique to the UK and has been described in other healthcare systems, for example in 
the USA. 18 
1.5 Outcome Measures in the Surgical Patient 
Surgical patients represent a large and heterogeneous group with varied disease. 
Overall mortality after surgery is actually very low, 30-day mortality has recently 
been quoted at 1.4% in the UK 11 and those at the highest risk often have extensive 
co-morbidities, which pose a threat to life and may have a requirement for on-going 
medical management and hospitalisation. Perioperative management may have a 
limited impact on longer-term outcomes and considerations such as stage of 
malignancy, surgical procedure itself (e.g. curative or palliative) or need for other 
treatments (for example radiotherapy or chemotherapy) become increasingly 
important as time passes from the operative procedure itself. Morbidity arising from 
surgery may lengthen hospital stay and decrease quality of life even if survival is 
extended. 
For these reasons, selecting appropriate outcome measures for research and 
comparative audit in this population can be extremely challenging. Surgery itself 
fulfils many of the aspects of a complex intervention as outlined by Medical 
Research Council (MRC) guidance 19 and so can have very varied outcomes within 
similar patient groups. Therefore selecting the right outcome measures (or even 
range of outcomes) is important to ensure adequate assessment of complex 
interventions given the intervention may have multiple effects. Not choosing right 
outcomes could mean potential benefits are missed because the outcomes used were 
inappropriate or lacked discrimination or responsiveness. 
Outcomes often used in this group of patients include: mortality, morbidity, quality 
of life, hospital length of stay and societal outcomes (e.g. costs and resource 
utilisation). However increasingly, "composite" outcomes being are used such as 
"death or complications" as the overall incidence of death itself is low and 
complications are more prevalent (as described above). Hence it may be easier to 
demonstrate the overall effect for a chosen intervention. 
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Some of the common endpoints used m the study of surgical patients are now 
considered: 
1.5.1 Mortality 
Mortality is attractive as an outcome measure; it has a binary outcome with minimal 
observer bias and hospital mortality is usually reliably measured in large 
administrative databases. 
As discussed previously, it is postulated that the pro-inflammatory and other 
deleterious physiological effects of surgery may last well beyond the immediate 
postoperative period, so the time period over which mortality is measured is 
important. Typically "acute hospital mortality" or 30-day mortality is used to 
categorise operative or short-term mortality. In his analysis of long term 
determinants of survival from the NSQIP database Khuri et al (considered by many 
to be a seminal publication in this field) 20 used 30-day mortality as "perioperative" 
mortality and 1-yea:r and 5-year mortality as medium-term and long-term survival. 4 
More recently however, commentators have suggested that this should be extended, 
as 30 day mortality is too short to reflect true operative mortality and is subject to 
influence by external factors (e.g. bealthcare targets). The recent EuSOS study 
measured mortality at both 30 days and 60 days and in the case of the UK 60-day 
mortality was more than twice as high (1.6% vs. 3.6%). 11 
Some commentators have even suggested that 90-day mortality more accurately 
reflects the operative mortality, for instance in major colorectal surgery. 21 However 
the further one moves from the intervention of interest (in this case surgery) the 
greater the influence of other external factors, for instance the underlying and pre-
morbid disease, which for example in the case of malignancy, may be considerable. 
1.5.2 Morbidity 
Morbidity is increasingly recognised as an important predictor of long-term 
mortality. Khuri et al used the NSQIP database to examine the effect of postoperative 
morbidity on operative (30-day) and long-term (1-year and 5-year) mortality in 105 
951 patients undergoing 8 types of operation between 1991 and 1999. The NSQIP 
database was developed in 1991 to allow comparative audit between multiple 
surgical facilities. It collects data on patient demographics, preoperative laboratory 
measurements, comorbidity and surgical factors. It also collects postoperative 
outcome data; mortality and 22 pre-defined postoperative compl ications occurring 
during the first 30 days following surgery (Table 1 ). Khuri concluded "the 
occurrence of a 30-day postoperative complication was more important than 
preoperative risk and intraoperative factors in determining survival after major 
surgery". 4 Development of any complicati.on in the postoperative period was a better 
predictor of operative mortality than age, ASA class or emergency surgery. In the 
Khuri et al cohort, approximately 15% of patients developed complications. 
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Table 6 illustrates the relative importance of pre-, intra- and postoperative variables 
on 30-day and long-term mortality. Chafer et al prospectively examined the rate of 
postoperative complications and their effect on mortality using the same NSQIP 
dataset on patients undergoing surgery between 2005 and 2007. 22 He found 
complication rates were very similar - approximately 25% - in both high and low 
mortality hospitals and that complications alone may not predict mortality foUowing 
surgery; mortality in patients with major complications was almost twice as high in 
hospitals with very high overall mortality as in those with very low overall mortality 
(21.4% vs. 12.5%, P<O.OOI). 
Bennet Guerro et al sought to characterise postoperative morbidity in a cohort of 438 
patients undergoing major non-cardiac surgery. 23 They found that although the 
overall mortality following major surgery was low (1 .6% in thi s cohort), 
postoperative complications were common and often not related to the site of the 
surgery. They found that gastrointestinal complications were most common (51%) 
followed by pulmonary (25%) then renal (21 %) and infectious (13%). 
The authors developed the "Postoperative Morbidity Survey" (POMS), a 9-domain 
survey that assesses complications in the major organ systems and is outlined in 
Table 7. Its aim is to identify patients with significant postoperative complications 
and is designed to minimise observer bias in comparative audit, clinical trials and for 
healthcare providers and funders. It has been validated in a variety of surgical 
populations and has been recently shown to be a valid and reliable measure of short-
term morbidity. 24·25 
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Table 6. Relative importance of pre-, intra- and postoperative variables on 30-day 
and long term mortality (Top 1 0). 4 
Step 30-Day Mortality OR (95%CI) Long Term OR (95%CI) 
Mortality 
1 Cardiac Arrest 125.0 (106.3- Cardiac Arrest 7.3 (6.9-7.8) 
147.3) 
2 Failure to Wean 1.5 (1.3-1.8) ASA Class 1.4 ( 1.3-1.4) 
3 Serum Albumin 0.7 (0.6-0.7) Age 1.035 (1.034-
1.036) 
4 ASA Class 1.7 (1.6-1.9) Serum Albumin 0.8 (0.8-0.9) 
5 Systemic Sepsis 3.6 (3.0-4.3) Dissemjnated 2.4 (2.3-2.5) 
Cancer 
6 CVA 6.7 (5.1-8.7) Failure to Wean 1.3 (1.2-1.4) 
7 Emergent Surgery 1.7 (1.5-2.0) History of COPD 1.29 ( 1.26-1 .33) 
8 Disseminated 2.9 (2.4-3.5) BUN >40mg/dl 1.4 (1.3-1.4) 
Cancer 
9 Renal Failure 4.8 (3.7-6.1) Functional Status 1.1 (1.1-1.2) 
10 Myocardial Infarct 4.7 (3.7-5.9) Smoking 1.3 (1.3-1.4) 
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Table 7. Postoperative morbidity survey (POMS) criteria. 23 
Pulmonary ~e novo requirement for supplemental oxygen or other respiratory 
support (e.g., mechanical ventilation or CPAP) 
~fectious k:urrently on antibiotics or temperature >38 oc in the last 24 h 
Renal Presence of oliguria (<500 mUd), increased serum creatinine 
(>30% from preoperatively), or urinary catheter in place for a 
nonsurgical reason 
Gastrointestinal Unable to tolerate an enteral diet (either by mouth or via a feeding 
ube) for any reason, including nausea, vomiting, and abdominal 
distension 
Cardiovascular Diagnostic tests or therapy within the last 24 h for any of the 
ollowing: de novo myocardial infarction or ischemia, hypotension 
(requiring pharmacological therapy or flu id therapy >200 mL/h), 
atrial or ventricular an·hythmias, or cardiogenic pulmonary oedema 
Neurological Presence of a de novo focal deficit, coma, or confusion/delirium 
Wound Wound dehiscence requiring surgical exploration or drainage of pus 
complication rom the operation wound with or without isolation of organisms 
Haemato logical ~equirement for any of the following within the last 24 h: packed 
~rythrocytes, platelets, fresh-frozen plasma, or cryoprecipitate 
Pain Surgical wound pain significant enough to require parenteral 
1.5.3 Length of Stay 
Acute hospital length of stay or ICU length of stay has been used as an outcome 
measure in clinical trials, however there are several issues with its use as an 
endpoint. Firstly it makes no distinction for patient status at discharge (e.g. "alive" or 
"dead") and so interventions that increase mortality may give a false impression of 
benefit by reducing length of stay. While it is possible to report length of stay data in 
survivors and non-survivors, it has become increasingly common to report "ICU-free 
days" as a means of overcoming this problem, with patients who die in ICU being 
assigned a score of zero. Several noteworthy ICU trials have used this approach, 26•27 
however in this author's opinion its utility is limi ted in surgical patients as many are 
only admitted to ICU for short periods of time, are discharged rapidly and the 
availabil ity of downstream beds may have more bearing on length of stay. 
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1.5.4 Quality of Life 
Health related quality of life has been measured after a variety of surgical 
. . l 1 28 . . l 29 d . mtervent10ns e.g. co orecta surgery, upper gastro-mtestma surgery, an maJor 
joint surgery. 30 Examples of such "Patient Reported Outcome Measures" are the 
EQ-5D system developed by the Euro-Qol group. This system asks patients to score 
mobility, pain, anxiety, self-care and usual activities on a visual analogue scale of 0-
100. It has been used in surgical settings, often in orthopaedic surgery where control 
of painful symptoms may be the overriding issue around the decision to operate. 31 
Other health-related quality of life measures used in survivors of cri6cal illness but 
not specificaJly validated in the postoperative population include: Sickness Impact 
Profile (SlP), Perceived Quality of Life (PQOL) and Short Form 36 (SF-36). 32 
Many of these were developed for health economic evaluation (e.g. EQ-5D), whereas 
some are more focused on truly reflecting quality of life (e.g. SF-36). Thus all have 
potential limitations, depending on the reason and the population for which they 
were developed. Quality of life scoring systems are also usually self reported and are 
exposed to a high degree of subjectivity and bias. This can be patient related 
(affected by pa6ent beliefs, attitudes etc.) or a feature of the questionnaire itself (e.g. 
closed or open questioning). Moreover, other disease processes and co morbidity 
may affect the outcome. 
The "quality adjusted life year" or QAL Y is used to assess both the duration and 
quality of additional longevity attributed to a particular treatment and is used by the 
National Institute for Clinical Excellence (NICE) in the UK to assess new therapies. 
33 The QAL Y is calculated by multiplying the number of additional years the patient 
might live as a result of the treatment, by a measure of "quality of life" with "0" 
being the worst possible health and "1" being the best possible health. "Cost utility 
analysis" can make comparisons between therapies for example in health technology 
assessment; this might typically involve using incremental cost-effectiveness ratio 
(ICER) to measure differences in cost and patient benefit (assessed using QALYs). 
There are issues around this approach, including ethical, applicability and economic 
criticisms and these are discussed more fully elsewhere. 34•35 
1.5.5 Economic Outcomes 
Hospital or intensive care length of stay is often used as a crude or surrogate of 
healthcare costs and resource utilisation, despite the fact that it is affected by a range 
of geographical and patient factors e.g. local policy, discharge to step down units, 
community nursing arrangements, patient preference and home arrangements. Due to 
ease of measurement and ready availabiJity it remains a popular outcome measure 
and it is usually reliably documented in large administrative databases. 
Full healthcare economic analysis involves calculation of QALYs (e.g. by use ofEQ-
5D questionnaire at specific time points) and calculation of hospital resource use 
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from hospital admission data. An example of tills ill the surgical setting is the 
"FOCCUS" trial of fluid loading in rugh-risk surgery. 36 
1.6 Identification of the High Risk Surgical Population 
Identifying the rugh-risk surgical population prior to operative intervention remains a 
major challenge and several methods of stratification of the surgical population 
according to risk exist. These include: scorillg Systems, tests of functional capacity 
(e.g. Cardiopulmonary Exercise Testing) and biomarkers. 
1.6.1 Risk Stratification and Scoring Systems 
Scoring systems, which stratify patient risk on the basis of patient characteristics, are 
generally low cost, easy to perform and may estimate population risk (e.g. used to 
adjust for case mix or patient level factors in comparative audit), individual risk 
(used to make predictions of risk for individual case.c;) or both. 
When scoring systems are introduced it is necessary to validate them. Usually an 
appropriate population is used to develop the model i.e. determine which variables 
are important and assign weights. The model is then validated on another cohort. 
"Calibration" determines the correlation between predicted and observed mortality 
and uses goodness of fit tests (e.g. the Homer-Lemeshow C-Statistic). Calibration is 
thought to be "good" if the Standardised Mortality Ratios (SMR) i.e. the ratio 
between predicted and observed rates of death is close to 1. Model discrimination is 
also tested using receiver operating characteristic (ROC) curves. The area under the 
curve (AUC) should be greater than 0.70. 
Age is often used as a measure of physical status and although a poor indicator of co 
morbidity, it is often accurately documented in databases. Scoring systems serve two 
functions: firstly to permit co-morbidity adjustment across different populations and 
reduce confounding effects of physical status in epidemiological s tudies. Secondly 
they may assist with prediction of individualised risk for patients undergoing 
surgery. The most widely used preoperative scoring system is the American Society 
of Anaesthetist Physical Status (also known as the "ASA-PS" or simply "ASA 
score"). Other scoring systems, which have been utilised in this setting, include the 
Charlson Co-morbidity Index (CCI), the Surgical Risk Score (SRS) and the 
Physiological and Operative Severity Score for enumeration of Morbidity and 
Mortality (POSSUM). The APACHE II score has also been used to stratify risk in 
surgical patients. Also considered are predictors of cardiovascular risk: the Goldman 
Cardiac Risk Score and the Lee Revised Cardiac Risk Index (LRCI). Each of these 
will be considered in turn . 
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American Society of Anaesthesiologists - Physical Status 
The ASA-PS score is a somewhat subjective assessment of a patient's overall health 
and physical status and was developed by SakJad et al and first used in 1941. 37 It 
initially had seven categories and this was rationalised to five in 1963. 38 The ASA 
score is set out in Table 8. 
The ASA-PS score is not strictly speaking a preoperative scoring system and was 
developed as a categorisation system for statistical study. 39 It does not take into 
account the scope and nature of the surgery and therefore its predictive use in 
individual patients is limited. Its simplicity makes it a common and useful 
descriptive tool of a patient's physical status prior to surgery although 
inconsistencies in both its application and interpretation are well documented. 4042 
Several studies have shown ASA-PS to correlate well with postoperative outcome. 
Wolters et al undertook a retrospective study of 6301 patients undergoing surgery in 
a German university teaching hospital and found ASA-PS correlated well with length 
of ICU stay, postoperative complications and death (Table 9). 43 
Davenport et al used the NS-QIP database to validate ASA-PS m almost 6000 
patients and again found it to be a strong predictor of outcome. The investigators 
found the predictive power of ASA-PS was increased by the addition of 20 "co-
morbidities" identified in previous work (Table 1 0). 44 
In conclusion ASA-PS correlates well with outcome; however, subjectivity, poor 
inter-observer consistency and lack consideration of nature of surgery limit its 
usefulness as a predictive tool. 
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Table 8. Tbe ASA scoring system. 38 
Category Description 
ASA 1 A fit and healthy patient with no co morbidities 
ASA2 The patient has mild systemic disease 
ASA3 The patient has severe systemic disease whjch is not a constant threat to life 
ASA4 The patient has severe disease wruch is a constant threat to life 
ASA5 The patient is moribund and unlikely to survive 24h with or without surgery 
*The suff1x E IS often applied to denote emergency surgery. 
Table 9. Association of ASA-PS class with morbidity and mortality from Wolters et 
al. 43 
ASAI ASAII ASA III ASAIV p 
N 1133 2685 2181 290 
%age 18 42.6 34.6 4.6 
ICU LOS (days) 0.2 0.8 1.9 5.4 <0.05 
Hospital LOS 9.3 16.4 20.8 17.6 <0.05 
(days) 
Pneumonia 0.5 2.2 5.2 12.1 <0.05 
Cardiac 0.1 1.5 5.5 18 <0.05 
Complication 
Wound Infection 1.8 3.8 6.3 10.6 <0.05 
Hospital 0.1 0.7 3.5 18.3 <0.05 
Mortality 
LOS =Length of stay 
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Table 10. The 20 most influential risk factors in predicting ASA-PS with incidence 
rates and odds ratios for a higher ASA-PS Level (Davenport et al). 44 
Preoperative Risk Variable Incidence(%) Odds Ratio 
Preoperative coma 0.2 18.01 
Dyspnoea at rest 1.8 5.34 
Preoperative impaired sensorium 2.1 5.04 
On ventilator 1.2 4.36 
Morbid obesity (BMI:::: 39) 7.1 4.22 
Totally dependent functional status 2.5 3.29 
Previous PTCA 2.7 3.12 
Previous cardiac operation 4.2 3.11 
Current smoker 31.6 2.94 
History of CVA Without Neurologic 1.3 2.54 
Deficit 
Dyspnoea with moderate exertion 9.2 2.50 
History of hypertension 32.2 2.48 
Insulin-dependent diabetes 3.8 2.38 
COPD 7.1 2.30 
Orally treated diabetes 4.8 2.01 
Age (10-yr increment) 47 yr* 1.57 
High WBC 13.8 1.53 
Albumin <3.5 9.7 1.47 
Obesity (25 <BMI< 39) 46.7 1.22 
*mean age 
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Charlson Age-Co morbidity Index and Associated Scores 
The Charlson Age-comorbidity index or Charlson Comorbidity Index (CCI) is a list 
of 19 medical conditions each of which is an assigned a "weight" of 1-6. The CCI 
was developed as a prospective method of adjusting for co-morbid conditions, which 
might alter the risk of mortality and was designed for use in longitudinal studies. In 
the original paper Charlson et al developed the index in a cohort of 559 medical 
patients then subsequently tested its ability to predkt risk of death from co-morbid 
disease in the second cohort of 685 patients with breast cancer during a ten-year 
follow-up. 45 CCI was predictive of increased risk (OR 2.3; 95% CI: 1.9-2.8) of death 
per increment in co-morbidity and this index was further validated in postoperative 
patients suffering from hypertension or diabetes. 46 A list of co-morbidities and their 
respective weights is outlined in Tablell. 
Deyo et al mapped out the original 19 conditions described by Charlson to ICD-9 
diagnoses and performed a further validation in 27 000 patients undergoing spinal 
surgery. The investigators found strong associations between CCI and length of stay, 
costs and perioperative morbidity and mortality. 47 
Further modification to the CCI was made by Ghali et al 48 who reduced the number 
of co-morbidities and altered their weights to select those whkh best predicted 
mortality in 257 333 patients who had undergone cardiac surgical procedures in 
Massachusetts. The five co morbidities and their altered weights are shown in Table 
12. 
Although the CCI has been shown to strongly predict adverse outcomes in large 
administrative databases it fails to take account of surgical factors in prediction of 
outcome and has not been validated to predict risk on an individual basis. Therefore 
it cannot be used for this purpose. 
Michael Gillies Doctor of Medicine (2014) 33 
Table 11. Weighted indices of co-morbidity. 
Condition Charlson Ghali 
Weights Weights 
Myocardial Infarct 1 1 
Congestive Heart Failure 1 4 
Peripheral Vascular Disease 1 2 
Cerebrovascular Disease 1 1 
Dementia 1 -
Chronic Pulmonary Disease 1 -
Connective Tissue Disease 1 -
Ulcer Disease 1 -
Mild Liver Disease 1 -
Diabetes I -
Hemiplegia 2 -
Moderate or severe renal disease 2 3 
Diabetes with end organ damage 2 -
Any tumour 2 -
Leukaemia 2 -
Lymphoma 2 -
Moderate or severe liver disease 3 -
Metastatic solid tumour 6 -
AIDS 6 -
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Table J 2. Outcomes of lumbar spine surgery and resource use according to adapted 
Charlson co-morbidity index scores. 47 
Charlson Score 0 I 2 >3 p 
N 19,167 5478 1626 840 <0.0005 
Mean age (yr.) 71.7 71.8 72.2 72.7 <0.005 
ln-bospital 7.9 8.4 9.1 10.5 <0.01 
complications (%) 
LOS (d) 12.9 14.0 15.0 16.1 <0.0005 
6 Week Mortality 0.5 1.0 1.8 2.7 <0.0005 
Physiological and Operative Severity Score for the Enumeration. of Mortality and 
morbidity (POSSUM) score 
The POSSUM score was originally described by Copeland et al 49 as a tool to 
compare surgical morbidity and mortality across a range of procedures and allow 
comparative audit of different surgical units. The investigators examined 62 
physiological variables and used multi-variate analysis to select the 12 most 
predictive variables (Table 13). Physiological and operative severity scores are then 
generated and used to give a predicted morbidity and mortality using the equation: 
Ln R/1-R = -7.04 + (0.13 x PSS) + (0.16 x OSS) 
PSS = Physiological Severity Score; OSS = Operative Severity Score; R= risk of 
mortality 
Because of concerns regarding the over prediction of death (by 2-fold in low risk 
patients) the "Portsmouth" POSSUM or "P-POSSUM" score was developed. P-
POSSUM uses the same dataset but a different equation to calculate predicted 
mortality. 50 
Ln R/1-R = -9.065 + (0.1692 x PSS) + (0.1550 x OSS) 
Drawbacks with the POSSUM system are: There remains a degree of subjectivity 
when assessing variables. Some variables are unknown until after the surgery has 
taken place (e.g. blood loss). The scoring system is complex and difficult to use at 
the bedside. The lowest possible mortality risk is 1.08% and this may over-estimate 
mortality in low risk patients. Still POSSUM has been validated across a large 
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number of patients, through a range of surgical specialties 5 1-53 in different healthcare 
systems 1 and the P-POSSUM equation produces very close fit with observed 
hospital mortality. Subspecialty specific POSSUM scoring systems exist, e.g. Cr-
POSSUM and V-POSSUM for colorectal and vascular surgery respectively. 
Table 13. Variables used in the POSSUM score 
Physiological Variable Operative Variable 
Age Operative Severity 
Presence of Cardiac Signs Multiple Procedure 
Respiratory History Total Blood Loss 
Blood Pressure Peritoneal Soiling 
Pulse Presence of Malignancy 
Glasgow Coma Score Mode of surgery (Urgency) 
Haemoglobin 





Surgical Risk Scale 
The surgical risk scale was proposed by Sutton and co-workers in 2002 and 
incorporates the ASA-PS Score, the Confidential Enquiry into Perioperative Deaths 
(CEPOD) classification for surgical urgency (elective, scheduled, urgent, 
emergency) and the British United Provident Association (BUPA) classification of 
surgical complexity (minor, intermediate, major, major plus, complex major) to 
create a weighted score of between 3-14. 54 This composite score was strongly 
predictive of death (p<O.OOOl) and a subsequent study in a larger coho1t of patients 
from a single centre found it compared favourably to POSSUM. 55 
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Critical Illness Scoring Systems 
Severity sc01ing systems for the critically ill are used to estimate severity of disease 
and can be used to predict acute hospital mortality. In the UK severity of illness 
scores are generally used to adjust for patient level factors (sometimes referred to as 
"case mix") in clinical and comparative audit and to compare critically ill 
populations for research purposes. ICU severity of illness scoring systems attempt to 
consider three factors: physiological disturbance, physiological reserve (from the 
chronic health evaluation) and the pathological process. To enable this, detailed 
physiological and demographic data is collected for each ICU patient. A weighting is 
applied to each variable and this in turn is used to generate a score related to severity 
of illness. 
Critical illness scoring systems have been in use for over three decades, commonly 
used systems include: Acute Physiology and Chronic Health Evaluation (APACHE); 
Simplified Acute Physiology Score (SAPS); Multiple Organ Dysfunction Score 
(MODS); Mortality Prediction Model (MPM); Sequential Organ Failure Assessment 
(SOFA). 
APACHE II Scoring System 
The APACHE system is the most widely used scoring system in critical care. It is 
commonly used to permit control for case mix in clinical audit, in comparison of 
ICU outcomes and in clinical trials. The original APACHE system was devised by 
Knaus in 1981 56 and has undergone 2 major revisions since then; APACHE III 
superseded APACHE II in 1991 57 and APACHE IV was developed in 2006. 58 
However APACHE II remains the most familiar and widely used system within the 
UK; it forms the basis of the Intensive Care National Audit and Research Centre 
(ICNARC) Model used in the Case-Mix Programme (CMP) and has been 
recalibrated twice for this purpose. 59 
APACHE II was originally validated on 5030 non-cardiac surgery general ICU 
patients in the USA. It is the sum of 3 components: 
1. Acute Physiology Score (APS) 
2. Chronic Health Score (based on certain premorbid conditions) 
3. A score based on age 
The APACHE II is measured during the first 24 hours of ICU admission. The 
maximum possible score is 71. A score of 25 represents a predicted mortality of 50% 
and a score of over 35 of 80%. 
APACHE II is less useful in diagnostic groups which were not reflected in the 
original validation cohort e.g. patients who have undergone cardiac surgery or 
patients with burns. APACHE II has been shown to correlate well with outcome in 
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emergency gastrointestinal 60 and vascular surgery 6 1 however it should be 
remembered that the APACHE II scoring system was validated in a cohort of ICU 
patients and also that 24 hours of patient data are required. Commentators have 
argued that it is too complex for routine surgical use 62. 
Cardiac Risk Scoring 
The link between co-existing cardiovascular disease and adverse surgical outcomes 
has been the focus of various scoring systems for a number of years. Several scoring 
systems have been developed with the aim of identifying patients at risk of adverse 
cardiac events in the perioperative period. 
Goldman et al first devised a risk index based in 1977 63. The Goldman Cardiac Risk 
Index attributed points to 9 risk factors identified by retrospective analysis of 1001 
patients and provided an estimated risk of death or major cardiovascular 
complication. In the decade that followed Detsky et al and Eagle et al proposed other 
cardiac risk indices. 64•65 Gilbert et al prospectively evaluated these scoring systems 
in 2035 patients in 2000 and found no system to be superior, although all performed 
"better than chance". 66 
Lee et al revised the Goldman Index, reducing the number of predictors from nine to 
six: high-risk type of surgery, history of ischaemic heart disease, history of 
congestive heart failure, history of cerebrovascular disease, preoperative treatment 
with insulin, and preoperative serum creatinine greater than 2.0 mg/dL. These factors 
were prospectively validated in a cohort of 4 135 patients. Rates of major cardiac 
complication with 0, I, 2, or 3 of these factors were 0.5%, 1.3%, 4%, and 9%, 
respectively. 67 Boersma further refined and validated the Lee Revised Cardiac Risk 
Index (LRCRI) prospectively in 108 593 patients from a Dutch administrative 
database and found substantial improvement in predictive value if the type of 
procedure was added. 68 Current guidance from the American College of 
Cardiology/ American Heart Association stratifies patients into High, Intermediate 
and Low Risk based on functional capacity, clinical factors and nature of surgery. It 
is recommended that patients at increased risk undergo non-invasive stress testing or 
angiography prior to surgery. 69 
1.6.2 Cardiopulmonary Exercise Testing (CPET) 
In recent years the formal assessment of functional capacity has been used 
increasingly to stratify perioperative risk. Assessment of functional status has been 
part of routine pre-operative history taking for many years and self reported poor 
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Cardiopulmonary exercise testing, often abbreviated to CPET, involves measurement 
of physiological variables - usually electrocardiogram (ECG) and respiratory 
function- during incremental exercise for example on a treadmill or an exerdse bike. 
Although CPET has been used as a tool for functional assessment in a variety of 
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medical disorders it has enjoyed increasing popularity following a landmark paper 
publ ished by Older et al in 1993 in which 187 patients aged 60 or more were 
evaluated using CPET testing and found that low anaerobic threshold (AT) and 
preoperative myocardial ischaemja were predictive of increased perioperative 
mortality. 72•73 
Conduct of CPET Test 
The conduct of CPET testing varies but typically involves incremental exercise 
testing on a cycle ergometer. The patients ECG is morutored and he or she wears a 
nose clip and exhaled gases are collected via the mouth and analysed. This allows 
calculation of oxygen consumption and carbon dioxide production. Following an 
initial period of famil iarisation the ramping stage begins which involves increasing 
the intensity of the exercise in 2-3 minute intervals with the aim of completing the 
test in 10 minutes. In a submaximal test, the test continues until the anaerobic 
threshold is reached. In a maximal test the test continues until the subject is unable to 
maintain the desired intensity of exercise. Symptoms of chest pain or pre-syncope or 
ST segment depression on ECG would trigger early termination of the test. Detailed 
protocols and gu idelines on CPET testing have been published by the American 
Heart Association/ American College of Chest Physicians 73 and is described by 
Older et al. 72 
Data Obtained During CPET Testing 
Several physiological variables are measured during CPET testing and these include: 
Work (Watts) 
Work is the power generated by the subject in Joules U) per second. 
Oxygen Uptake CVOv 
The amount of oxygen extracted by the subject per unit time, usually expressed in 
ml!min. 
Anaerobic Threshold (AT) 
This is the exercise level at which anaerobic Adenosine Triphosphate (ATP) is 
required to supplement aerobic production. The method described by Beaver et al 
uses computerised regression analysis of the C02 uptake (VC0 2) vs . 0 2 uptake 
(V0 2) plot. Additional C02 production occurs at the transition to aerobic 
metabolism due to buffering of increased lactate in blood. This is detected and used 
to determine the AT. 74 
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Maximum Oxygen Uptake (VOzmax) 
This is the V02 that cannot be exceeded by the subject and is detennined when V02 
reaches a plateau during CPET. 
Heart Rate Reserve 
This is the difference between the observed maximum heart rate and that observed at 
peak exercise. 
Oxygen uptake divided by heart rate. The amount of oxygen extracted by the tissue 
in each stroke volume. 
Ventilatory Equivalents for COz and Oz (Ve!VC02 and VeNOiJ_ 
These are the ventilatory requirements for each metabolic rate. 
Clinical Use of Data from CPET 
V02 Max, AT and VeNC02 have been shown to identify high-risk surgical 
patients, hence they are used most commonly for risk stratification purposes. 72•75•76 
CPET has now become a widely used tool for stratification of high-risk patients prior 
to abdominal surgery. 72•75•76 It has also been investigated prior to vascular 77 thoracic 
78 and upper gastrointestinal surgery. 79 It is available in 40% of NHS Hospitals and 
not widely used outwith the UK. 
Most of the data regarding the use of CPET as a stratification tool are from single 
centres and larger multicentre studies involving different patient subgroups are 
warranted. 
1.6.3 Biomarkers 
The use of biologically plausible markers to predict perioperative mortality, 
morbidity or risk of specific postoperative complications is an attractive proposition. 
They are generally easy to measure and can easily be validated in large patient 
cohorts. 
Several biomarkers have been evaluated in the high-risk surgical population. 
Biomarkers Predicting Postoperative Cardiac Injury- Troponin 
Troponins are protein complexes found in skeletal and cardiac muscle. Three 
subtypes of cardiac troponin exist: Troponin C (TnC), Troponin I (Tni) and Troponin 
T (TnT). Cardiac troponins are highly specific and sensitive and specific markers of 
myocardial necrosis and accurately predict mortality in patients with acute coronary 
syndromes. 80•81Troponins have been used to accurately predict both preoperative 
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myocardial infarction and short and long term outcomes in patients with stable 
coronary artery disease 82 and those who have undergone major vascular surgery. 
83
•
84A systematic review by Levy et al examined fourteen studies (n=3318). In this 
study, increased troponin measurement after surgery was an independent predictor of 
mortality (OR 3.4, CI 2.2-5.2). 85 
Increasingly sensitive 4th and 51h generation Troponin assays have been developed 
which can improve the early detection of myocardial necrosis. 86•87Whether the 
benefits of earlier detection of myocardial necrosis using so-called "highly sensitive 
Troponins" (HST) result in patient benefit is controversial. 88Lopez-Jimenez 
evaluated the incidence and prognostic significance of cardiac TnT in 772 patients 
who had undergone major non-cardiac surgery. 12% of patients had elevated TnT 
and elevated TnT was associated with increased relative risk for cardiac events of 5.4 
(95% confidence interval: 2.2 to 13, p = 0.001). 89 
The more recent "Vascular Events in Non Cardiac Surgery Patients Cohort 
Evaluation" (VISION) Study evaluated major cardiac complications in 15,133 
patients over the age of 45 undergoing major non-cardiac surgery. In this study, there 
was a high prevalence of cardiac risk factors in the study cohort. After adjustment for 
cardiovascular and respiratory risk factors and also for various operative factors 
logistic regression analysis suggested that elevated 4th generation Troponin I assay 
was associated with mortality. 90 
VISION used a 41h generation Tnl assay, however as part of a sub-study in this 
cohort, Kavsak and co-workers investigated the incidence of elevated 5th generation 
troponin in these patients. Elevated 5th generation Tni above the 99th centile was 
demonstrated to be 45% in a cohort of 325 of these patients. Whether this was 
associated with worse outcomes was not reported. 91 
Biomarkers Predicting Postoperative Cardiac Injury- Brain Natiurietic Peptides 
Brain Natiurietic Peptide (BNP) is a neurohormone released by the ventricular wall 
in response to increased ventricular wall tension associated with volume overload. It 
is analogous to Atrial Natiurietic Peptide (ANP) however it has a tenth of the affinity 
for the ANP receptor. It has vascular and renal effects causing vasodilation and 
promotion of sodium and water loss respectively. Wall stress of the cardiac muscle 
can be measured by monitoring BNP or its non-biologically active N-terminaJ 
fragment (NT pro-BNP) as both have significantly longer half-lives than ANP. BNP 
and NT pro-BNP have been used both as prognostic and diagnostic tools. 92 
Two recently published meta-analyses demonstrated that measuring either BNP or 
NT proBNP perioperatively (including pre-operatively) could independently predict 
cardiovascular events in the first 30 days after vascular surgery and significantly 
improve the predictive performance of the revised cardiac risk index. 93•94 
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Markers of Postoperative Renal Dysfunction - Neutrophil Gelatinase-Associated 
Lipocalin (NGAL) 
Neutrophil Gelatinase-Associated Lipocalin (NGAL) is a protein released by 
neutrophils and epithelial ceJls. It is released into the urine by the proximal 
convoluted tubule epithelium following Acute Kidney Injury (AKI). NGAL is 
measurable in both serum and urine and has been shown to peak at 6 hours of 
cardiopulmonary bypass. 95 NGAL has been shown to be correlated with and an 
independent predictor of duration and severity of A.Kl and duration of intensive care 
stay after adult cardiac surgery. 95•96 A systematic review and meta-analysis found 
that NGAL accurately predicted AKI in cardiac surgery, critically ill and post 
contrast patients and that both serum and urinary NGAL were equally effective. 97 
NGAL appears to have a better predictive ability in children than in adults. A further 
study by Ronco et al found plasma NGAL a useful marker of AKI in a 
heterogeneous ICU population, even when the timing of insult was unknown. In 
addition it accurately predicted severity of AKI and the need for renal replacement 
therapy (RRT). 98 The role of NGAL in the non-cardiac surgical population is less 
dear. A small study (n=74) undertaken by Shavit et al found that serum NGAL did 
not correlate with postoperative AKI but did correlate with postoperative infection 
and death. 99 
Markers of Inflammation- C-Reactive Protein (CRP) 
CRP is an acute phase protein, i.e. plasma levels rise in response to inflammation. Its 
role is to bind to injured or dying ceJls or bacteria and activate the complement 
cascade, hence the name. CRP rises in acute inflammation and is routinely measured 
to assess the inflammatory response. CRP has been shown in several prospective 
studies to predict both cardiovascular events and cardiac death. 100 CRP has also 
been used with varying success to predict major postoperative complications: 
elevated serum CRP concentration has been shown to correlate negatively with 
V02max in asymptomatic men. 
101 CRP has been used to successfully predict 
anastamotic leak 102 and infectious and other complications in the colorectal 
population. 103•104 Preoperative levels of "Highly Sensitive" CRP (hsCRP) are 
associated with increased length of stay in elective orthopaedic patients. 105 
Markers of Inflammation -Inflammatory Cytokines 
Cytokines are a diverse group of small immunomodulatory peptides, which are 
released by a variety of tissues in response to injury. They have been linked to 
numerous diseases and clinical syndromes including the systemic inflammatory 
response syndrome. Several groups of cytokines exist and act both locally and 
systemicaJly to generate a variety of pro-and anti-inflammatory responses. After 
major surgery levels of interleukin- l (IL- 1), tumour necrosis factor- a. (TNF- a.) 
and IL- 6 are known to be elevated. 106 A recent study undertaken by Kvarnstrom et 
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al examined levels of complement (C3a and SC5b-9) and the release of pro- and 
anti-inflammatory interleukins (tumour necrosis factor-a. (TNF-a.)), interleukin-lP 
(IL- l p), IL-6, IL-8, ll...--4 and IL-l 0) fol1owing major abdominal surgery in 50 
patients. Levels of complement, pro-inflammatory interleukins IL-6 and ll...--8 and 
anti-inflammatory interleukins IL-10 were elevated during and following major 
colorectal surgery. Type of anaesthesia (intravenous versus inbalational) had no 
effect on cytokine levels. 107 Whether cytokine levels can be used to prognosticate 
following major surgery is unknown. 
1.7 Strategies to Improve Outcomes the High Risk Surgical Population 
1.7.1 Volume of Surgery Effect 
Several studies in the Jast decade have suggested that there was an inverse 
relationship between volume of surgery and adverse outcomes for selected surgical 
procedures in both the UK and North America. 108" 110 Tbjs bas led to the 
concentration of selected high risk surgical procedures in so called "high volume 
centres". A recent study undertaken by the "Leapfrog Group" examined data for 
more than 3.2 million Medicare patients undergoing one of eight cancer operations 
or cardiovascular procedures at hospitals in the Unjted States between 1999 and 
2008. 111 The authors found reduced mortality for all eight procedures over the study 
period in centres performing higher surgical volumes; in abdominal aortic aneurysm 
repair this was by 36% (4.4% to 2.8%). Higher hospital volumes were also thought 
to explain a large portion of the decline in mortality for pancreatectomy (67% of the 
decline), cystectomy (37%), and oesophagectomy (32%). Similar data have been 
reported in the UK echoing data using the Health Episode Statistics (HES) database. 
108 More recently, Chowdhury et al undertook a systematic review and meta-analysis 
examjning 163 papers of 42 different surgical procedures, over 13 surgical 
specialities. He found that high volume and centre specialisation were associated 
with improved outcomes and that this varied between surgical procedure and 
subspecialty with vascular surgery, cardia-thoracic surgery and surgical oncology 
among those benefitting most. 112 The recent paper published by Holt et al in 2014 
comparing outcomes in the UK with the USA also found reduced mortality 
associated with increased hospital volumes. 12 
1.7.2 Critical Care Provision 
Bennett-Guerrero et al compared a large prospective cohort of patients undergoing 
high-risk non -cardiac surgery from the US (n=l539) with a similar cohort from the 
UK (n=l056) to determine the applicability of the P-POSSUM score. 1 In this study, 
for any given risk level, mortality rates were significantly higher in the UK cohort 
than in the US cohort (OR 4·50; p < 0·001). Routine use of Critical Care beds (both 
ICU and HDU) for high-risk surgical patients was been postulated as a potential 
reason for the disparity seen between the UK and the USA. In the study undertaken 
by Pearse et al only 36% of the high risk group were admitted to the Intensive Care 
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Unit (ICU) following surgery and the highest mortality rate was found in those 
patients who were admitted to ICU after initial care on a standard ward. 15 
The UK is known to have fewer ICU beds than other developed nations. Wunsch et 
al examined the effect of resource use and hospital and ICU bed numbers per head of 
population on mortality in the USA, Canada and six European countries, including 
the UK. 113 The numbers of critical care beds and volume of admissions varied 
widely between countries and the UK lay at the lower end, both in tenns of per 
capita bealthcare spend and number of ICU beds. This was found to correlate 
negatively with hospital mortality. 
Jhanji et al investigated utilisation of critical care beds by high-risk surgical patients 
in a large NHS Trust in England. He found only one-third of patients considered 
"high risk" were admitted to ICU at any stage of their inpatient episode. Moreover, 
only approximately half of those who died were admitted to critical care and only 
25% of the deaths occun·ed within a critical care area. The authors concluded, "The 
outcome of high-risk general surgical patients could be improved by adequate 
provision and more effective utilisation of critical care resources". 114 
Wunsch et al undertook a further study examining medical ICU admissions in the 
United States and United Kingdom. 1 13•1 15 United Kingdom ICU admissions were 
less likely to be admitted directly from the emergency department, were younger, 
had longer hospital stays before ICU admission, and were sicker. Patients also had a 
higher APACHE score and were more frequently mechanically ventilated within 24 
hours after ICU admission. Although there was considerably higher overall hospital 
mortality in the UK there was no difference in outcome for patients admitted for 
mechanical ventilation in ICU directly from the Emergency Department. The authors 
concluded that interpretation of between-country hospital outcomes is confounded by 
differences in case mix, processes of care, and discharge practices. 
In summary, there is evidence of wide international variation in ICU bed provision in 
the developed world. The UK lies at the lower end of ICU bed provision compared 
with many other western nations. ICU outcomes are significantly worse in the UK 
than in the USA, however this could be confounded by process of care issues, as the 
healthcare systems in each nation are very different. There is widespread speculation 
that this may account for observed differences in surgical outcome but little objective 
evidence to support this assertion. 
1.7.3 Goal Directed Haemodynamic Therapy 
In 1973 Shoemaker et al observed that patients suffering from "surgical shock" were 
more likely to survive if they were able to achieve higher levels of cardiac output 
(CO) and tissue oxygen delivery (D02). 116 He postulated that patients who were 
unable to maintain adequate tissue oxygen delivery were at risk of complications and 
death and that increasing oxygen delivery to supranormal levels may improve 
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outcome. In a study conducted 15 years later he randomised 398 high-risk surgical 
patients to have CVP guided haemodynamic management or "pulmonary artery 
catheter (PAC) protocol" guided management. PAC protocol management involved 
increasing CO to greater than 4.5Umin and D02 to greater than 600 ml/min using 
fluids and inotropes (principally dobutamine). The targets used were the median peak 
values achieved in the survivor group in the previous observational study. In this 
study he demonstrated reduced length of hospital and rcu stay, reduced duration of 
mechanical ventilation, reduced complications and reduced costs in patients assigned 
to "P A protocol" management. 117 There is significant evidence that covert tissue 
hypoxia may be implicated in the development of postoperative complications. This 
generated interest in using so-called "goal-directed haemodynamic therapy (GDHT)" 
in the high-risk surgical group. This approach involves using cardiac output 
monitoring and giving fluid and inotropes to maximise cardiac output and hence 
oxygen delivery. There is significant evidence that overt or covert failure of oxygen 
delivery may be implicated in the development of postoperative complications and 
hence or morbidity and mortality following major surgery. For example, a study of 
118 patients conducted by Pearse et al suggested that significant fluctuations in 
central venous oxygen saturation (Scv02) (a surrogate for mixed venous oxygen 
saturation) occur in the immediate post-operative period. Reductions in Scv02 were 
independently associated with post-operative complications although these 
fluctuations were not always associated with changes in oxygen delivery, suggesting 
that oxygen consumption was also relevant. 118 However alterative hypotheses do 
exist: GDHT may improve microvascular flow 119 or modulate the inflammatory 
response after surgery. 120 
There are more than 30 randornised controlled trials investigating goal directed 
haemodynamjc therapy involving at least 5000 patients. A summary of selected trials 





135 Although many of these trials have shown benefit, the largest study, a 
multicentre trial of almost 2000 patients conducted by Sandham et al did not. 129 
Use of GDHT routinely for all high-risk surgical patients remains controversial. The 
clear beneficial effects in studies utilising PAC or investigating GDHT in patients 
undergoing vascular or trauma surgery appear to be less obvious 122•124•129 than in 
studies of patients undergoing gastrointestinal surgery utilising non invasive cardiac 
output monitoring e.g. Oesophageal Doppler Monitoring (ODM) or Lithium 
Indicator Dilution (LiDCO). 
Meta-analyses of randomised controlled trials (RCTs) investigating the effect of 
GDHT on gastrointestinal complications 136, renal dysfunction 137, and postoperative 
infection 138after major surgery indicate these complications are significantly 
reduced if GDHT is used. More recently Grocott et al published large meta-analyses 
examining the use of therapy to increase perioperative blood flow using fluids with 
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or without inotropic agents. This study examined data from 31 clinical trials and 
5292 patients. The main findings of this study were that there was no improvement 
in survival associated with this therapy RR 0.89 (95% CI 0.76-1.05; p=0.18). 
However studies with differing interventions, patient groups and measured outcomes 
were included. The use of this therapy did appear to reduce complications (especially 
renal, respiratory and wound infections) and reduce hospital length of stay. 139 
Another controversy surrounding GDHT centres on the use of pre-emptive inotropic 
agents and their potential contribution to myocardial ischaemia. Pearse et al 
conducted a post hoc analysis of troponin levels in blood samples taken at 24 and 48 
hours following surgery in patients who had participated in a GDHT trial using 
dopexamine 140 and found no significant increase in troponin levels in the GDHT 
group. Controversy however remains regarding pre-emptive use of inotropic agents, 
in particular dopexamine. 
A multicentre study of 412 patients undergoing major abdominal surgery conducted 
by Takala et al compared the use of placebo with dopexamine at 0.5 mcg-1kg'1min' 1 
and 2.0 mcg'1kg-1min-1• Although there was no difference in 28-day mortality (the 
primary outcome measure) between groups, post-hoc subgroup analysis suggested 
survival benefit in the high-risk group. 141 There was a higher incidence of 
arrhythmias in the group receiving dopexamine. 
Two recent meta-analyses of dopexamine have been published. Both suggested no 
overall survival benefit associated with dopexamine however in the analysis Pearse 
et al suggested a survival benefit (OR 0.50 [0.28-0.88]; p = 0.016) and reduced 
length of stay associated with low-dose dopexamine. 142 The meta-analysis conducted 
by Gopal et al did not report the effect of dopexamine at lower doses. 143 
Commentators have pointed out that although the two studies included largely the 
same papers, different endpoints were used and also different analytic techniques; the 
study by Gopal et al used meta-analysis with Cochrane's "Revman" software and 
that of Pearse et al used meta-regression. 144 
Since then a single centre randomised, double blind, placebo-controlled trial of low-
dose dopexamine vs. placebo in 124 high risk colorectal or urology patients, 
conducted by Davies et al and published in 2011, again failed to demonstrate any 
difference in survival or complications between groups. There was no difference in 
incidence of myocardial infarction between groups. 145 Recent animal studies have 
suggested that dopexamine may have significant anti-inflammatory effects, which 
may attenuate the organ damage associated with surgery. 120 
These data show that it has not yet been fully elucidated whether goal directed fluid 
management alone or in combination with inotropic therapy can improve outcomes 
in this group and the current evidence does not support widespread implementation 
of thi s approach. 
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Table 14. Selected studies of goal directed therapy in surgical patients. 
Study Year n Surgery Intervention CO Modality Inotrope Outcome 
Boyd 1993 107 General Auids and InoLrOpes PAC Dopexamine Reduced mortality and complications 
Bishop 1995 77 Emergent Trauma Auids and lnoLrOpes PAC Not specified Reduced mortality and LOS 
Bender 1997 104 Vascular Auids and lnolrOpes PAC Dopamine No change 
Shoemaker 1998 398 General Surgery Au ids and lnotropes PAC Dobutamine Reduced Complications and LOS 
Wilson 1999 138 Mixed Au ids and lnoLrOpes PAC Adrenaline and Dopexamine Reduced Monaliry and LOS 
Velntahos 2000 75 Trauma Auids and lnotropes Bioimpedance/PAC Not specified No change in outcome 
Lobo 2000 37 General Fluidsflnotropes PAC Dobutamine Reduced monality and complications 
Can 2002 100 GeneraJ/Urology Auids OOM N/A Reduced Complications and LOS 
Conway 2002 57 Major Bowel Resection Auids ODM N/A Reduced critical care admission 
Sandham 2003 1994 Vascular. Thoracic. Onhopaedic Auids, lnotropes PAC Not specified No difference 
Chytra 2007 80 Trauma Auids OOM N/A Reduced complications. LoS and Monality 
Pearse 2005 122 General Auids and Inotropes uoco Dopexan1ine Reduced Complications and LOS 
Wakeling 2005 128 Colorectal Auid OOM N/A Reduced LoS and GI complications 
Noblett 2006 108 Colorectal Auid ODM Reduced LoS and morbidity 
Lopes 2007 33 General/Urology Auids PPV N/A Reduced hospital and ICU LoS, Reduced Complication 
ChaUand 2012 179 Colorectal Auids ODM N/A No difference 
. ---·-····-
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1.7.4 Beta Blockade 
For decades there has been interest in g1vmg patients at risk of perioperative 
myocardial infarction beta-blocking drugs, in particular patients with known 
atherosclerotic disease undergoing vascular surgery. Beta-blockers may reduce 
myocardial oxygen demand or stabilise coronary atherosclerotic plaques. Several 
studies and meta-analyses have been published on this subject, often with conflicting 
results. 
Early randomised controlled trials in the 1990s suggested that use of perioperative 
beta-blockade could reduce the incidence of myocardial infarction and cardiac 
deaths. 146•147 Subsequent studies, however have not demonstrated evidence to 
support widespread implementation of this strategy. The "Perioperative Beta 
Blockade for Patients Undergoing Infra-renal Vascular Surgery" (POBBLE) study 
was a multicentre trial of 103 patients undergoing infra-renal vascular procedures 
published in 2005. Patients were randomised to receive the oral beta-blocker 
Metoprolol or placebo until 7 days after surgery. A high proportion (one third) of 
trial participants suffered a postoperative myocardial infarction in this study and this 
was not attenuated by the perioperative use of beta-blockers. 148 The larger 
"Perioerative Ischaemic Evaluation" (POISE) study, published in 2008, investigated 
the effects of perioperative beta-blockade in 8351 patients from 190 hospitals in 23 
countries. Participants in this trial were either known to have, or were at risk of 
having atherosclerotic disease and were undergoing non-cardiac surgery. The 
primary endpoint of this trial was a composite of cardiac death, non-fatal myocardial 
infarction and cardiac arrest. The group randomised to receive beta-blockers 
(Metoprolol) had a reduced incidence of the primary endpoint (5 .8% vs. 6.9%; 
p=0.0399), myocardial infarction (4.2% v 5.7%; p=0.0017), coronary 
revascularisation or new-onset atrial fibrillation. However there was an excess 
mortality demonstrated in the intervention group (3.1% v 2.3%; p=0.032) attributed 
to an increased incidence of ischaemic stroke (1% v 0.5%; p=0.0053). Commentators 
have attributed this to an increase in hypotension and bradycardia associated with 
beta-blocker administration. It has also been pointed out that although the use of 
beta-blocking drugs in the perioperative period has attractions, for every 15 
myocardial infarctions prevented by beta-blockade per 100 patients there would be 8 
excess deaths. 149 Unsurprisingly a subsequent meta-analysis echoes these results, 
however the vast majority of subjects included come from this trial. 150 At present, 
routine use of beta blockade in the perioperative period cannot be recommended. 
1.7.5 Neuraxial Blockade 
Neuraxial blockade, for example epidural or spinal anaesthesia and analgesia, has 
theoretical cardiorespiratory benefits in the perioperative period and for at least two 
decades there has been great interest in investigating its routine use to reduce 
complications after major thoraco-abdominal surgery. 151 
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In the last 15 years at least 6 meta-analyses exammmg perioperative neuraxial 
blockade have been conducted. 152-157 Benefits demonstrated include: superior 
analgesia when compared to patient controUed opioid analgesia, reduced 
perioperative myocardial infarction, acute kidney injury, venous thromboembolism 
and mortality. The meta-analysis published by Rodgers et al in the British Medical 
Journal in 2000 included 9559 patients from 141 trials and demonstrated a significant 
reduction in perioperative mortality (OR 0.7 95%CI 0.54-0.9;p=0.0006). 153 Despite 
meta-analytic data demonstrating a consistent signal that exposure to perioperative 
neuraxial blockade confers benefit; large RCTs have failed to demonstrate this. The 
large RCT of more than 1000 patients undergoing vascular and gastro-intestinal 
surgery conducted by Park et al suggested that epidural analgesia provided 
significantly better analgesia and reduced intensive care admission but did not 
significantly alter mortality, except in the vascular surgery subgroup. 158 Similarly, 
the "Multicentre Australian Study of Epidural Analgesia" (MASTER study) of 915 
patients did not demonstrate reduction in major morbidity or mortality after major 
abdominal surgery. 159 It is likely that these trials have all been underpowered and 
investigators in Canada attempted a multicentre pilot study to assess the feasibility of 
conducting a very large multicentre RCT of epidural analgesia in patients undergoing 
non-cardiac surgery. Participants in this trial experienced high crossover rates 
(26.5% of the epidural group and 9.8% of the intravenous analgesia group) and low 
recruitment rate. The authors concluded that for this reason a large multicentre RCT 
might not be a feasible study design to assess this intervention. 160 
1.7.6 Other Considerations 
Other factors may influence outcome after surgery: 
Ventilatory Management 
Futier et al recently published a study in the NEJM where 400 patients undergoing 
abdominal surgery who were at high risk of pulmonary complications were assigned 
to receive either lung protective or non-protective ventilation. The primary endpoint 
was a composite of major respiratory and non-respiratory complications within 7 
days of surgery. The primary endpoint was met by 10.5% of patients in the lung 
protective group v 27.5% of patients in the non-protective ventilation group (RR 0.4 
CI 0.24-0.68; P=O.OOl). Requirement for mechanical ventilation and length of 
hospital admission was also reduced in the lung protective group. 161 
Timing and Contextual Phenomena 
Other contextual phenomena may have a bearing on outcomes after high-risk 
surgery. AyEn et al recently examined 4.1 million inpatient surgical procedures over 
a 3 year period and demonstrated a "weekday" effect on 30 day mortality in patients 
undergoing surgery i.e. mortality was higher if patients were operated on a Friday 
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(odds ratio 1.44, 95% CI 1.39- 1.50) or a weekend (1.82, 95% CI 1.71-1.94) 
compared with Monday. 162 The authors speculated that organizational effects for 
example: increased use of locum and agency staff at weekends; reduced staffing 
levels and reduced access to senior clinician input at the weekend might explain 
these findings. 
1.8 Conclusion 
This chapter has considered the epidemiology of high-risk surgery in the UK and 
worldwide, methods of predicting patients at the highest risk of perioperative death 
and complications and strategies to improve outcomes in this group. Surgical science 
is increasing in complexity and being offered to an increasingly elderly and co-
morbid population. This presents challenges to those involved in delivering 
perioperative care. 
Regional and international differences in outcomes suggest that improvements in 
quality care can be made. Organisational factors, improved utilisation of critical care 
resources, perioperative haemodynamic therapy and choice of anaesthetic technique 
may have some influence on outcome. 
Improved and more consistent definitions of perioperative outcomes may help to 
assess these interventions. Use of functional testing, biomarkers and scoring systems 
may help to stratify risk in such patients and identify those most likely to benefit 
from these interventions. 
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Chapter 2: Thesis Aims 
2.1 Key Questions Arising from the OPTIMISE Trial Addressed by this Thesis 
The research undertaken in this thesis was to inform aspects of the OPTIMISE trial, a 
large multicentre trial of a goal directed haemodynamic therapy in patients 
undergoing high-risk surgery. 
Goal directed haemodynamic therapy is a complex intervention typically comprised 
of fluid therapy, inotropic therapy and invasive monitoring. It is usually, although not 
exclusively delivered in a critical care environment. This thesis will explore meta-
analysis, epidemiological investigations and the use of biomarkers of cardiac injury 
to further investigate whether these components could have individually affected the 
outcome of the OPTIMISE trial. These research questions are developed further in 
the next chapter. 
The research outlined in this thesis was in the context of the OPTIMISE trial and 
intended to inform interpretation its results and future studies. The OPTIMISE study 
itself is included to give context to this thesis, however should not be considered as 
the main body of the work. 
The questions addressed by this thesis were as follows: 
Could the choice of colloid used in the perioperative period or trial intervention be 
associated with harm or benefit? 
The OPTIMISE trial intervention required administration of intravenous colloid 
solution; however, the trial protocol did not specify a particular solution or product. 
During the trial period evidence appeared which suggested that use of Hydroxyethyl 
Starch (HES) solutions in critically ill patients was associated with increased 
mortality and acute kidney Injury 169·172 although it was not known if these harmful 
effects extend to its use in the perioperative period. A meta-analysis was therefore 
warranted to determine if there was increased risk of death or kidney injury 
associated with the perioperative use of HES solutions. 
A high proportion of patients recruited to the OPTIMISE trial were admitted to 
Critical Care following surgery. Is the use of Critical Care in itself associated with 
improved outcomes after surgery? 
Critical care beds have typically been necessary to deliver GDHT in surgical 
patients. Therefore a "snapshot" of critical care beds per capita and per surgical 
procedure in the UK was created. Several commentators have suggested that lack of 
access to critical care beds is a reason for variation in outcome after surgery. As 
discussed above, cardiac output guided treatment algorithms are now widely used to 
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optimise the dose and timing of intra-venous fluid and vasoactive drug therapies. 
However the systematic review by Grocott et al 139 has suggested that the treatment 
benefit may be more marginal than previously believed. Postoperative use of this 
technology is variable and there is evidence that patients undergoing high-risk 
surgery may not routinely be admitted to critical care for monitoring postoperatively 
in many institutions and whether this confers any benefit. In the light of the 
OPTIMISE trial, this was particularly relevant given intervention patients received 
individualised therapy during the post-operative period, which appeared to alter the 
patterns of fluid use between the groups. 
The enhanced monitoring and ability to deliver timely interventions available in 
critical care may explain the improved outcomes seen with GDHT rather than the 
intervention itself. Is Critical Care essential for optimal outcomes after high-risk 
surgery or can protocolised delivery of postoperative care achieve comparable or 
better outcomes outwith the Critical Care setting? 
To answer this question in the UK it was necessary to create a cohort of surgical 
patients admitted to ICU following surgery and use this to examine casemix, activity 
and outcome. Data on population, volume of surgery and critical care bed provision 
was then used to explore whether differences in outcome could be explained by rcu 
bed provision. 
Is GDHT associated with increased myocardial mJury as measured by 5111 
Generation Troponins? 
Concerns remain regarding the safety of GDHT in patients with or at risk of 
ischaemic heart disease 173 and its incidence in this group is high. 174 Five patients in 
the intervention group experienced serious adverse cardiac events within 24 hours of 
the end of the intervention period (two cases of tachycardia, two of myocardial 
infarction and one of arrhythmia) compared with none in the usual care group 
(p=0.062). At 30 days, the incidence of cardiovascular events was similar between 
the groups. Evidence of increase in myocardial injury associated with GDHT in the 
OPTIMISE trial was sought using 51h generation serum troponin measurement on 
samples taken at 0, 24 and 72 hours following the intervention. 
The remainder of this thesis sets out to address these questions in some detail. 
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Chapter 3: Optimisation of Peri-operative Cardiovascular Management to Improve 
Surgical Outcome: The OPTIMISE Trial 
3.1 Introduction 
As discussed in Chapter 1, improvements in the peri-operative care pathway may 
have a significant impact on patient outcomes. In particular perioperative GDHT and 
utilisation of Critical Care may reduce complications, hospital length of stay and 
improve outcomes. Clinical trials have suggested that these interventions may be 
fl' . . th d . . . 1 lJ7 121 126-128 131- 134 most e ~ectrve tn e group un ergomg gastromtestma surgery. · · · 
Over time, GDHT protocols have been refined with an aim of addressing key issues 
of safety and practicality, whilst remaining as effective as those used in earlier trials. 
131 However subsequent meta-analyses have demonstrated the converse of this i.e. 
reduced effectiveness over time. 163 The aim is to deliver perioperative GDHT in a 
fashion that maximises patient benefit and safety and minimises the requirement for 
additional resources, in particular the need to routinely admit patients to a critical 
care unit. If effective, this intervention could therefore be rapidly introduced into all 
NHS hospitals after a short period of training. Refinements to cardiac output guided 
treatment algorithms have improved the feasibility, safety and cost of this treatment 
through less invasive forms of monitoring and lower doses of inotropic therapy for 
shorter periods. Nonetheless, controversies regarding potential harm associated with 
fluid excess and myocardial injury and the need or otherwise to conduct this 
intervention in a critical care setting remain unresolved. The clinical effectiveness of 
this treatment approach remains unconfirmed and as a resu lt, there is widespread 
partial implementation into clinical practice. OPTIMISE was a large, multi-centre 
randomised controlled trial to evaluate the clinical effectiveness of a cardiac output 
guided baemodynamic therapy algorithm for the administration of intra-venous fluid 
and a low dose inotrope (dopexamine) in comparison with usual care in patients 
undergoing major gastrointestinal surgery. 
My Role in the OPTIMISE Trial 
The OPTIMISE trial was developed and designed by Professor Rupert Pearse at 
Queen Mary's University London and this included the intervention and analysis 
plan although local Principal Investigators (PI) were given the opportunity to 
contribute to this. I was principal investigator for OPTIMISE at the Royal Infirmary 
of Edinburgh site and as such was responsible for all aspects of the safety and 
delivery of the trial on this site. I obtained Research and Development approval for 
the trial in Edinburgh, was responsible for training of relevant staff to use the 
LIDCOrapid technology and for the safe storage and administration of the 
investigational medical product (IMP, Dopexamine) to trial patients. I was 
responsible for maintaining the trial documentation including Standard Operating 
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Procedures and Trial Amendments. I ensured accurate data collection for the trial 
intervention and that assessors were suitably blinded. I supervised a Clinical 
Research Facility nurse who assisted me in the running of this triaL By the 
conclusion of the OPTIMISE trial I recruited 108 patients to the trial and personally 
obtained consent and delivered the trial intervention to these patients. In addition I 
led the OPTIMISE biomarker sub-study, developed analysis plans and protocols and 
ensured that the samples were collected, processed and stored correctly. I organised 
transportation to Edinburgh of samples collected at other sites and developed the 
study protocol and analysis plan for the biomarker sub-studies. I was involved in the 
interpretation of the trial results, drafting of the manuscript and presenting trial 
results at international meetings. In this chapter I describe the trial design, conduct 
and results as the main work of the thesis is informed by the OPTIMISE trial. 
3.2 Methods 
Trial Design 
The OPTIMISE trial was a multi-centre, open label, randomised controlled trial to 
establish whether the use of minimally invasive cardiac output monitoring to guide 
protocolised administration of intra-venous fluid, combined with low dose 
dopexamine infusion would reduce the number of patients who experienced 
complications witbjn 30 days following major surgery involving the gastro-intestinal 
tract. 
Inclusion Criteria 
Adult patients undergoing major abdominal surgery involving the gastrointestinal 
tract expected to take longer than 90 minutes were eligible for recruitment provided 
they satisfied one of the following criteria: age 65 years and over OR Age 50-64 
plus, one or more of: non-elective surgery; acute or chronic renal impairment (serum 
creatinine > 130 !lmoJ/1); diabetes mellitus; presence of a risk factor for cardiac or 
respiratory disease. 
Exclusion criteria 
The exclusion criteria were: 
• Refusal of consent 
• Patients receiving palliative treatment only (likely to die within 30 days) 
• Acute myocardial ischaemia (within 30 days prior to randomisation) 
• Acute pulmonary oedema (within 7 days prior to randomisation) 
• Septic shock 
• Thrombocytopenia (platelet count <50 x 1 09/J) 
• Patients receiving Monoamine Oxidase Inhibitors (MAOis) 
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• Phaeochromocytoma 
• Severe left ventricular outlet obstruction e.g. due to hypertrophic obstructive 
cardiomyopathy or aortic stenosis 
• Known hypersensitivity to dopexamine hydrochloride or disodium edetate 
• Participating in another randomised trial 
• Pregnancy at time of enrolment 
• Failure to meet the inclusion criteria. 
• Trial interventions 
The trial intervention period commenced at the start of general anaesthesia and 
continued for six hours after surgery was completed (maximum total duration: 24 
hours). 
Peri-operative management (for all patients) 
Care was defined for all patients in order to avoid extremes of clinical practice or 
practice misalignment. All patients received standard measures to maintain 
oxygenation (Sp02 94% or greater), haemoglobin (8 g/dl or greater), core 
temperature (aim 37 °C) and heart rate (less than 100 bpm). 5% dextrose was 
administered at 1 ml kg-1 h-1 as maintenance fluid but an alternative maintenance 
fluid could be administered using the same rate at the discretion of the treating 
clinician. Additional fluid could also be administered at the discretion of the clinician 
guided by pulse rate, arterial pressure, urine output, core-peripheral temperature 
gradient, serum lactate and base excess. Mean arterial pressure was maintained 
between 60 and 100 mmHg using an alpha adrenoceptor agonist or vasodilators as 
required . The trial interventions commenced with induction of anaesthesia and 
continued until six hours after surgery ended. Post-operative analgesia could be 
provided by epidural infusion (bupivacaine and fentanyl) or intra-venous opioid 
infusion (morphine or fentanyl). Regular monitoring of plasma potassium and 
glucose levels was recommended. The intervention period could last a maximum of 
24 hours. 
Additional peri-operative management for the intervention group 
The trial intervention began at induction of general anaesthesia and continued for six 
hours following surgery. Cardiac output and stroke volume were measured using the 
LiDCOrapid system. This system uses uncalibrated arterial pulse waveform analysis. 
It was stipulated in the trial protocol that no more than 500ml of intra-venous fluid 
was to be administered prior to commencing cardiac output monitoring. In addition 
to the maintenance fluid and blood products described previously, patients received 
250ml fluid challenges with a colloid solution as required in order to achieve a 
maximal value of stroke volume. The type of co]]oid used in tbe trial intervention 
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was not stipulated in the trial protocol. The absence of fluid responsiveness was 
defined as the absence of a sustained rise in stroke volume of at least 10% for 20 
minutes or more (Figure 1 ). 
Patients in the intervention group also received dopexamine at a fixed rate of 0.5 
Jlg/kg/min, which was commenced after fluid replacement bas been initiated. The 
protocol recommended that the dose of dopexamine was reduced to 0.25 Jlg/kg/min 
if the heart rate increased to either greater than 120% of the baseline value or 
IOObpm (whichever was the greater) for more than 30 minutes despite adequate 
anaesthesia and analgesia. If, despite dose reduction, the heart rate did not decrease 
below tills level, the dopexamine infusion was discontinued completely. All other 
management decisions were taken at the discretion of clinical staff. 
Additional Peri-operative Management for the Control Group 
Patients in the control group were managed by clinical staff according to usual 
practice. Tills could include 250mJ fluid challenges with a colloid solution 
administered at the discretion of the cJinician guided by pulse rate, arterial pressure, 
urine output, core-peripheral temperature gradient, serum lactate and base excess. If 
a specific haemodynamic end-point for flu id challenges was to be used, it was 
suggested that the most appropriate would usually be a sustained rise in central 
venous pressure of at least 2 mmHg for 20 minutes or more. Cardiac output 
monitoring was not to be routinely used in the control group unless specifically 
requested by clinical staff. 
Randomisation and Procedures to Minimise Bias 
Randomisation was performed through a secure internet based data entry system. 
Participants were centrally allocated to treatment groups using a computer generated 
dynamic procedure (minimisation) with a random component. Participants were 
allocated with an 80% probability to the group that minimised between group 
differences in trial site, urgency of surgery and surgical procedure category among 
all participants recruited to the study. OPTIMISE was a pragmatic effectiveness trial 
of a treatment algorithm and it was not possible to conceal treatment allocation from 
research staff involved in delivery of the intervention. 
The possibility of bias was minimised by the following procedures: Patients were 
followed up for complications by a member of research staff who was unaware of 
trial group aJlocation; complications were then verified by the PI or designee at each 
site who was also unaware of trial group allocation; the principal investigator could 
nominate a senior clinician to assist with this task if he/she became aware of the trial 
group allocation; the decision to admit a trial participant to a critical care unit was 
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made by clinical staff and this decision was not to be affected by trial group 
allocation. 
Figure 1 Haemodynamic Management Protocol for Trial Intervention Group 
( Summary I 
General haemodynamic measures 
1. 5% dextrose at 1 mllk9'hr oc m ~ millintenmce fluid may be 
illidminisiered (using tM same rate of1mllltglhr) at tM discrdon of the treating 
dinician 
2. Transfuse blood to ~ran haemoglobin >8 glcl 
3.. Clinician rebins a!Sefttion to aqust thenpy if concerned about risks of 
hypovolaem~ or ftuid overload 
4.. Me.m arteri~ pressure 60-100 nmHg; Sp02 ~; core temper.d:ure 37"C; 
Administering fluid to a stroke volume end-point 
1. 250ml c:oUoid botuses to ~w a maximal Yolllue of stroke wtume( 
2. No~ than 500ml fluid to be given before c.vtf.ac output monitor is ntllched 
3.. Ruid challenges should not be continued in patients who Me not fluid 
responsiw in terms of a stroke volume in~se 
4.. Auid responsiwness is defined as a stroke volume increase ~10% 
5. tf stroke volwne ~ fl.riher fluid challenge(s) are incicated 
6.. Persistent stroke volume resoonsivl.!o~ suaaests continued fluid loss 
Dopexamine 
1. St~ dope-.umine infusion at fixed rate of 0.5 ~!Jimin after first c:oUoid fluid 
dullen~ 
2. HaM! dose if~ r.rte rises to the gl't'iltB of: (a) >120% of baseline value, o r 
(b} >100bpm foe more thm 30 minutes. 
3.. Stop dope:xamine if bchycard:ia persists 
What if blood or N fluid is required regardless of stroke volume? 
1. If blood ~cts or additional fluid challenges are required, then stroke volume 
sh ould stiD be monitored to identify any change in maximal stroke volume 
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Trial endpoints 
The primary effect estimate was the relative risk of pre-defined moderate or major 
post-operative complications (or death) at 30 days. 
Full definitions of post-operative complications were as follows: 
Myocardial ischaemia or infarction: Acute ECG changes with appropriate clinical 
findings and changes in cardiac troponins. 
Arrhythmia: ECG evidence of rhythm disturbance resulting in a fall in mean arterial 
pressure of greater than 20% and considered by clinical staff to be severe enough to 
require treatment (anti-arrhythmic agents, vasoactive agents, intra venous fluid, etc.). 
Cardiac or respiratory arrest: As per UK Resuscitation Council Guidelines. 
Limb or digital ischaemia: Sustained Joss of arterial pulse (as determined by 
palpation or Doppler) or obvious gangrene. 
Cardiogenic pulmonary oedema: Appropriate clinical history and examination 
with consistent chest radiograph. 
Pulmonary embolism: Computed tomography (CT) pulmonary angiogram with 
appropriate clinical history. 
Acute respiratory distress syndrome: According to consensus criteria: 
i) Suitable precipitating condition 
ii) Acute onset of diffuse bilateral pulmonary infiltrates on chest radiograph; 
iii) No evidence of cardiac failure or fluid overload (PAOP < 18 mmHg); 
iv) Either: 
Pa02:Fi02 < 40 kPa (Acute Lung Injury) 
Pa02:Fi02 < 27 kPa (Acute Respiratory Distress Syndrome). 
Gastro-intestinal bleed: Unambiguous clinjcaJ evidence or endoscopy showing 
blood in gastro-intestinal tract. 
Bowel infarction: Demonstrated at laparotomy. 
Anastomotic breakdown: Demonstrated at laparotomy or by contrast enhanced 
radiograph or CT scan. 
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Paralytic ileus: Persistent cJinical evidence of intestinal ileus and failure to tolerate 
enteral fluid or feed associated with valid cause. 
Acute kidney injury: A two-fold increase in serum creatinine or sustained oliguria 
of< 0.5 mJ kg·' hou{1 for twelve hours. 
Infection, source uncertain: Two more of the following associated with strong 
clinical suspicion of infection (sufficient to require intra-venous antibiotic therapy, 
etc.): 
(i) Core temperature <36C or >38C (ii) white cell count > 12 x 109 L·' or <4 x 109 L-1 
(iii) respiratory rate >20 breaths per minute or PaC02 < 4.5 kPa (iv) pulse rate >90 
bpm 
Multi-organ dysfunction syndrome: A life threatening but potentially reversible 
physiologic derangement involving failure of two or more organ systems not 
involved in the primary underlying disease process. 
Acute psychosis: Acute episode of severe confusion or personality change which 
may result in hallucinations or delusional beliefs in the absence of a pre-existing 
diagnosis, which may account for the clinical symptoms and signs. 
Urinary tract infection: A symptomatic urinary tract infection must meet at least 
one of the following criteria: 
(i) Patient has at least one of the following signs or symptoms with no other 
recognized cause: fever (>38C), urgency, frequency, dysuria, or supra-pubic 
tenderness and patient has a positive urine culture, that is, > 105 microorganisms per 
cm3 of urine with no more than two species of microorganisms. 
(ii) Patient has at least two of the following signs or symptoms with no other 
recognized cause: fever (>38C), urgency, frequency, dysuria, or supra-pubic 
tenderness and at least one of the following: 
a. Positive dipstick for leucocyte esterase and/or nitrate; 
b. Pyuria (urine specimen with >10 WBC mm.3) ; 
c. Organisms seen on Gram stain of unspun urine; 
d. At least two urine cultures with repeated isolation of the same uro-pathogen with 
> 102 colonies/ mL in non-voided specimens; 
e. > 105 colonies/mL of a single uro-pathogen in a patient being treated with an 
effective antimicrobial agent for a urinary tract infection; 
Michael Gillies Doctor of Medicine (2014) 59 
f. physician diagnosis of a urinary tract infection; 
g. physician institutes appropriate therapy for a urinary tract infection. 
Other infections of the urinary tract (kidney, ureter, bladder, urethra, etc.): 
Other infections of the urinary tract must meet at least one of the following criteria: 
(i) Patient has organisms isolated from culture of fluid (other than urine) or tissue 
from affected site. 
(ii) Patient has an abscess or other evidence of infection seen on direct examination, 
during a surgical operation, or during a histopathology examination. 
(iii) Patient has at least two of the following signs or symptoms with no other 
recognized cause: fever (>38C), localized pain, or localized tenderness at the 
involved site and at least one of the following: 
a. Purulent drainage from affected site; 
b. Organisms cultured from blood that are compatible with suspected site of 
infection; 
c. Radiographic evidence of infection, for example, abnormal ultrasound, computed 
tomography or magnetic resonance imaging; 
d. Physician diagnosis of infection of the kidney, ureter, bladder, urethra, or tissues 
surrounding the retroperitoneal or perinephric space; 
e. Physician institutes appropriate therapy for an infection of the kidney, ureter, 
bladder, urethra, or tissues surrounding the retroperitoneal or perinephric space. 
Surgical site infection (SSI) (superficial incisional): A superficial SSI must meet 
the following criteria: 
(i) Infection occurs within 30 days after the operative procedure and involves only 
skin and subcutaneous tissue of the incision and patient has at least one of the 
following: 
a. Purulent drainage from the superficial incision; 
b. Organisms isolated from an aseptically obtained culture of fluid or tissue from the 
superficial incision; 
c. At least one of the following signs or symptoms of infection: pain or tenderness, 
localized swelling, redness, or heat, and superficial incision is deliberately opened by 
surgeon, unless incision is culture-negative; 
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d. Diagnosis of superficial incisional SSI by the surgeon or attending physician. 
Surgical Site Infection (deep incisional): 
A deep incisionaJ SSI must meet the following criteria: 
i) Infection occurs within 30 days after the operative procedure if no implant is left in 
place or within I year if implant is in place and the infection appears to be related to 
the operative procedure and involves deep soft tissues (e.g., fascial and muscle 
layers) of the incision and patient has at least one of the following: 
a. Purulent drainage from the deep incision but not from the organ/space component 
of the surgical site; 
b. A deep incision spontaneously dehisces or is deliberately opened by a surgeon 
when the patient has at least one of the following signs or symptoms: fever (>38C) or 
localized pain or tenderness, unless incision is culture-negative; 
c. An abscess or other evidence of infection involving the deep incision is found on 
direct examination, during reoperation, or by histopathology or radiologic 
examination; 
d. Diagnosis of a deep incisional SSI by a surgeon or attending physician. 
An infection that involves both superficial and deep incision sites should be 
classified as a deep incisional SSI. 
Surgical Site Infection (organ/space) 
An organ/space SSI involves any part of the body, excluding the skin incision, fascia, 
or muscle layers, which is opened or manipulated during the operative procedure. 
Specific sites are assigned to organ/space SSI to further identify the location of the 
infection. An example is appendectomy with subsequent sub-diaphragmatic abscess, 
which would be reported as an organ/space SSI at the intra-abdominal specific site. 
An organ/space SSI must meet the following criteria: 
i) Infection occurs within 30 days after the operative procedure if no implant is left in 
place or within 1 year if implant is in place and the infection appears to be related to 
the operative procedure and infection involves any part of the body, excluding the 
skin incision, fasc ia, or muscle layers, that is opened or manipulated during the 
operative procedure and patient has at least one of the following: 
a. Purulent drainage from a drain that is placed through a stab wound into the 
organ/space; 
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b. Organisms isolated from an aseptically obtained culture of flu id or tissue in the 
organ! space; 
c. An abscess or other evidence of infection involving the organ/space that is found 
on direct examination, during reoperation, or by histopathology or radiologic 
examination; 
d. Diagnosis of an organ/space SSI by a surgeon or attending physician. 
Laboratory Confirmed Bloodstream Infection: Laboratory confirmed bloodstream 
infection must meet at least one of the following criteria: 
i) Patient has a recognized pathogen cultured from one or more blood cultures and 
the organism cultured from blood is not related to an infection at another site. 
ii) Patient has at least one of the following signs or symptoms: fever (>38°C), chills, 
or hypotension and at least one of the following: 
a. Common skin contaminant is cultured from two or more blood cultures drawn on 
separate occasions. 
b. Common skin contaminant is cultured from at least one blood culture from a 
patient with an intravascular line, and the physician institutes appropriate 
antimicrobial therapy. 
c. Positive antigen test on blood. 
Signs and symptoms and positive laboratory results are not to be related to an 
infection at another site. 
Nosocomial pneumonia Ventilator-associated pneumonia (i.e. pneumonia in persons 
who had a device to assist or control respiration continuously through a tracheostomy 
or by endotracheal intubation within the 48-hour period before the onset of infection) 
will be classified separately. Care will be taken to distinguish between tracheal 
colonization, upper respiratory tract infections and early onset pneumonia. 
Nosocomial pneumonia will be characterized as early or late onset i.e. before or after 
first 4 days of hospitalisation. Where repeated episodes of nosocomial pneumonia are 
suspected, a combination of new signs and symptoms and radiographic evidence or 
other diagnostic testing will be required to distinguish a new episode from a previous 
one. This category inc ludes venti lator-associated pneumonia (i.e. pneumonia in 
persons who had a device to assist or control respiration continuously through a 
tracheostomy or endotracheal tube), however care will be taken to distingu ish 
between tracheal colonization, upper respiratory tract infections and early onset 
pneumonia. 
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Nosocomial pneumonia must meet the following criteria: 
i) Two or more serial chest radiographs with at least one of the following: 
a. New or progressive and persistent infiltrate; 
b. Consolidation; 
c. Cavitation. 
And at least one of the following: 
a. Fever (>38°C) with no other recognized cause; 
b. Leukopenia (WCC<4 x 109 L-1) or leucocytosis (WCC> 12 x 109 L-1) 
c. For adults > 70 years old, altered mental status with no other recognised cause. 
And at least two of the following: 
a. New onset of purulent sputum or change in character of sputum, or increased 
respiratory secretions, or increased suctioning requirements 
b. New onset or worsening cough, or dyspnoea, or tachypnoea; 
c. Rales or bronchial breath sounds; 
d. Worsening gas exchange 
Post-operative haemorrhage: Overt blood loss requiring transfusion of two or more 
units of blood in two hours. 
Stroke: Clinical diagnosis, with confirmation by CT scan. 
Secondary outcomes were Post-Operative Morbidity Survey (POMS) defined 
morbidity on day seven; all cause mortality, infectious complications, critical care 
free days (number of days alive and not in critical care) at 30 days and all cause 
mortality at 180 days. The level of post-operative critical care was defined according 
to ICS "Levels of Care" definitions. 164 Patients were followed for 30 days by visit 
and using local computerised records whilst in hospital. All patients were contacted 
at 30 days, either by telephone for those who had left hospital or by visit for those 
who had not. Where necessary, investigators contacted community physicians or 
other hospitals by telephone and in writing for outstanding information describing 
the primary outcome. Mortality at 180 days was assessed through Office for National 
Statistics records. Data entry was performed through a secure internet site. 
Automated validation checks included plausibility ranges and cross checks between 
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data fields. Further manual data checks were performed both centrally and through 
source data verification during site visits. 
Statistical analysis 
A previous GDHT trial of 122 patients undertaken in 2005 and using similar trial 
endpoints showed a reduction of the primary endpoint from 68% in the usual care 
group to 41% in the intervention group. 13 1 A more conservative estimate in 
incidence of primary endpoint and absolute risk reduction were used for this trial . 
Assuming a type I error rate of 5%, 345 patients per group (690 total) were required 
to detect with 90% power a reduction in 30-day complications from 50% in the 
control group to 37.5% in the intervention group (absolute risk reduction 12.5%; 
relative risk reduction 25%). Allowing for a 3% one way crossover rate due to use of 
cardiac output monitoring in the usual care group, this was increased to 367 per 
group (734 total). A planned interim analysis was performed after the recruitment of 
376 patients. Predefined stopping guidelines permitted early termination of the trial 
for harm but not effectiveness. 
Analyses were performed according to an a priori statistical analysis plan including 
all patients on an intention to treat basis, regardless of protocol compliance. 
Categorical data were compared using Fisher's exact test. Differences in length of 
stay and critical care-free days were tested using the Wilcoxon rank-sum test. 
Kaplan-Meier curves were plotted for mortality up to 180 days following surgery. 
Adjustment for baseline data was made using a logistic regression model including 
age, gender, urgency of surgery, surgical procedure category, ASA grade, planned 
location following surgery, renal impairment, diabetes mellitus, risk factors for 
cardiac or respiratory disease and random effect of site. Baseline variables were 
selected for inclusion in the adjusted analysis according to anticipated relationship 
with outcome including all variables used in the minimisation algorithm. Results of 
primary and secondary outcomes were reported as relative risks (RR) with 95% 
confidence intervals (CI); results of the primary analysis were additionally reported 
as absolute risk reduction (ARR) with 95% CI. Results of the logistic regression 
model were reported as adjusted odds ratios (OR) with 95% CI with unadjusted OR 
for comparison. Pre-specified secondary analyses were a modified intention to treat 
analysis excluding patients who did not undergo surgery, a compliance-adjusted 
analysis in which patients who experienced protocol deviations were assumed to 
have the same outcome as if they had been assigned to the alternative treatment 
group, and scenario-based sensitivity analyses for missing primary outcomes (a best 
cases analysis assuming aJJ missing outcomes in the intervention group were 
favourable and all missing outcomes in the usual care group were unfavourable, and 
a worst case analysis assuming the reverse). Pre-specified sub-group analyses were 
performed by surgical procedure category, urgency of surgery and the first ten 
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patients recruited at each site compared with subsequent patients (sites recruiting 
fewer than ten patients were excluded from this analysis). Continuous variables are 
presented as mean (SD) where normally distributed or median (quartiles) where not. 
Categorical variables are presented as n (%). Analyses were performed using Stata 
SE version 10.1 . Significance was set at p<0.05 (two-tailed). 
3.3 Results 
734 patients were enrolled between June 2010 and November 2012~ 368 patients 
were allocated to the haemodynarnic intervention and 366 to usual care (Figure 2). 
Baseline characteristics were similar between the groups (Table 15). Most sub-
groups were well represented with the exception of emergency surgery (25 patients) 
and urological or gynaecological surgery involving the gut (nine patients). Patient 
care outside the trial intervention was also similar (Table 16), including admissions 
to critical care. Overall volumes of intra-venous fluid (colloid and crystalloid 
combined) administered during the intervention period were similar (intervention 
group 4190 ml vs. usual care 4024 ml) (Table 16). For usual care patients most of 
this fluid was administered during surgery whilst intervention group patients 
received similar volumes during and after surgery. Intervention group patients 
received more colloid and less crystalloid solution than usual care patients. Use of 
other vasopressor and inotropic agents (other than dopexamine) was similar between 
the groups. Protocol compliance was good with fewer than 10% of patients in each 
group experiencing a deviation from the allocated intervention (Table 17). This was 
achieved through the presence of trained investigators where necessary, to observe, 
advise or deliver the intervention. Investigator self-assessment of blinding also 
suggested a high rate of compliance with trial procedures (Table 18). 
36.6% (134 of 366) of patients in the intervention group and 43.4% (158 of 364) of 
usual care patients met the primary outcome. This difference was not statisticalJy 
significant (RR 0.84 [0.71-1.01], ARR 6.8% [- 0.3% to 13.9%]; p=0.07) (Table 19). 
Adjustment for baseline risk factors had little impact on the observed treatment effect 
(adjusted OR 0.73 [0.53-1.00]; p=0.05, unadjusted OR 0.75 [0.56-1.01]~ p=0.07). 
This was also the case for the modified intention to treat analysis in which three 
patients (all usual care) who did not undergo surgery were excluded (RR 0.84 [0.70-
1.00] ; p=0.059). In the pre-specified compliance-adjusted analysis conducted using 
estab.lished methodology, 165 the observed treatment effect was strengthened by 
assuming that 65 patients who experienced protocol deviations would have 
experienced the same outcome if they had been allocated to the alternative group 
(RR 0.80 [0.61-0.99]; p=0.037). Scenario based sensitivity analyses demonstrated 
that the very small number of patients with missing primary outcomes would have 
had a minimal influence on treatment effect (RR 0.84 [0.70-1.00] to 0.85 [0.71-
1.02]). There were no significant differences in POMS defined morbidity on day 7 or 
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m duration of hospital stay, critical care-free days, infectious complications or 
mortality at 30 days (Table 20). There was a non-significant reduction in mortality in 
the haemodynamk intervention group at 180 days (intervention group 28 deaths 
(7.7%) vs. usual care 42 deaths (11.6%), RR 0.66 [0.42-1.05] ; p=0.08) (Table 19, 
Figure 3). 
Pre-specified subgroup analyses included a comparison between the first ten recruits 
at each site (160 patients) with all other patients, the findings of which were 
consistent with an improvement in the primary outcome in the intervention group 
(RR 0.59 [0.41-0.84]; p=0.019) (Table 21). Following elective surgery, fewer 
patients in the intervention group met the primary outcome (RR 0.72 [0.52-0.99]) but 
outcomes were similar for patients fo1lowing emergency surgery (RR 1.24 [0.23 -
6.74]). The intervention was also associated with a reduction in the primary outcome 
measure in patients undergoing small bowel +1- pancreas surgery (RR 0.53 [0.28-
0.99]) but not in the other procedure subgroups. Five patients in the intervention 
group experienced serious adverse cardiac events within 24 hours of the end of the 
intervention period (two cases of tachycardia, two of myocardial infarction and one 
of arrhythmia) compared with none in the usual care group (p=0.062). At 30 days, 
the incidence of cardiovascular events was similar between the groups (Table 19). 
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Figure 2 CONSORT flow diagram 
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Urgency of surgery*t 
Elective 
Non-elective 
Baseline risk factors*=!= 
Renal impairment 
Diabetes mellitus 
Risk factors for cardiac or respiratory 
disease 
Planned surgical proceduret 
Upper gastrointestinal 
Lower gastrointestinal 
Small bowel+/- pancreas 







Planned location following surgery 
Critical care unit (level 3) 
Critical care unit (level 2) 





















































Table 16. ClinicaJ management of patients during intervention period. 
Data presented as mean (SO), median (IQR) or n (%). 
Four patients (one goal -directed haemodynamic therapy, th.ree usual care) who did not undergo surgery excluded. 
*Two patients (one in each group) missing data for anaesthetic technique 
!'Two patients (both usual care) missing data for flu ids during and after surgery; one patient (haemodynamic intervention) missing data 
for fluids post-surgery; one patient (haemodynamic intervention) missing data for in tra-venous fluid during surgery; one patient (usual 
care) missing data for intra-venous crystaJ.loid after surgery; one patient (haemodynamic intervention) missing data for b.lood products 
following surgery 
§Two patients (one haemodynamic intervention, one usual care) missing all data for vasopressor or inotrope agents; one patient (usual 
care) missing data for vasopressor or inotrope infusion 
Duration of surgery (minutes) 
Anaesthetic technique* 
General anaesthetic only 
General anaesthetic plus epidural 
Intravenous crysta lloid (ml)t 
During surgery 
During six hours following surgery 
Intravenous colloid (ml)t 
During surgery 
During six hours following surgery 
Blood products (ml)t 
During surgery 
During six hours following surgery 
Bolus vasopressor or inotrope agent used during 
intervention period§ 
Vasopressor or inotrope infusion (other than 
dopexamine) used during intervention period§ 
Actual location fo llowing s urgery 
Critical care unit (level 3) 
Critical ca re unit (level 2) 







































Table 17. Deviations from intervention guidance as pre-specified in protocol. 
Failure to administer dopexamine to a haemodynamic 
intervention group patient 
Administration of incorrect dose of dopexamine to 
intervention group patient without reason consistent with 
protocol: 
Lowest rate of dopexamine Jess than 0.5 J-ig/kg/min 
Highest rate of dopexamine greater than 0.5 J-ig/kg/min 
Dopexamine administered for <6 hours following surgery 
Failure to monitor cardiac output in intervention group 
patient 
Administration of dopexamine to a usual care group 
patient 
Use of cardiac output monitoring in a usual care group 
patient 
























*Data presented as n (%). One patient (usual care) randomized in error and four patients (one haemodynamic 
intervention, three usual care) who did not undergo surgery excluded. One patient (haemodynamic intervention) 
missing data for additional staff present. 
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Table 18 Additional staff present from investigating team during intervention period. 
Haemodynamic intervention Usual care 
(n=366} (n=362) 
During After During After 
surgery surgery surgery surgery 
Additional staff present 








Additional nurse & 
60 (16·4) 33 (9·0} 7 (1·9} 0 (0} 
doctor 
Role of additional staff 








54 (14·8) 36 (9·9) 8 (2·2} 
Delivered intervention 239 (65·3) 274 (74·9} 15 (4·1) 5 (1·4} 
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Figure 3 Kaplan-Meier survival curves by treatment allocation for l80 days 


























Number at risk 
Intervention 368 
Usual care 365 
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Table 19 Data describing primary outcome of moderate or severe compljcations or 
death within 30 days of surgery. 
Complications I death within 30 days 
Death 
Pulmonary embolism 
Myocardial ischaemia or infarc tion 
Arrhythmia 
Cardiac or respiratory arrest 
Limb or digital ischaemia 
Cardiogenic pulmonary oedema 







Acute kidney injury 
Infection, source uncertain 
Urinary tract infection 
Surgical site infection (superficial/deep 
incisional) 
Surgical site infection (organ/space) 
Laboratory-confirmed bloodstream infection 
Nosocomial pneumonia 
Post-operative haemorrhage 
Blinding of outcome assessment* 
Assessor was suitably blinded 
Assessor may have known allocation 
Assessor definitely knew allocationt 






























Usual care Relative risk 
(n=364) (95% Cl) 

























6 (1 .7) 
*Six patients (three haemodynamic intervention, three usual care) missing data for blinding of outcome 
assessment 
tlncludes three patients (two haemodynamic intervention, one usual care) who died within 30 days 
following surgery 
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p-vaJue 
0.07 
Table 20. Data describing secondary outcomes. 
Haemodynamic Usual care Relative risk 
intervention (95% CI) 
Death within 30 days 12 (3.3) 11 (3.0) 1.08 (0.48-
following surgery (n=366) (n=364) 2.43) 
Post-Operative Morbidity (n=275) (n=287) 
Survey* 182 (66.2) 195(67.9) 0.97 (0.87-
1.09) 
Infectious complications 87 (23.8) 108 (29.7) 0.80 (0.63-
within 30 days following (n=366) (n=364) 1.02) 
surgery 
Duration of post-operative 10 (7-14) 11 (7-17) 
hospital stay (n=359) (n=356) 
Survivors 10 (7-14) 11 (7-17) 
(n=343) (n=343) 
Non-survivors 7 (3-33) 16 (9-36) 
(n=l6) (n=13) 
Critical care free days 27 (26-29) 28 (25-29) 
within 30 days following (n=366) (n=364) 
surgery 
Death within 180 days 28 (7.7) 42 (11.6) 0.66 (0.42-
following surgery (n=363) (n=361) 1.05) 
Unadjusted odds ratio for 30-day mortality: 1.09 (0.48-2.45). Adjusted odds ratio for 30-day mortality: 
1.20 {0.51-2.82); p=0.68. 
Unadjusted odds ratio for 180-day mortality: 0.63 {0.39-1.04). Adjusted odds ratio for 180-day mortality: 
0.61 {0.36-1.04); p=0.071. 
Data presented as mean (SD), median (quartiles) or n {%). 
*For patients alive and in hospital on day 7 following start of surgery 









Table 21. Pre-specified sub-group analyses for primary outcome of comp.lications or 
death within 30 days of surgery. 
Haemodynamic Usual care Adjusted odds 
intervention ratio (95% Cl) 
Urgency of surgery 
Elective 127 (35.9) 152 (43.3) 0.72 (0.52-0.99) 
(n=354) (n=351) 




Upper gastrointestinal 39 (36.1 ) 47 (41.2) 0.83 (0.47-1.47) 
(n=108) (n=ll4) 
Lower gastrointestinal 56 (33.5) 62 (38.0) 0.82 (0.51-1.31) 
(n=l67) (n=l63) 
Small bowel +1- pancreas 37 (43.0) 47 (56.6) 0.53 (0.28-0.99) 
(n=86) (n=83) 
Urological or 2 (40.0) 2 (50.0) 0.62 (0.04-
gynaecological surgery (n=5) (n=4) 10.20) 
involving gut 
Timing of recruitment* 
Early (first 10 patients per 33 (42.3) 28 (34.1) 1.51 (0.75-3.01) 
site) (n=78) (n=82) 
Late (al l subsequent 100 (35.0) 129 (46.7) 0.59 (0.41-0.84) 
patients) (n=286) (n=276) 
Data presented as n (%). p-values represent tests for interaction. 
*Eight patients (two haemodynamic intervention, six usual care) excluded from two sites, which recruited 
fewer than 10 patients 







The findings of this large multi -centre effectiveness trial suggest that widespread 
implementation of a peri-operative haemodynamic therapy algorithm into routine 
clinical practice is feasible, although in 60-70% of cases the intervention was 
delivered by the research staff. The intervention was not associated with a significant 
reduction in 30-day complication rates when compared with usual cJinical care. 
There were no differences in the secondary outcomes of POMS defined morbidity at 
day 7, hospital stay or mortality at 30 days. However, a pre-specified compliance 
adjusted analysis and a comparison of the first ten patients recruited at each site with 
those recruited subsequently, suggest a stronger treatment effect and consequently 
that the haemodynami.c algorithm was associated with a reduction in complications. 
There was a decrease in complications amongst the large sub-group of patients 
undergoing elective surgery but not in the smaller emergency surgery sub-group. 
There was a non-significant reduction in mortality at 180 days for intervention group 
patients. 
The trial was designed to address important methodological limitations associated 
with smaller trials of this complex intervention and the measures taken to minimise 
bias are more robust than any previous studies. 166•168 The large patient sample 
aiJowed us to compare the intervention to usual clinical care, avoiding problems 
associated with an alternative 'control' treatment algorithm, which might not reflect 
standard practice. 168 The primary outcome measure was a composite of post-
operative complications and mortality at 30 days. Bias was controlled by assessing 
and grading this outcome according to predefined criteria. There is a plausible 
biological mechanism for a reduction in the incidence of some of the complications 
included in the primary outcome measure, for example infection. Concerns however 
remain that the intervention itself may have caused harm to some groups, especially 
as 3.9% of patients in the intervention group suffered a cardiovascular serious 
adverse event (SAE). Harm related to myocardial injury is the most important 
adverse effect of haemodynamic therapy algorithms and this might explain the 
smaller than predicted reduction in the primary outcome, although the incidence of 
cardiovascular events was similar between the groups at 30 days. The event rate in 
the usual care arm was slightly lower than expected and group crossover in terms of 
cardiac output monitoring in the usual care group was more frequent than predicted. 
It seems likely that these factors reduced the power of the trial , perhaps resulting in a 
failure to achieve statistical significance. The trial was powered for large absolute 
and relative risk reductions and smaller differences would still be clinically important 
but need a larger trial to demonstrate. 95% CI suggest a high probability of benefit 
and there is a chance of type 2 error in this trial. 
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Although it is not possible to blind staff administering complex interventions, our 
data suggest excellent compliance with blinding procedures for patient follow-up. 
In keeping with the pragmatic nature of the trial, no attempt was made to standardise 
the choice of colloid in either group. As the trial was nearing completion, new 
evidence was published suggesting an increased incidence of acute kidney injury in 
critically ill patients receiving starch based colloid solutions. 169· 170 Whilst individual 
patient data describing the use of starches was not collected a post hoc survey of 
investigators suggests few patients received this fluid with no differences in use 
between the treatment groups. 
A number of haemodynamic therapy algorithms have been published representing 
options in terms of haemodynamic end-points, inotropic agents and cardiac output 
monitoring. 139 An algorithm was used that was suited to the care of patients during 
and after major gastrointestinal surgery, that was supported by solid clinical and 
mechanistic evidence with a good cardiovascular safety profile. 12u 25•131.139 The 
algorithm was developed to maximise clinical effectiveness whilst being readily 
implemented into clinical practice. It specifically aimed to be deliverable in the 
operating room and post-anaesthetic care unit by both medical and nursing staff 
ensuring that critical care admission was not necessary for compliance, although in 
the trial itself a high proportion of patients were in fact admitted to a critical care 
unit. A cardiac output monitoring technology, which can be used both during and 
after surgery (in awake, extubated patients) was used, which is accurate and has been 
in widespread clinical use for more than ten years. The algorithm was readily 
implemented in clinical practice with high levels of protocol compliance and few 
safety concerns. Additional staff from the investigating team were often present and 
although this would not necessarily be required in clinical practice, in the setting of a 
clinical trial the effect of this on outcome is unknown. The CONSORT guideline 
extension published in 2008 acknowledges this as an issue in non-pharmacologic 
trials. 171 An observed learning effect is not uncommon for complex interventions 
and the analysis with the first 10 patients excluded from each site suggests that this 
effect might have been present. The high levels of compliance observed with this 
trial intervention contrast with the findings of a previous large trial where patients 
were randomised to receive a pulmonary artery catheter. 129 In this previous trial, no 
attempts were made either to standardise patient care or to monitor compliance with 
recommended treatment goals. The additional haemodynamic monitoring was not 
linked to any apparent changes in treatment and consequently clinical outcomes were 
unaffected. It should also be noted that a high proportion of patients (approximately 
75%) were treated in an ICU (level 3) setting in both arms of the study. 
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Figure 5. Tirrung of fluid administered 















Interestingly the overall volumes of intra-venous flu id administered were similar 
between the groups despite a clear difference in the approach to fluid dosing. 
Patterns of fluid administration are described in more detail in figures 2a. and 2b. 
During surgery the intervention group received less fluid whereas after surgery, 
continued active haemodynarnic management resulted in administration of greater 
volumes. This finding is interesting and suggests that timing of fluid may be 
important as well as type and volume. 
3.5 Conclusions 
The trial findings require careful interpretation but appear consistent with those of a 
recent Cochrane review of published randomised trials. This analysis suggested that 
fewer patients receiving cardiac output guided haemodynarnic therapy develop 
complications after surgery (Intervention 275/960 [28.6%] vs. Controls 350/881 
[39.7%]; RR 0.68 [0.58-0.80]) with a similar effect size to that identified in the 
current trial. 139In keeping with the OPTIMISE findings, these results were sensitive 
to analytical technique suggesting some uncertainty regarding the benefits of this 
treatment approach. Whilst there is evidence of international differences in the peri-
operative use of cardiac output monitoring, 7 treatment algorithms informed by such 
technology are in widespread use and are strongly promoted in at least the UK. All 
patients undergoing major gastro-intestinal surgery require some form of fluid 
therapy and the majority also require vasoactive drug therapy. Whilst there was no 
significant reduction in 30-day complication rates, findings of pre-specified 
secondary and subgroup analyses and the non-significant reduction in mortality at 
180 days were all consistent with a beneficial effect of the intervention. A larger 
clinical trial would be required to resolve this. 
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Chapter 4. Is Perioperative Use of i.v. 6% Hydroxyethel Starch Solution Associated 
with Increased Postoperative Death or Acute Kidney Injury: A Systematic Review and 
Meta-analysis 
4.1 Introduction 
There is great interest in the optimal approach to intra-venous fluid therapy in the 
peri-operative period, which may have important effects on patient outcome. 175 The 
choice of intra-venous fluid solution is a central aspect of fluid therapy but the 
evidence base informing this decision is limited with wide international variations in 
practice. 176 Hydroxyethyl starch (HES) solutions which are derived from maize or 
potato starch are commonly used for intravenous fluid therapy. Modern starches are 
typically presented in a concentration of 6%, molecular weights (MW) of 130-200 
kDa and a molecular substitution ratio of 0.4 or 0.42 (tetrastaches). Older starch 
solutions have higher substitution ratios e.g. 0.5 (pentastarch) or 0.7 (hetastarch); 
some of these solutions are still commercially available. 177 The findings of two 
recent large randomised trials have suggested a sma11 but important increase in the 
incidence of acute kidney injury and mortality associated with the use of HES 
solutions in critically ill patients. 169•170 Potential mechanisms for starch mediated 
kidney injury are unclear but may be associated with more concentrated solutions 
(e.g. 10% HES) as well as molecules with high MW and greater degree of 
substitution. 177' 179 Concerns have also been raised regarding the effects of HES on 
coagulation profile. These solutions have since been withdrawn from use in the 
critically ill. 180 
However, the generalisability of these findings to other patients groups is uncertain 
and use of HES for intra-venous volume replacement continues in cardiac and non-
cardiac surgical patients. There is a paucity of quality data regarding the safety of 
starch solutions in the surgical population. To compound matters several studies 
investigating the use of HES in surgical patients conducted by Joachim Boldt have 
been retracted following allegations of scientific misconduct. 181 At least five meta-
analyses on the safety of starch have been published in the last three years. 182' 186 The 
majority of these reviews have focused on the use of starch in critically ill, septic or 
acutely unwell adults. 182•184 Three of these studies have considered the safety of 
starch in other groups. The extensive systematic review and meta-analysis conducted 
by Dart et al included a non-sepsis subgroup largely (but not exclusively) composed 
of surgical trials. 182 Two further reviews and meta-analyses focus on the use of 
starch primarily in surgical patients, 185•186 but these are l imited because they only 
evaluate the effects of tetrastarch, in some cases in comparison to other starch 
solutions. These reviews also include a heterogeneous group of studies including 
those undertaken in trauma, burns, paediatric and transplant surgery. A systematic 
review and meta-analysis on the effect of all 6% HES solutions compared with non-
starch solutions in clinical use on mortaEty and acute kidney injury exclusively in the 
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adult surgical population was undertaken. This work was undertaken with 
collaborators, and is now published. 187 
4.2 Methods 
Search Strategy 
Ovid MedJine (1946-present), Embase, Cinhal and Cochrane Database of Systematic 
Reviews were searched for suitable studies using the following search strategy: 
Starch.mp or starch/ OR Hetastarcb.mp or hetastarch/ OR Voluven.mp OR 
Volulyte.mp OR Haes-stedl.mp OR Hespan.mp OR Tetraspan.mp AND Surgery.mp 
or General Surgery/. 
Search results were limited to randomised controlled trials of adult subjects. Non-
English language papers were included. The bibliographies of evaluable studies and 
other selected papers were hand searched. Experts were contacted to ascertain if they 
were aware of any other studies not identified by our search strategy, namely Prof. 
M. Mythen (MM), Prof. Michael Sander (MS) and Dr. M. Hamilton (MH). Search 
strategy and analysis were carried out according to the "Preferred Reporting Items 
for Systematic Review and Meta-analysis" (PRJSMA) statement 2009. 188 
The literature search was conducted independently by two collaborators. The results 
were reviewed and RP assisted with resolution of disparities in the literature search. 
The final list of papers was further reviewed and evaluated independently by two 
collaborators and disagreements adjudicated by me. The data was then extracted 
from the selected studies and analysed as described below. 
Study Selection Criteria 
Randomised controlled trials (RCT) in surgical patients were included where hospital 
mortality, requirement for post-operative renal replacement therapy (RRT) or author 
defined post-operative acute kidney injury (AKI) were reported. Trials comparing 
peri-operative administration of 6% HES of any MW or substitution ratio with any 
non-starch fluid were included, with the exception of trials where comparator fluids 
were experimental haemoglobin based flu ids (MPOX4 and HBOC21) and hypertonic 
saline which are not in routine use in surgical patients. Trials in subjects undergoing 
all types of surgery were considered with the exception of neurosurgery, 
transplantation, burns or obstetric surgery. Studies where Joachim Boldt was a 
named author were also excluded. Studies were screened for methodological quality 
using the Jadad Score, an established method of assessing methodological quality of 
studies to be included in meta-analysis. 189 Assessment was made of the 
appropriateness of randomisation, blinding and whether patient withdrawal 
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information was provided. The maximum score attributable was five. Only studies 
with a Jadad score of 3 or greater were included. Disagreements on studies to be 
included in the final analysis were resolved by consensus between MG, RP and the 
expert collaborators (MM, MH, MS), 
Data Extraction 
Data extracted for each eligible study included: author; year of publication; surgical 
group studied; number of subjects; starch used; comparator fluid used; primary and 
other study outcomes; commercial support; hospital mortality; incidence of post-
operative RRT; incidence of author defined AKI (where reported). 
Outcomes 
Primary outcomes studied were hospital mortality and post-operative requirement for 
RRT. Secondary outcome was the incidence of author-defined post-operative AKI. If 
data on mortality was not reported, data on AKI or RRT was used; conversely if data 
on mortality only was available then this was used. It was decided a priori that a 
subgroup analysis would be performed on patients undergoing cardiac surgery and 
patients receiving 6% HES. 
Statistical Analysis 
Statistical analysis was carried out using Review Manager (RevMan) v5.2. RevMan 
is the software used for preparing and maintaining Cochrane Reviews and forms part 
of the Cochrane Information Management System. Between-study statistical 
heterogeneity was assessed by "l test and P test; values of the index of 25, 50, and 
75% indicated the presence of low, moderate, and high between-trial heterogeneity, 
respectively. A p-vaJue of 0.1 was considered to denote statistical significance of 
heterogeneity. Estimation of potential publication bias used the funnel plot method 
for any of the outcomes, either primary or secondary. Dichotomous outcomes were 
expressed as a difference of proportions (risk difference, RD). For all analyses 
performed, if no significant heterogeneity was noted, fixed effect model (FEM) 
analysis using the Mantel-Haenszel (M-H) method was used; otherwise, results of 
the random-effects model (REM) analysis using the DerSimonian-Laird method were 
presented. 
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4.3 Results 
Study Selection 
The process for literature searching and study selection is outlined in Figure 6. 456 
non-duplicate citations were screened of which 34 studies underwent full scoring and 
data extraction. However only 19 trials were suitable for inclusion in the meta-
analysis, including a total of 1567 subjects. 179•190·206 
Study Quality 
A funnel plot for selected studies did not reveal evidence of publication bias (Figure 
7). Funnel plots are scatterplots of study size plotted against treatment effect and are 
a useful means of detecting publication bias in studies selected for meta-analysis. It 
assumes that larger studies will be near the mean and smaller studies will exhibit 
more variation. A "nonnal" funnel plot looks like a symmetrical inverted funnel. 207 
Study heterogeneity can be estimated using the Chi-squared test to produce the P 
statistic. In brief, this tests the consistency of confidence intervals between study 
results; if this is poor then there is a high chance of heterogeneity between studies. P 
statistic was 0% for the primary outcome and therefore did not suggest evidence of 
between study heterogeneity. Event rates of death, requirement for RRT and new 
author defined AKI in selected studies were low. 
Characteristics of Included Studies 
The characteristics of included studies are summarised in Table 22. Two trials were 
multicentre, the remainder single centre trials. In ten studies the subjects were 
undergoing cardiac surgery; two studies were of patients undergoing major vascular 
surgery and one a mixture of cardiac and major vascular surgery. The study 
undertaken by Gondos was in a mixed group of surgical patients including those 
undergoing cardiac surgery. 194 Two trials used HES 450/0.7 and one HES 400/0.7; 
the remainder used molecular sizes of 200kDa or less. Comparators included 
crystalloid solutions, gelatin solutions and albumin. In seven studies there was a 
commercial sponsor. Funnel plot of studies used in the hospital mortahty analysis 
showed no evidence of publication bias (Figure 7). Studies excluded after full 
scoring and data extraction were conducted are summarised in (Table 23) in six of 
these studies hospital mortality, incidence of RRT or AKI was not reported. 208-213 
The remainder were excJuded because the comparator fluid was not valid, 208•21 4-220 
or because the study population underwent transplant surgery. 221 
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Figure 6 Preferred reporting items for systematic reviews and meta-analyses 
(PRISMA) flow diagram detailing search strategy and identification of studies used 
in data synthesis. 
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Table 22 Characteristics of included studies. 
Jadad Reports Reports Reports Author Defined 
Score Mortality RRT AKI AKI 
Study Design Type of Surgery n Starch Comparator Commercial Support 
Alavi2012 RCT Cardiac 92 6% HES 130/0.4 4% gelatin, RL 3 Yes No No - Not stated 
6% HES-200/0.5 Yes No No -
6% HES-200/0.62 
Dehne 2001 RCT ENT 60 6% HES-450/0.7 RL 4 Fresenius 
Diehl 1982 RCT Cardiac 60 6% HES-450/0.7 5% Albumin 3 Yes No Yes SCr >l.Smg dr Not stated 
Balanced 4 Yes No No -
Peldheiser 2013 RCT Gynaecological 50 6% HES 130/0.4 Crystalloid Fresenius-Kabi 
4 Yes Yes Yes Rise in SCr from 
Multicentre baseline of 
Godet 2008 RCT Vascular 65 6% HES 130/0.4 3% Gelatin >0.5mg dr 1 Fresenius-Kabi 
Multicemre RL, 4% Gelatin, 3 Yes No No -
Gondos 2010 RCT Mixed 200 6% HES 130/0.4 5% Albumin Fresenius-Kabi 
Guo 2003 RCT Gynaeco1o!!ical 42 6% HES-200/0.5 RL 3 Yes Yes No - Not stated 
Hecht-Dolnik 4 Yes No No -
2009 RCT Cardiac 156 6% Hetastarch 5% Albumin None 
Hung 20 12 RCT Vascular 84 6% HES 130/0A RL 4 Yes Yes Yes Not specified Edwards 
6% HES 120/0.7 Yes No No -
Kuitunen 2004 RCT Cardiac 45 6% HES 400/0.7 4% Albumin 4 Not stated 
Lee 20ll RCT Cardiac 106 6% HES 130/0A RL 3 No Yes Yes AKIN Criteria None I 
6% HES 200/0.6 Yes Yes No -
Mahmood 2009 RCT Vascular 62 6% HES 130/0.4 4% Gelatin 4 Freseni us-Kabi 
Marik 1997 RCT Vascular 30 6% Hetastarch RL 4 Yes No No - Not stated 
Plasma protein 3 Yes No No -
Munsch 1988 RCT Cardiac 40 6% HES-450/0.7 fraction (PPF) Not stated 
Ooi 2009 RCT Cardiac 90 6% HES I 30/0A 4% Gelatin 4 Yes Yes Yes Not specified Not stated 
Sirvinskas 2007 RCT Cardiac 80 NaCI 0.72%/6% HES RL 3 Yes No No - Not stated 
Van der Linden 3 Yes No No -
2004 RCT Cardiac 6% HES-200/0.5 3.5% Gelatin Not stated 
Vander Linden 6% HES 130/0.4 Yes No No -
2005 RCT Cardiac 132 (Voluven) 3% Gelatin 3 Not stated 
Cardiac or Major 4% Gelatin, NaCJ 4 Yes No No -
Verheij 2006 RCT Vascular 67 6% HES 200/0.5 0.9% Braun 
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Table 23 Articles scored but not included in data synthesis. 
*HES: hydroxyl-ethyl starch; AKI: acute kidney injury; RRT: renal replacement 
therapy; HBOC-21 and MP4-0X are artificial haemoglobin solutions 
Paper n Reason Excluded 
Ando 2008 21 Jadad Score <3; Incidence of hospital mortality, RRT and 
AKI not reported. 
Belcher 1 984 73 Jadad Score <3 ; Incidence of hospital mortality, RRT and 
AKI not reported. 
Challand 2012 179 Control group received HES solution 
Harten 2008 29 Incidence of hospital mortality, RRT and AKI not reported. 
Honkonen 2009 49 Comparator hypertonic saline. 
Kaspar 1996 l3 Comparator HBOC-21 
Magder 2010 237 Control group given HES solution 
Mukhtar 2009 40 Population studied liver transplant surgery 
Olofsson 2011 189 Comparator MP4-0X 
Senagore 2009 64 Incidence of hospital mortality, RRT and AKI not reported. 
Shahbazi 20 II 70 Incidence of hospital mortality, RRT and AKI not reported. 
Sirieix 1999 64 Control group given RES solution 
Standi 1998 12 Comparator HBOC-21 
Tiryakioglu 140 Jadad Score <3; Incidence of hospital mortality, RRT and 
2008 AKI not reported. 
Van Der Linden 274 Comparator MP4-0X 
2011 
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Primary Outcomes 
Hospital Mortality 
Hospital mortality was available in eighteen of the nineteen included RCTs, a total of 
1461 patients. Of the 685 patients receiving HES, 19 (2.8%) died and of 776 patients 
receiving comparator fluid, 46 (5.9%) died. There were no deaths in twelve of the 
eighteen included studies. There was no difference .in mortaUty between compared 
arms (p=0.91, P=O%; FEM: RD 0.00, 95% CI -0.02, 0.02). Subgroup analysis of 
studies of 872 cardiac surgery patients from 10 studies also did not demonstrate any 
difference (p=l.O, f=O%; FEM: RD 0.00, 95% CI -0.02-0.01) (FigureS). 
Secondary Outcomes 
Incidence of Author Defined AKI 
Data on post-operative incidence of author defined AKI was available in five of the 
nineteen trials included, a total of 401 patients. Of 204 patients receiving HES, 11 
(5.4%) developed author-defined AKI and in 197 patients receiving comparator 
fluid, 7 (3.6%) developed author-defined AKI. In two studies no patient developed 
author-defined AKI. No difference in incidence of author-defined AKI was observed 
between compared arms (p=0.34, P=O%; FEM: RD 0.02, 95% CI -0.02, 0.06). Two 
of these studies (n= 196) were undertaken in cardiac surgery patients. No difference 
was observed in author defined AKl between arms (p=0.56, P=O%; FEM: RD 0.01, 
95% CI -0.02, 0.04) (Figure 9). 
Requirement for Post-operative Renal Replacement Therapy (RRT) 
Data on new requirement for postoperative RRT was available in six of the nineteen 
included RCTs, a total of 445 patients. Of 233 patients receiving HES, 4 developed a 
new requirement for postoperative RRT (1.7%) and of the 212 patients receiving 
comparator fluid, 4 (1.9%) developed new requirement for postoperative RRT. There 
were no instances of new requirement for postoperative RRT in two of these studies. 
No difference in incidence of new requirement for postoperative RRT was observed 
between compared arms (p=0.62, 12=0%; FEM: RD -0.01, 95% CI -0.04, 0.02) 
(Figure 1 0) 
Studies Involving Tetrastach Only 
Nine studies (n=856) compared tetrastarch (substitution ratio of 0.4 or 0.42) with 
other non-starch fluids. Analysis of these studies did not detect any difference in 
either mortality (n=750, p=0.83, 12=0%; FEM: RD 0.00, 95% CI -0.04-0.04) or new 
requirement for RRT (n=382, p=0.73, 12=0%; FEM: RD -0.01 , 95% CI -0.04-0.03) 
(Figure 11 ). 
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Figure 8 Forest plot of hospital mortality 
HES Control 
Events Total Events Total 
0 32 0 60 
Diehl 1982 0 33 0 27 
Hecht-Dolnik 2009 0 78 0 78 
Kuitunen 2004 0 30 0 15 
Munsch 1988 0 20 0 20 
Ooi 2009 0 45 0 45 
Sirvlnskas 2007 0 40 0 40 
Van der linden 2004 0 55 0 55 
van der Linden 2005 0 64 68 
Vemeij2006 0 17 2 50 
Subtotal (95% Cl) 414 458 
Total events 0 3 
Heterogeneity: Chi' = 1.12, df " 9 (P = 1 .00); I' = 0% 
Test for overall effect: Z = 0.58 (P = 0.56) 
1.1.2 Non-Cardiac/Mixed Surgery 
Dehne 2001 Mar 0 45 0 15 
Feldheiser 2013 1 26 0 24 
Godet2008 2 32 2 33 
Gondos 2010 15 50 38 150 
Guo2003 0 20 0 22 
Hung 2012 0 41 0 39 
Mahmood 2009 1 42 3 20 
Marik 1997 0 15 0 15 
Subtotal (95,-. Cl) 271 318 
Total events 19 43 
Heterogeneity: Chl2 = 3.27, df = 7 (P = 0.86); 1• = 0% 
Test for overall effect: z = 0.16 (P = 0.87) 
Total (95,-. Cl) 685 776 
Total events 19 46 
Heterogeneity: Chi2 = 4.33, df = 17 (P = 1.00); 12 = 0% 
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Figure 9 Forest plot of acute kidney injury. 
HES Control Risk Difference 
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Heterogeneity: Chi2 = 0.33, df = 1 (P = 0.56); 12 = 0% 
Test for overall effect: Z = 0.58 (P = 0.56) 
1.3.2 Non-cardiac/mixed Surgery 
Diehl1982 2 33 0 
Godet2008 8 32 7 
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Figure 10 Forest plot of renal replacement therapy. 
HES Control 
Events Total Events Total Wei ht 
Risk Difference 
M·H Fixed 95% Cl 
1 53 0 53 24.3% 0.02 (-0.03. 0.07] 
Ooi 2009 
Subtotal (95% Cl) 
0 45 0 45 20.6% 0.00 (-0.04. 0.04] 
98 98 44.8% 0.01 [-0.02, 0.04) 
Total events 0 
Heterogeneity: Chi2 = 0.33, df = 1 (P = 0.56); 12 = 0% 
Test for overall effect: Z = 0.58 (P = 0.56) 
1.2.2 Non-cardiac/Mixed Surgery 
Godet2008 0 32 1 33 
Guo 2003 0 20 0 22 
Hung 2012 1 41 0 39 
Mahmood 2009 2 42 3 20 
Subtotal (95% Cl) 135 114 
Total events 3 4 
Heterogeneity: Chl2 = 3.13, df = 3 (P = 0.37); I'· = 4% 
Test for overall effect: Z = 0.87 (P = 0.38) 
14.9% -0.03 (-0.11 , 0.05) 
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55.2% -0.02 [-0.08, 0.03) 
Total (95% Cl) 233 212 100.0% -0.01 (-0.04, 0.02) 
Total events 4 4 
Heterogeneity: Chi2 = 3.69, df = 5 (P = 0.60); 12 = 0% 
Test for overall effect: Z = 0.49 (P = 0.62) 
Test for subQroup differences: Chi2 = 1.10, df = 1 (P = 0.30), 12 = 8.8% 
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Figure 11 Forest plot of mortality of trials involving tetrastarch only. 
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Hung 2012 0 41 0 39 11.6% 0.00 (-0.05, 0.05) 
Mahmood 2009 1 21 3 20 5.9% -0.10 [-0.28. 0.08) 
Ooi2009 0 45 0 45 13.0% 0.00 [-0.04, 0.04) 
van der Unden 2005 0 64 68 19.1% -0.01 (-0.06, 0.03) 
Total (95% Cl) 311 439 100.0% 0.00 (-0.03, 0.04] 
Total events 19 44 
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4.4 Discussion 
The principal finding of this systematic review and meta-analysis was that there was 
no difference in hospital mortality associated with the use of 6% HES solution in the 
treatment of patients undergoing surgery. Sirrlilarly, there were no differences in the 
secondary outcomes of acute kidney injury and the use of renal replacement therapy. 
These findings were consistent in sub-group analyses of patients undergoing cardiac 
and non-cardiac surgery and in patients receiving tetrastarch only. 
In total 19 studies with less than 1600 pruticipants were suitable for inclusion in this 
meta-analysis. Seven of the included studies were commercially sponsored, raising 
the possibility of publication bias although we found no evidence of this. Despite 
widespread use for more than three decades, studies comparing peri-operative use of 
HES with other intra-venous fluids are small, largely single centre and vulnerable to 
bias. The most likely cause of RES-associated harm (and hence increased mortality) 
in the critically ill is causation or exacerbation of kidney injury. However, data 
describing kidney-associated harm are not well reported in surgical studies. Few 
studies consistently report the requirement for renal replacement therapy or acute 
kidney injury using internationall y defined criteria (e.g. Acute Kidney Injury 
Network (AK.lN) or RIFLE Classification 222) and in those that did , patients may not 
have been systematically followed up for these outcomes. All studies reporting post-
operative RRT describe either no difference or increased use of RRT in the HES 
group; however this tendency towards increased use of RRT in the HES group was 
not statistically significant. The incidence of death, use of RRT and AKI is higher in 
the critically ill than in the surgical population and it is therefore possible that the 
low event rates for both death and acute kidney injury in incJuded studies resulted in 
insufficient statistical power to detect a difference in these outcomes. It remains 
possible that HES solutions are associated with either undetected harm or benefit in 
the surgical popula6on. We believe thi s approach offers significant advantages over 
previously published work investigating the effects of starch solutions in surgical 
patients. The non-sepsis subgroup of the meta-analysis undertaken by Dart et al 
included studies by Boldt, and those enrolling trauma, paediatric and renal transplant 
patients. They also include four studies of 10% HES which is no longer in common 
use. 182 The study by Vander Linden et al also included studies of paediatric patients, 
trauma and burns. 186 These heterogeneous groups were excluded from our analysis. 
The reviews conducted by Van der Linden et al and Martin et al only investigated 
tetrastarch and compared it with other solutions, including alternative HES solutions. 
Moreover Martin et al's study, which appears to be industry initiated, investigated 
only a single product (6% HES 130/0.4, Voluven, Fresenius, Germany). The authors 
of this study made no assessment of methodological quality of included studies, were 
supported by Fresenius-Kabi, manufacturers of the HES solution, Voluven and 
utilised their "study tracking system" for the li terature search. 185 Several studies 
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included in other meta-analyses were excluded in this analysis. This included the 
studies by Harten, 2 10 (excluded because outcomes and care in the control arm were 
unclear), Challand (excluded because 6% HES may have been used in the control 
group), 220 and Tirakioglu (excluded because Jadad score was 2 and the incidence of 
outcomes of interest was not reported). 2 13 
Strengths of our review include a rigorous assessment of methodological quality of 
identified trials and selection of a homogeneous group of trials of direct relevance to 
perioperative medicine. The P statistic confirms a low risk of between-study 
heterogeneity and this combined with narrow confidence intervals suggests our 
findings are valid. There are also potential limitations of this analysis. We included 
trials of 6% HES solutions of any MW or substitution and did not restrict inclusion to 
one particular HES product. It has been suggested that HES solutions with higher 
MW and greater substitution may be associated with an increased incidence of acute 
kidney injury and use of these solutions has declined in recent years. Included trials 
were mostly small single centre trials with a greater possibility of bias. 
Synthetic colloidal solutions were introduced in the 1960s, 223 without large phase m 
trials. Despite little published evidence suggesting advantages over other intra-
venous fluids, and emerging evidence of harm in septic and critically i11 patients, 
they remain a popular choice for peri-operative fluid therapy. Although our 
systematic review did not demonstrate any harm associated with the use of 6% HES 
solutions these findings cannot be considered definitive. The Crystalloid versus 
Hydroxyethyl Starch Trial (CHEST) and 6S trials have provided robust evidence to 
the critical care community that resuscitation of the critically ill with 6% HES was 
associated with an increased incidence of acute kidney injury.6 7 Many surgical 
patients receiving HES are considered at high risk of both acute kidney injury and 
death and may require periods of critical care following their surgery. The findings 
of this analysis suggest that although there should be equipoise to conduct such a 
trial in surgical patients, the low event rates of both death and new requirement for 
RRT in the surgical population indicate that a very large clinical trial would be 
required to confirm the safety of starch solutions in the surgical patient population. 
The implications of this for the OPTIMISE trial are thus: In keeping with the 
pragmatic nature of the trial, we made no attempt to standardise the choice of colloid 
in either group. Whilst individual patient data describing the use of starches was not 
collected, a post hoc survey of investigators suggested few patients received this 
fluid with no differences in use between the treatment groups. This systematic review 
identified no evidence of acute kidney injury associated with the use of starch 
solutions in surgical patients and provides reassurance that use of starch was unlikely 
to affect the findings of the trial. 
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4.5 Conclusion 
The principal finding of this chapter was that there was no difference in hospital 
mortality, requirement for RRT or author defined AKI associated with peri-operative 
use of intra-venous 6%HES solutions. Although most studies were small with low 
event rates there was l ittle between-study heterogeneity and narrow confidence 
intervals. A very large randomised trial of 6% RES solutions would be required to 
demonstrate either significant benefit or harm associated with use of these solutions 
in surgical patients. Given the absence of demonstrable benefit, the clear risks in 
critically ill patients and the additional cost over more widely used fluids; these data 
do not enable a recommendation for routine clinical use of 6% HES solution in 
surgical patients. However, it seems unlikely to have had an important effect on the 
findings of the OPTIMISE trial. 
Michael Gill ies Doctor of Medicine (2014) 94 
Chapter 5: Volume of Surgery and Provision of Acute and Critical Care Beds in the 
UK. 
5.1 Introduction 
Evidence of variation in surgical outcomes is known to exist between healthcare 
systems. As discussed in Chapter 1, a study suggested greater than 3-fold higher 
mortality among the highest risk surgical patients in the UK compared with the USA 
1 and the more recent EuSOS study, a Europe-wide multinational prospective cohort 
study of 46,539 patients, demonstrated significant variation in outcome following 
surgery among European nations. 11 The causes of this phenomenon are uncertain but 
availability of Intensive Care Unit (ICU) beds, institutional differences in care 
pathways, 224 volume of surgery effects 111 and other factors have been suggested as 
contributing to outcome variation. Where there is evidence of variation in outcome, 
there may also be opportunities to improve it, so identifying causes is important. 
In the particular case of the UK, poor outcomes are often attributed to reduced 
numbers and poor utilisation of critical care beds. 1 Wunsch and co-workers have 
demonstrated that the UK has Jess Critical Care beds than many other developed 
nations, 11 3 however little objective evidence exists to support the asse1tion that this is 
the cause for observed outcomes in the surgical group. 
The United Kingdom is comprised of England and 3 devolved nations: Scotland, 
Wales and Northern Ireland with devolved governments responsible for delivery of 
bealtbcare. All regions within the UK have similar population demographics, a 
publicly funded healthcare system which is free at point of use, and similar medical 
training and practices. The largest of these, England, has historically been divided 
into NBS Strategic Health Authorities (SHAs) responsible for provision of 
healthcare and delivery of UK Department of Health (DR) Policy at regional level in 
England. SHAs typically had population sizes similar to a devolved nation. On the 
31 51 of March 2013, SHAs in England and Wales were abolished by the Health and 
Social Care Act (2012) and their responsibilities taken over by NHS England. 
Little is known about regional variation in volume of surgery, provision of acute and 
critical care beds, outcomes after high-risk surgery and patterns of critical care 
utilisation within the UK. This information was required to test the hypothesis that 
regional variations in surgical outcomes could be explained by variation in ICU bed 
provision. 
As previously discussed Weiser et al estimated that 230 million surgical procedures 
are carried out each year worldwide. 2 Tnis paper was published in 2008, but was 
based on data from different years in different countries; in the case of the UK it was 
based on data from 2004. He estimated the number of major surgical procedures (i .e. 
"any intervention occurring in a hospital operating theatre involving the incision, 
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exciSIOn, manipulation, or suturing of tissue") carried out in the UK in 2004 as 
13,635 per I 00 000. 
In order to undertake an analysis comparing outcomes after high-risk surgery in the 
UK and to evaluate the possible effect of ICU bed provision on this, it would be 
necessary to have: 
I. Detailed outcome data on a cohort of patients undergoing hjgh risk surgery 
taken from the whole of the UK 
2. Accurate denominator data on regional population 
3. Accurate denominator data on regional volume of surgery 
4. Accurate data on critical care bed provision. 
Exact figures regarding volume of surgery for the UK as a whole or by region, along 
with associated outcomes are difficult to extract from existing sources. In the year 
2000 the NHS Executive estimated the annual number of surgical procedures carried 
out in the NHS as approx imately 2.3 million with an estimated mortality of 1.4%. 13 
Subsequent work by Pearse and co-workers (discussed earlier) examined 4.1 million 
non-cardiac surgical procedures carried out at 94 NHS Trusts in England over a 70-
month period between 1999 and 2004. 
5.2 Hospital and Intensive Care Data Collection in the UK 
5.2.1 England 
Hospital Episodes Statistics 
In England data on all surgical admissions is collected by the Hospital Episode 
Statistics (HES) database. HES is the English national statistical data warehouse for 
care provided by NHS hospitals. HES provides data for a number of organisations 
including national regulators, commissioners, researchers, as well as patients, carers 
and other individuals who are undertaking healthcare analyses. Data on all hospital 
admissions, outpatient appointments and emergency department attendances is 
supplied to HES by individual NHS trusts and also independent healthcare providers. 
The data is collected at local level; hospital administratve staff collect administrative 
and clinical data for patient care and to inform the commissioning process in 
England. Data is submitted to the Secondary Users Service (SUS), a data warehouse 
managed by British Telecom (BT) on behalf of the NHS. At prearranged dates 
during the year, an extract of this data is uploaded to HES. 225 The HeaJth and Social 
Care Information System (HSCIS) then validates, cleans and analyses the data before 
it is used for published reports. The cleaning and validation process includes the 
removal of duplicate data and detailed provider mapping. Regular quality checks are 
carried out and monthly data quality check reports are published on the HES website. 
226 HES data is used for commissioning and Payment by Results (PbR) in England; 
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however, in the most recent report "The Quality of Health and Social Care Data, 
England, Annual Report 2013", data inaccuracies were e timated to be 6.5% and the 
need to improve the quality assurance process was highlighted. 227 
Intensive Care National Audit and Research Centre 
The Intensive Care National Audit and Research Centre (ICNARC) is a charitable 
company etablished in 1994 and sister organisation of the Intensive Care Society 
(ICS). ICNARC co-ordinates the Casemix Programme (CMP). The CMP is a 
national comparative audit of adult critical care un its in England, Wales and 
Northern Ireland. Currently (2013) 94% of adu lt intensive care units participate 
(https://www.icnarc.org). Critical care units volunteer to join and collect case mix, 
patient outcome and activity data, according to a standardised dataset, on al l the 
patients they admitted to ICU. Participation in the CMP is voluntary although the 
Department of Health and the NHS Executive have recommended that all units take 
part. Data collected on each patient are: patient identifiers, demographics, reason for 
admission, detai led physiological and clinical information, outcome and activi ty. 
ICNARC Model, APACHE II, APACHE ill, Simplified Acute Physiology Score 
(SAPS) II and Mortality Probability Model (MPM) II are calculated from the data 
obtained. Admissions are excluded from the calculation of severi ty of illness scoring 
if: age at admission to ICU is less than 16 years or length of stay in ICU is Jess than 8 
hours. Additionally, admjssions are excluded from the calculation of APACHE II 
predicted hospital mortality if: the admission is for primary burns; the admission is 
following coronary artery bypass graft (CABG) surgery; the admission is transferred 
in from another critical care unit; all twelve physiological variables are miss ing. 
5.2.2 Scotland 
In Scotland, data on all hospital admissions is collected by Information Services 
Division (ISD) a division of National Services Scotland, part of NHS Scotland. lSD 
provides health information and statistical services for the NHS in Scotland. The 
Scottish Morbidity Record (SMROl) coJiects episode-level data on hospital inpatient 
and day-case admissions and attendances in aJJ hospitals in Scotland. Data is 
collected at hospital or general practice level through Patient Administration System 
software (PAS). Validation rules are applied both locall y (prior to data submission) 
then centrally at lSD. The data is also subject to regular validation checks, and the 
most recent quality assurance report indicated good levels of accuracy (>90%) for 
the fields used in this study. Up to four surgical procedure codes can be recorded on 
each SMRO I episode along with the date of procedure. These fields have an accuracy 
of more than 95% and it is recognised that health services data collected by lSD is 
amongst the best in the world. 228 
In Scotland the Scottish Intensive Care Society Audit Group (SICSAG) fulfils a 
similar role to ICNARC in England and collects data on patient demograph ics, 
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reason for admission, detailed phys iological and clinical information, outcome and 
activity on those admitted to ICUs in Scotland. Severity of illness scoring uses the 
APACHE II model. Data is collected by clinical staff via a bespoke program called 
WardWatcher and again is extensively validated at local and central level. The 
database provided by ISD/SICSAG offers some advantages over that collected in 
England, Wales and Northern Ireland. All ICUs and HDUs in Scotland contribute 
data. Through patient linkage, data can be Linked through multiple hospital 
admissions, to the SICSAG dataset and also to the General Register Office (GRO) in 
Scotland, which gives information on long-term outcomes. 
5.2.3 Wales 
The Welsh Government Statistics Directorate produces health and social care data 
including data on hospital admiss.ions and outpatient/emergency department 
attendances in a similar manner to HES. Data on Critical Care admissions and 
outcomes is collected by ICNARC as described above. 
5.2.4 Northern Ireland 
Northern Ireland Statistics and Research Agency (NISRA) is the principal source of 
healthcare statistics in Northern Ireland and collects data on hospi tal admissions and 
outpatient/emergency department attendances. Data on Critical Care admissions and 
outcomes is collected by ICNARC as described above 
5.2.5 SICSAG and CMP Data 
Data for both SICSAG and CMP is collected locally according to strict definitions 
and validated extensively. Broadly, both systems collect data on patient 
demographics, source of admission, hjstory and admission diagnosis, physiological 
derangement, nature and duration of organ support received on ICU, duration of ICU 
and hospital admjssion and ICU and hospital outcome. 
In order to create as complete a cohort as possible of high risk surgical patients 
admitted to ICUs across the UK it would be necessary to combine the datasets held 
by ICNARC and SICSAG. To date this has not been done. Extensive advice was 
sought from the Chair of SICSAG, the Director of ICNARC and analysists at both 
ICNARC and ISD on the practicalities of doing this. The year 2009 was chosen as 
the most suitable year to undertake the planned analysis. This is because in 2007 and 
2008 SICSAG and ICNARC made changes in their data col lection manuals, and this 
would have made merging of datasets more problematic. 
As an initial step it was of vital importance to have good quaility denominator data 
on regional volume of surgical procedures and acute and critical care bed provision 
in the UK. We set out to undertake this for the year 2009, as this was the year for 
which patient data could be most easily studied. 
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5.3 Methods 
Ethical Considerations 
The data accessed was in the public domain and so formal ethics approval was not 
required. 
My Role in Work Undertaken 
All data wa ourced, extracted, reported and analysed by me. 
Statistical Analysis 
Analys is was perfonned using Excel (Microsoft, Seattle, WA) and STATA 
II (Statacorp,TX) 
To undertake the proposed analysis, the most accurate data avail able at national and 
SHA level was required on the fo llowing for the calender year 2009: 
5.3.1 UK and Regional Population and Geography 
Total population, adult population (for the purposes of this analysis defined as age 
greater than I 6 years) and adult population over the age of 65 years for each 
devolved nation and SHA. 
Population estimates were made using the fo llowing documents: 
"Mid-2009 Population Estimates for Scotland" published by The General Register 
Office for Scotland (http://www.gro-scotland.gov.uk/fi les2/stats/population-
estimates/mid-2009/mid-2009-pop-est-scotland.pdf accessed on 26/02/20 I 2) 
"Population Estimates for UK, England and Wales, Scotland and Northern Ireland, 
mid 2009" Published by the Office for National Staistics 
(http://www .ons. gov. uklons/pu b I ications/re-reference-
tables.html?edition=tcm%3A 77-213645 accessed on 26/02/20 J 2) 
Total population, population over J 6 and population over 65 were extracted for each 
devolved nation and region. Population density was ca lculated by dividing total 
number of inhabitants by geographical area of the region (km2) (source ONS data). 
5.3.2 Volume of Inpatient Surgery 
Number of inpatient sugical procedures, excluding as far as possible, daycase 
procedures, cardiac procedures, imaging, radiological and injection procedures. To 
do this standard Office of Population Censuses and Survey - 4 (OPCS4) codes were 
used. OPCS-4 i a standard coding system of surgical and other procedures used in 
the NHS. It is used as standard throughout the UK (i.e. Scotland, England, Wales and 
Northern Ireland). It is an alphanumeric four character sy tern with 26 chapters 
rea lting to a specific organ system. It is similar to International Classification of 
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Diseases-! 0 (ICDl O) or the American Medical Associations "Current Procedural 
Terminology". 229 Diagnostic codes OPCS Codes "Heart" (KO 1-078) and "Diagnostic 
testing & rehabilitation" (U01 -U54) were excluded for thi analysis and only surgical 
procedures requiring inpatient admission were considered. 
Volume of urgery was estimated by using data from the following resources: 
Scotland 
"Inpatient and Day case Surgical procedures and operations - All Ages 2009" 
Published by Wormation Services Divis ion, Scotland; 
(http://www. isdscotland .erg/Health-Topics/Hospital-Care/Operations-and-
Procedures/ accessed on 26/02120 13) 
From the report described above the number of "TOTAL MAIN PROCEDURES" 
excluding imaging, injections, infusions, x-ray and cardiac procedure codes (as 
outlined above). 
England 
"Provider Level Analysis for HES Admitted Patient Care 2009-1 0)", Published by 
Health Episodes Statistics; 
(http://www .hesonl ine.nhs.uk!Ease/ContentServer?siteiD= 1937 &categoryiD= 1453 
accessed on 26/02/20 13) 
From "Admitted Patient Care", "Finished Consultant Episodes (FCE) with a main 
procedure or intervention" excluding imaging, injections, infusions, x-ray and 
cardiac procedure codes (as outlined above). 
Wales 
"NHS Wales Informat ics Service, PEDW Statistics 2009/10 
(http://www. infoandstats. wales.nhs.uk/page.cfm?orgid=869&pid=41 0 I O&subjectlist 
=Totai+Procedures&patientcoverlist=Welsh+Residents&period=2009&keyword=&a 
ction=Search accessed 15/03/2013) 
"All Operations" excluding "Day Case "procedures, imaging, injections, infusions, 
x-ray and cardiac procedure codes (as outlined above). 
Northern Ireland 
"Acute Programme of Care Total Operations 
(http://www .dhsspsn i .gov. u k/index/stats_research/hospi tal -
stats/episode_based_activity/operations.htm accessed 15/03/20 13) 
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From the report described above: "All Operations" excluding "Day Case 
"procedures, imaging, injections, infusions, x-ray and cardiac procedure codes (as 
outlined above). 
For each dataset, only admitted patient care episodes were considered. The same 
procedure codes were excluded in all the datasets. The HES data was further 
stratified by SHA. It should also be noted that HES collect data from start to end of 
fiscal year (1 51 April), so 2009-10 was used. lSD uses calendar year (commencing 1st 
January) and so the year 2009 was used. 
5.3.3 Acute and Critical Care Bed Data 
There is no agreed definition of an acute hospital bed. In England, Wales and 
Northern Ireland KH03a is a quarterly bed census, whkh reports to the Department 
of Health and provides a count of available and occupied beds by healthcare 
provider. This includes a count of "General and Acute Beds". ln Scotland, ISD 
defines acute beds as "acute specialty beds (excluding obstetrics and long term 
geriatrics)". For Critical Care beds, the definitions from the Intensive Care Society 
document "Levels of Critical Care for Adult Patients" were used. 164 In this 
document Critical Care Beds are defined as follows: 
Level 0 - Normal ward care 
Level 1 - Ward care with enhanced level of monitoring 
Level 2 - Patients requiring more detailed observation or intervention, support for a 
single failing organ system or stepping down from higher levels of care. 
Level 3 - Patients requiring mechanical ventilation alone, basic respiratory support 
plus support of two or more failing organ systems, patients in multiple organ failure. 
Data was collected as outlined above. Population, surgical activity and critical care 
bed provision were reported by devolved nation and strategic health authority. 
Details of Acute and ICU bed provision were gathered from the Department of Heath 
(DH) Adult Critical Care Beds census (KH03a), reporting the number of available 
staffed beds in England on 15 July 2009; equivalent figures for the devolved nations 
were obtained from data held by the Intensive Care National Audit & Research 
Centre (ICNARC). 
Scottish Intensive Care bed data was derived from The Scottish Intensive Care 
Society Audit Group Report "Audit of Critical Care in Scotland 2010 Reporting on 
2009". ICU beds were defined as beds in adult, general ICUs or mixed intensive 
care/high dependency units (ICU/HDUs), excluding beds in specialist critical care 
units (e.g. cardiothoracic, neurosciences) and standalone HDUs. 
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Acute bed data for Scotland was gathered from Infonnation Services Scotland, 
"Annual Trends m Available Beds" (http://www. isdscotland.org/Health-
Topics/Hospitai-Care/Beds/) Accessed J 5/03/20 13 
5.4 Results 
Population 
Population, volume of surgery and provision of acute and critical care beds by region 
is summarised in Table 24. Total population ranged from I ,7888,900 (Northern 
Ire land) to 7,753,555 (London SHA) and the mean regional population size was 
4,756,270. London also had the highest population density (by almost a factor of 10) 
and one of the lowest percentages of poulation over 65 ( 13%; mean 15.8%) although 
North East England was the lowest, at 10%. Scotland on the other hand had a very 
low population density (66.3/krn2; median 302/krn2) compared with other regions of 
the UK and the highest proportion of population over 65 (23%). Northern Ireland had 
the highest population under the age of 16, at 21 %. 
Volume of Surgery 
Volume of surgery varied from 12,536 per 100 000 popu lation (South Central SHA) 
to 19,779 per 100 000 population (North East SHA) with a mean value of 16,123 per 
I 00 000 (Table 24). 
Bed Provision 
Acute hospital beds similarly varied across region from 193 per 100,000 (South 
Central SHA) to 328 per 100,000 (Scotland) with a mean of 245 per I 00 000. 
Northern Ire land had the lowest number of critical care units and beds (9 and 78 
respectively). Scotland had the highest number of ICUs at 23, while London SHA 
had the highest number of ICU beds at 448. Scotland also had the lowest number of 
ICU beds per ICU and London the highest (Range 7 .52-26.34; mean 1 0.4). There 
was evidence of a greater than 2-fold variation in provision of ICU beds; mean 
number of rcu beds per 100 000 adults was 4.9 (range 3.4-7 .2) and mean number of 
ICU beds per 100,000 surgical procedures was 24.9 (range 17.7-39.6) (Table 24, 
Figure 12). 
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Table 24 Population, volume of surgery and bed provision by region. 
Region Total Adult Population Population >65 Population Surgical Surgical General Acute Beds Number of Beds in Average Adult Intensive Adult Intensive 
Population years Density Procedures Procedures and Acute Per 100,000 adult ICUs adult ICUs beds/ICU Care Beds per Care Beds per 100 
N(%) per 100,000 Hospital or or 100,000 adults 00 Surgical 
N (%) (per km~) Population Beds ICU/HDUs ICU/HDUs Procedures 
East Midlands SHA 4,451,240 3,635,489 (82) 911,080 (20) 285 652,014 14,648 9,267 208.20 13 148 11.38 4.1 22.70 
East of England SHA 5,766,625 4,675,061(81) 887,485 (15) 302 890,500 15.442 11,771 204.12 16 158 9.88 3.4 17.74 
london SHA 7,753,555 6,254,866(81) 912,792 (12) 4941 1,277,092 16,471 17,926 231.20 17 448 26.35 7.2 35.08 
North East SHA 2,584,262 2,125, 717(82) 250,936 (10) 301 511,132 19,779 7,690 297.57 14 141 10.07 6.6 27.59 
North West SHA 6,897,905 5,600, 795(81) 644,337 (9) 487 1,267,002 18,368 18,622 269.97 24 299 12.46 5.3 23.60 
Northern Ireland 1,788,900 1,406,800(79) 254,400 (14) 129 343,235 19,187 4,255 237.86 9 78 8.67 5.5 22.72 
Scotland 5,194,000 4,281,000(82) 1,196,333 (23) 66.3 779524 15,008 17075 328.74 23 173 7.52 4.0 22.19 
South Central SHA 4,095,376 3,314,366(81) 743,385 (18) 445 513,412 12,536 7,911 193.17 11 121 11.00 3.7 23.57 
South East Coast 4,340,342 3,525,056(81) 890,080 (21) 466 582,796 13,427 8,794 202.60 11 160 14.55 4.5 27.45 
SHA 
South West SHA 5,231.243 4,308,873(82) 907,496 (17) 220 922,509 17,635 12,993 248.37 17 168 9.88 3.9 18.21 
Wales 3,038,872 2,449,888(81) 513,237 (17) 146 403,913 13,292 8,449 278.D3 16 160 10.00 6.5 39.61 
West Midlands SHA 5,431,079 4,378,188(81) 886,170 (16) 418 906,333 16,688 13,112 241.43 19 221 11.63 5.0 24.38 
Yorkshire and the 5,258,114 4,286,898(82) 671,837 (13) 341 900,679 17,129 13,126 249.62 20 172 8.60 4.0 19.10 
HumberSHA 
Mean 4,756,270 3,864,846 (81) 743,813(15.8) 302. 765,395.5 16,123.9 11614.7 245.5 18.1 188.2 10.40 4.9 24.9 
*denotes median value 
Michael Gillies Doctor of Medicine (2014) 104 
5 .5 Discussion 
To date, volume of surgery and critical care bed provision in the UK are not well 
reported. This data demonstrates regional variation in ICU bed provision across the 
UK when indexed either to population or to volume of surgical procedures. There 
was a 2.5 fold difference in Critical Care bed provision between worst and best 
provided regions. Differences in volume of surgery were less marked but still 
apparent; there was a 50% increase in volume of surgery between lowest and highest 
regions. The geograpaphy and population distribution of the UK may play a role in 
this. Densely populated urban areas (for example London) are more suited to fewer 
ICUs with a greater number of beds. In Scotland, where the population density is 
much lower, there are more ICUs with fewer beds. This may be necessary due to 
issues of distance and may have an impact on patient outcomes if, for example an 
increased number of inter-hosptal transfers are necessary. Another consideration is 
whether larger ICUs are able to provide better care with access to more specialist 
services and therapies. 
The "London Effect" itself is likely to be important. Regions with major urban 
centres are likely to host regional and supra-regional centres, perform more surgery, 
treat patients with complex disease or greater co-morbidities and hence require more 
ICU beds and other resources. This is reflected in these findings. 
Data on volume of surgery presented in this chapter are consistent with that reported 
by Weiser et al, 2 which estimated the number of surgical procedures carried out in 
the UK in 2004 as 13,635 per 100 000 population. Our figure was slightly higher at 
16,123 per 100 000 population. This may be due to an increase in surgical 
procedures in the intervening 5 years or inclusion of more minor or endoscopic 
procedures in this estimate of volume of surgery. Weiser does not specify how he 
calculated this figure for the UK in his paper, however he defines surgery as "any 
intervention occurring in a hospital operating theatre involving the incision, excision, 
manipulation, or suturing of tissue, and that usually requires regional or general 
anaesthesia or profound sedation to control pain". 
Wunsch et al compared critical care services across North America and Western 
Europe using large administrative databases in 2005. 224 She estimated UK acute 
hospital beds at 298 per 100,000 in 2005 and Critical Care beds at 3.5 per I 00 000 
population. The figures presented here of ~45 per 100 000 Acute Beds and 4.9 
Critical Care Beds per 100 000 are slightly different although Wunsch used identical 
data sources to this study so one would expect these figures to be close. UK and 
devolved government policy in the intervening 5 years to increase critical care 
capacity and reduce inpatient hospital beds may explain this finding. However even 
this current estimate of 4.9 per I 00 000 adult population falls well short of provision 
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in Canada, USA, Belgium, Germany or other developed nations and may explain the 
observed disparity in surgical outcomes between the nations. England and Wales 
spend less on healthcare per capital than Scotland and Northern Ireland 230 and this 
could be reflected in acute bed provision per I 00 000 although it does not seem to 
extend to critical care beds. 
The strengths of this data is that they are derived from several well-maintained 
databases and audit projects which undergo regular quality assurance (as described 
above) and provide detailed activity and benchmarking data to the NHS and other 
organisations. 
Possible limitations of the data are as follows: 
Population data was taken from the ONS and GRO, which are the two most 
definitive sources available. However the accuracy of census data and population 
estimates have been questioned before and a recent example of inaccuracy is the 
2001 census, where 900 000 men were reportedly missed. 231 A further source of bias 
may have been introduced into our data because we are examining population of 
SHA areas rather than nations. These boundaries are less distinct and SHA data is 
gathered from local council and GP lists. Moreover, patients who reside in the 
borders between SHAs may use some healthcare services in a different SHA or even 
country to the one in which they reside. 
Volume of surgery data may be inaccurate and hence biased for a number of reasons. 
Firstly data from HES is collected by fiscal year and by calendar year in lSD. 
Secondly, some surgical services are regional or supra-regional and so patients from 
one SHA or devolved nation may actually receive surgical care in a different region. 
These procedures are, by the nature of their complex ity, more likely to require 
critical care admission. Regions with high volume of surgery and critical care bed 
provision (e.g. London) may actually reflect a high concentration of tertiary and 
quaternary services. Thirdly, residents at the borders of SHAs and nations may not 
receive treatment in their region of residence as outlined above. Fourthly, due to 
coding practices, volume of surgery is likely to contain procedures such as 
endoscopy or other less invasive procedures which may result in this being an 
overestimate. Finally, inaccuracies in HES data in particular are known to be an issue 
227 and these have been acknowledged in other studies. 2•15•114 Similar problems exist 
in all large administrative databases 4 and for the purposes of a study such as this, 
these are the most accurate data available. Also, because definitions and data 
collection methods have been applied consistently across databases, it would be 
reasonable to expect that the variation and trends observed are real. 
The reliability of the acute hospital bed data also suffers from potential sources of 
bias. There are no consistent or nationally agreed definitions fo r acute hospital beds 
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which may make an exact estimation difficult. DH bed census definitions are 
different from those applied in Scotland and so this makes comparison between 
regions unreliable, and introduces the possibility of a systematic bias between 
regions. Unfortunately, it is not possible to exclude thi s possibility in the present 
study, or explore the directions of bias that might be present between different 
regions. However, these limitations are offset by the strength of a national study and 
large numbers of data from many different heaJthcare institutions. 
Critical Care beds on the other hand are defined according to nationally agreed 
standards 164 which makes these numbers far more reliable across regions and 
nations. In addition, because critical care outcomes are subject to detailed annuaJ 
aud its, these numbers are reviewed regularly for accuracy. For the purposes of this 
study number of beds in either ICUs or mixed ICU/HDUs are used, however local 
practices and bed pressures could result in Level 2 beds being frequently used as 
Level 3 and vice-versa and this effect would be difficult to quantify from a study 
such as this. Areas where "Level 3" care might be offered outside an ICU setting, for 
example in a theatre recovery area (so called "post anaesthesia care units" (PACU) or 
"overnight intensive recovery''(OIR)), might also not be included in these numbers. 
This data demonstrates regionaJ differences in surgical activity and critical care bed 
provision within the UK, which are broadly consistent with the results of other 
investigators. These differences are likely to be real but may reflect the geography, 
demographics and spread of population in the UK. The validity of a study such as 
this is dependant on the quality of the available data. Accurate and high quaJity data 
is necessary, not just to inform research and epidemiological studies such as ours, but 
also to inform commissioners, funders, healthcare providers, clinicians and patient 
groups. The current arrangements make a study such as this prone to bias at several 
levels and this could affect the findings of subsequent studies and reports made using 
this data. 
Whether thi s variation could be of any significance to the population undergoing 
surgery is not immediately apparent. Examining patient level data and outcomes for 
each region may allow a more detailed examination of the effects of this variation on 
patient care. 
5.6 Conclusion 
There is evidence of marked regional differences in volume of surgery and criticaJ 
care bed provision across the UK. Pooling of patient-level data and comparing 
clinical outcomes of surgical patients admitted to Critical Care in different regions 
may allow us to determine if this variation is important. 
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Chapter 6: Creation of a UK Critical Care Dataset 
6.1 Introduction 
Having described regional variation in volume of surgery and critical care provision 
within the UK it was necessary to summarise activity and outcome of surgical 
patients admitted to ICU by UK region and to investigate whether any regional 
differences in outcome persist after correction for case-mix and ICU bed provision. 
In order to undertake such an analysis it was necessary to create a cohort of high-risk 
surgical patients, drawn from the whole of the UK, with detailed demographic, 
physiological and outcome data. This would allow comparison of outcomes witrun 
the UK. Such data is collected by both ICNARC and SICSAG (held by ISD) on 
patients admitted postoperatively to intensive care units. However, as highlighted in 
the previous chapter, combining these two datasets to create a "UK wide" cohort of 
critically ill surgical patients has not previously been done and posed significant 
challenges. 
ICNARC co-ordinates the "Casemix Programme" (CMP), a national audit of adult 
critical care units in England, Wales and Northern Ireland. In Scotland there is a 
similar but separate audit, overseen by SICSAG and data is held by lSD. All ICUs in 
Scotland are required to submit data to SICSAG. In England, Wales and Northern 
Ireland, unit participation in ICNARC is not compulsory but recommended: currently 
92% of adult intensive care units in England, Wales and Northern Ireland participate. 
Both SICSAG and ICNARC collect detailed patient level data including outcome 
and activity data in order to undertake comparative audit and benchmarking. Data are 
collected according to a standardised dataset on all the patients admitted to ICU and 
this includes: patient identifiers, demographics, reason for admission, physiological 
and chronic heal th data, ICU and acute hospital mortality, length of stay and 
discharge destination. In order to make comparisons between ICUs it is necessary to 
adjust for severity of illness and other patient factors such as admission diagnosis and 
chronic health conditions. This is often referred to as ''casemix". 
In England, Wales and Northern Ireland data are collected by trained abstractors then 
submitted to ICNARC for analysis. ICNARC uses the "ICNARC Model", a risk 
prediction model similar to APACHE II, to adjust for casemix. ICNARC Model was 
developed in 2007 using a cohort of 200 000 UK critical care admissions and then 
prospectively validated in a separate cohort of 30 000 patients. 232•233 ICNARC 
Model underwent recalibration in 2011. Data required for APACHE IT, APACHE ill, 
Simplified Acute Physiology Score (SAPS) II and Mortality Probability Model 
(MPM) II are also collected by ICNARC and these scores are also calculated. 
Michael Gillies Doctor of Medicine {2014) 108 
In Scotland, the Scottish Intensive Care Society Audit Group (SICSAG) conducts a 
similar audit to the CMP England and all Critical Care Units in Scotland participate. 
Data is collected via "Wardwatcher", a data collection program provided by 
Information Services Division (ISD) a division of National Services Scotland, part of 
NHS Scotland. ISD provides health information and statistical services for the NHS 
in Scotland. "Wardwatcher" also collects data on patient demographics, reason for 
admission, physiological and chronic health data, ICU and acute hospital mortality, 
length of stay and discharge destination on those admitted to ICUs in Scotland. The 
database provided by ISD/SICSAG offers some advantages over that collected in 
England, Wales and Northern Ireland. Through patient identifiers, data can be linked 
through multiple hospital admissions, to the SICSAG dataset and also to the General 
Register Office (GRO) in Scotland, which gives information on long-term outcomes. 
APACHE ll is used as the ri sk-prediction model and to adjust outcomes for severity 
of illness and other patient-level factors. 
Data for both SICSAG and ICNARC are collected locally according to strict 
definitions and validated extensively. To date SICSAG and ICNARC datasets have 
never been combined to allow comparative analysis of acti vity and outcomes for 
surgical or other any other groups of ICU patients. 
Study objectives for this chapter were as follows: 
To construct a cohort of all adult patients admitted to Intensive Care foJJowing 
surgery in Scotland, England, Wales and Northern Ireland. 
To report age, gender, prior CPR, emergency surgery, APACHE IT score, APACHE 
ll Acute Physiology Score (APS), Admiss ion Diagnosis, ICU Length of Stay, ICU 
Mortality and Acute Hospital Mortality by region with no statistical testing. 
6.2 Methods 
Ethical Considerations 
The Chairs of South East Scotland Research Ethics Committees 0 I and 02 reviewed 
the proposed study protocol and the need for a full ethics submission was not deemed 
necessary. 
My Contribution to this Work 
I designed the analysis plan for the analyses carried out in thi chapter (Chapter 5) 
and the next (Chapter 6), with guidance from KR, DH, TW and BC. Matching 
SICSAG and ICNARC datasets was first undertaken by me and then checked by AF. 
KR and DB arbitrated disagreements. 
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Receding of the SICSAG data to enable import of SICSAG data into the CMP 
databa e and to then extract the summary data presented in this chapter was done by 
me. This was done by writing STATA "do fi les" (these are executable programs for 
the statistics and analysis package STATA (Statcorp, TX))) which were written and 
executed on ICNARC premises where both datasets were held. Following receding, 
the SICSAG data was imported into the CMP database for further analysis. SP 
checked and executed these "do files" to ensure no permanent alteration was made to 
ICNARC data. 
All work on ICNARC data must be done on ICNARC premises and supervised 
directly or performed by ICNARC analysts to comply with ICNARC data 
governance arrangements. 
Selection of Study Cohort 
Decisions on how to define and create the surgical cohort were taken with extensive 
advice from the Chairman of SICSAG (BC) and the Director and Senior Statistician 
at ICNARC (KR and DH). It was in itially decided that data on a cohort of 
admissions to Scottish reus over the period I Sl January 2007 to 31 Sl December 2009 
would be exported to ICNARC for analysis. However during the period 2007-2008 
both ICNARC and SICSAG updated to different versions of data collection. To 
avoid the requirement to effectively combine four different datasets we decided to 
Qn)y analyse patientS admitted tO JCU during the periOd 1 Sl January 2009 Unti) 31 Sl 
December 2009. Advice from the advisory group was that there would be sufficient 
numbers of patients admitted during this period to ensure adequate power in 
subsequent analyses. 
Because of previous unpublished work I was aware of a large group of HDU level 
patients within the SICSAG dataset who had not been scored for APACHE II; it is 
not normal practice for SICSAG to undertake severity of illness scoring on this group 
of patients. For this reason it was agreed that only patients admitted directly from 
theatre or recovery and requiring Level 3 care (i.e. ICU care) should be included in 
this analysis. 
In order to construct our cohort of surgical patients admitted to the ICU inclusion and 
exclusion Criteria were therefore as fo llows: 
Inclusion 
• Patients who's source of admission to ICU was theatre or recovery 
• Patients receiving Level 3 Care in the first 48 hours following admission 
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Exclusion 
• Patient under the age of 16 
• Patients who had undergone surgery with well structured perioperati ve care 
pathways which include planned admission to critical care (e.g. cardiac 
urgery, neurosurgery, transplant surgery, burns urgery) 
• Readmissions to critical care in the same hospital admission (do not have 
repeat APACHE scoring) 
• Miss ing acute hospital mortality data (primary outcome for the intended 
ana lysis) 
Data Management 
SICSAG data was provided from SICSAG/ISD in the form of an Excel (Microsoft, 
Seattle, W A) spreadsheet. This spreadsheet was imported into STAT A Version 1 1 
(StataCorp, TX) for further manipulation and analysis. Analysis took place on 
ICNARC premises in Holborn, London. 
In order to safely combine the two datasets it was necessary to closely examine the 
data collection manuals for both datasets to identify exactly how the data was 
defined, measured and collected. 
For SICSAG I used "Wardwatcher (2008 Version) Help Pages" which provides 
definitions for all mandatory pages and fields for the SICSAG dataset. For the 
ICNARC Casemix Programme I used " ICNARC Case Mix Programme Data 
Collection Manual Version 3.1" and "ICNARC Case Mix Programme Flows Version 
3. 1, 
I mapped SICSAG equivalents to Case Mix Programme "Reason for Admission" 
plus 83 further CMP variables used for determining source and nature of admission, 
acute physiological derangement and length of stay or outcome. There are 126 
SICSAG variables in total in Wardwatcher v203. A full list of variables and data 
flows in the SICSAG and CMP datasets can be found online. 234•235 
After SICSAG data fields were mapped to CMP data fields by an analyst at ICNARC 
(AF) corroborated the process. 
SICSAG variables fell into 4 categories: 
• SICSAG variable maps exactl y to equivalent CMP vari able 
• SICSAG variable maps to equivalent CMP variable but receding required 
• SICSAG variable similar but not exactly equivalent. 
• Equivalent SICSAG variable not available. 
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Inconsistencies in variable mapping were further reviewed by two statisticians at 
ICNARC (SP and DH). In the situation where the SICSAG variable was similar but 
not an exact match it was reviewed by aJJ five members of the group (MG, AF, SP, 
DH, KR) and a decision taken as to whether it could be included. 
Where SICSAG variables fell into categories 1, 2 or 3 (i.e. were suitable for 
merging) variable names were recoded to the CMP equivalent. 
Some categorical variables only required simple recoding. Where variables involved 
multiple categories, it was necessary to collapse the SICSAG data into the lowest 
common denominator and recode to the same categories as ICNARC before 
importing data. For some variables this required detailed specific field mapping, for 
example admission or discharge location. Following this a STA TA "Do-File" was 
created utilising a series of "replace" commands. This allowed the SICSAG data to 
be recoded into the same categories as the ICNARC data. 
SICSAG APACHE II diagnostic categories were mapped directly to the CMP 
"Reason for Admission" diagnostic category. 
61 SICSAG variables could be mapped exactly or with minimal recoding to an 
equivalent CMP variable. For 9 CMP variables there was no equivalent SICSAG 
variable available. These are summarised in Table 25. None of these either related to 
outcomes of interest or construction of the APACHE ll model that we planned to use 
to adjust for casemix so were not considered further. 
A further 6 variables required significant recoding following discussion among the 
collaborators and these are listed in Table 26. 
Individual solutions for each data field are outlined in this table. These mostly related 
to the way that time of death (or brainstem death) and discharge are recorded in the 
SICSAG database; in brief, to calculate time of death in the SICSAG dataset, unit 
outcome must equal 4 (death) and then time of death is equal to time of discharge. 
Finally 6 variables were not exact matches but thought to be close enough to safely 
include. These are outlined in Table 27. Variables used in the APACHE II model 
were of most concern, as being able to adjust for severity of illness and admission 
diagnosis was essential to compare outcomes. "Lowest pH" required transformation 
of [H+] to pH, which was simple to perform using a logarithmic transformation. 
SICSAG does not distinguish "Non-Ventilated Respiratory Rate" and "Ventilated 
Respiratory Rate" so in this case the highest value of the two in the CMP was 
mapped to "Highest Respiratory Rate" in SICSAG. Finally there was a subtle 
difference in the way that lowest systolic blood pressure is recorded between the two 
datasets. CMP uses "lowest systolic" and SICSAG uses "systolic paired with lowest 
diastolic". The APACHE II algorithm uses these to calculate mean arterial pressure 
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(MAP). 75 000 BP measurements from data coJJected for previous iterations of the 
CMP (years 2005-7 when both were collected) were used to see if this difference in 
calculation resulted in significant differences on the APACHE IT model. Comparison 
of MAPs generated by each of these two processes were examined and found to be 
practically identical (Table 28). Hence it was felt, in the opinion of DH, to be safe to 
import this value directl y and inc lude in the analysis. 
Figure 13 Flow diagram outlining lhe process fo r merging of SICSAG and CMP 
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Table 25 CMP variables for which there was no equivalent SICSAG variable 
available 
CMP Variable Definition Data Type Commentary 
chemox chemotherapy Boolean " IrrunuSup" only 
covers Steroid 
Therapy 
cicids Congenital Boolean No map -siCSAG 
imrnunohurnoral or "linmuSup" only 
cellular immune covers Steroid 
deficiency state Therapy 
hnctemp Highest non-central Decimal No longer collected 
temperature and not required in 
APACHE 2 model 
hv Home Ventilation Boolean No equivalent 
available 
lncternp Lowest non-central Decimal No longer collected 
temperature and not required in 
APACHE 2 model 




rdis_v3 Reason for String No equivalent 
discharge from available 
your unit 
Soh a Sector of other String No equivalent 
hospital (in) available 
Sohd Sector of other String No equivalent 
hospital (out) available 
*CMP=Case Mix Programme SICSAG = Scottish Intenstve Care Audit Group 
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Table 26 SICSAG Variables that required significant receding 
Variable CMP SICSAG v203 
Data Type Definition Variable Name SICSAG Definition Issue Solution 
Date of 
declaration Discharged on {date) Where Unit0utcome=4 & 
of brainstem (in conjunction with BrainStem=1, 
Ddbsd Date death Disc Date BrainStem) Data recorded differently DiscDate=DDBSD 
Date of 
discharge Discharged on (date) Where 
from your (in conjunction with Unit0utcome=1,2 ,3, 
Ddicu Date unit Disc Date UnitOutcome) Data recorded differently DiscDate=DDICU 
Discharged on (date) Where Unit0utcome=4 
Date of (in conjunction with and BrainStem=O, 
dod Date death DiscDate UnitOutcome) Data recorded differently DiscDate=DOD 
Where SICSAG VO 
Sedation=1,2,3, 
GCS_Available=O; 
Sedation not collected in Sedation=4,5, 
SICSAG V203; only have GCS_Available=1 ; 
GCS_Available field; Sedation=6,9, 
Sedated or GCS_Available=Able to GCS_Available=NULL; 
paralysed assess GCS, therefore CMP (both V's) where 
and sedated inference can be made SEDPAR=S,P, 
for whole of that patient was sedated if GCS_Available=O; 
first 24 hours No longer GCS could not be SEDPAR=N,V, 
sed par StrinQ in your unit collected assessed GCS Available=1 
Time of 
declaration Discharged on (time) Where Unit0utcome=4 & 
of brainstem (in conjunction with BrainStem=1 , 
tdbsd Time death Disc Time BrainStem) Data recorded differently Disc Time= TDBSD 
Time of 
discharge Discharged at (time) Where 
from your (in conjunction with Unit0utcome=1,2,3, 
tdicu Time unit UnitOutcome) Data recorded differently Disc Time= TDICU 
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Intubated only 
patients at the 
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setting (this is 
not the same); 






patients at the 
highest Fi02 
setting (this is 
not the same) 
Not an exact 
match. 
respiratory rate value, 
take highest value from 
LNVRR, HNVRR, LVRR 
and HVRR and map to 
SICSAG HighRR field 
For CMP High 
respiratory rate value, 
take highest value from 
LNVRR, HNVRR, LVRR 
and HVRR and map to 
SICSAG HighRR field 
Always in (H+]: (highest 
va.lue (in H+) out of the 
Lowp02pH & 
High02pH)=LPH_ V3 (in 
H+) Have to take lowest 
pH (or highest H+) value 
from those ABG results 
which are available 
Discussed by 
collaborators. Close 
enough to include (see 
text) 
First take highest value 
(in H+) out of the 
Lowp02pH & 
High02pH, then the 
PaC02 associated with 





col laborators. Close 
enough to include (see 
text). 
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Table 28 Three years of mean arterial pressure measurements calculated from two 
different sets of measurement (data taken from CMP 2005-7). 
MAP Calculated MAP calculated MAP Calculated MAP Calculated 
from Highest from Paired from Lowest from Systolic BP 
Systolic BP Systolic of systolic BP associated with 
Highest Lowest Diastolic 
Diastolic BP BP 
Number of 78561 76713 78884 77309 
measurements 
Mean 100.6 101.1 66.2 65.7 
SD 17.2 17.1 14.8 14.5 
P25 89 90 57 57 
PSO 99 100 65 65 
P75 110 Ill 75 74 
Following mapping and recoding of the SICSAG dataset to match the CMP dataset 
as outlined above, exclusion criteria were then applied: 
• Patients who did not receive level 3 care in the first 48 hours; defined as 
"Highest Level of Care Received" = Level 3 (ICS Levels of Care were used). 
164 
• Patients whose source of admission was not the operating theatre (OT) or 
recovery; defined from "Admission Source". 
• Patients aged under 16 years of age. 
• Patients who had undergone neurosurgery, cardiac surgery, bums or 
transplantation surgery; this was done as follows: if "Admission Specialty" 
(adspec) was "Burns surgery", "Cardiac Surgery", "Cardiology", 
"Neurology", "Neurosurgery", "Obstetrics", "Thoracic Surgery"; if APACHE 
n common descriptor (ap2desc_common), was: "ICHJSDH/SAH", 
"Cranjotomy for Neoplasm", "Head Trauma", "Renal Transplant"; if 
"Operation Performed" ( operperf) was "Liver transplant", "Other transplant 
surgery." This was excluded using APACHE ll diagnostic code. 
• Patients who were readmissions to ICU during the same hospital stay 
(readmit="yes") 
• Patients where "Acute Hospital Mortality" (ahsurv) was miss ing. 
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The final datasets for SICSAG and CMP were then merged to create a cohort of all 
critical care admissions in the SICSAG and CMP datasets for the year 2009. A 
flowchart of this process is shown in Figure 13. 
For subsequent analyses, APACHE II definitions were used to categorise patients as 
this was felt to be more consistent between groups. 29 diagnostic APACHE II groups 
remained in total following exclusion of unwanted groups and for ease of 
presentation of data; these codes were then broadly grouped by either type of surgery 
or disease process. MG and RP undertook this independently and then any disparity 
between groups was resolved by consensus by the other collaborators (TW, BC, KR, 
DH and SP). Descriptive statistics were applied to the dataset with no statistical 
testing. It should be noted that the modelling described in subsequent chapters uses 
the original APACHE ll diagnostic groups and not these groups, which are described 
only for ease of presentation of data in this chapter. The original APACHE ll reason 
for admission (prior to grouping) and numbers from CMP and SICSAG datasets are 
presented in Table 29. Some of these admission codes are medical in the CMP 
dataset. This is because CMP allows two APACHE ll common descriptors and we 
decided a priori to use the first as the primary reason for admission and to construct 
the model in chapter 6 accordingly. This may have led to a source of measurement 
bias (see below). 
6.3 Results 
Study Cohort Characteristics 
Prior to application of inclusion and exclusion criteria, the whole dataset contained 
106,623 patients from 208 ICUs. A flow diagram outlining patient selection for the 
study cohort is presented in Figure 13. Data from 16,147 surgical ICU admissions 
(1,708 SICSAG, 14,439 ICNARC) from 207 ICUs (23 Scotland, 184 England, Wales 
and Northern Ireland) was analysed. There was a slightly higher preponderance of 
surgical ICU admissions in the SICSAG cohort compared with the CMP cohort 
(19.5% vs. 15.6%). Patients were grouped according to country or SHA and numbers 
of admissions by region and this, along with demographics and casemix, is outlined 
in Table 30. The mean number of admissions per region was 1265 per year with a 
range from 695 (Northern Ireland) to 1754 (London SHA) per year. 
Study Cohort Demographics and Casemix 
Table 30 indicates that age and gender were broadly similar across the regions. The 
percentage of admissions having undergone cardiopulmonary resuscitation (CPR) 
prior to ICU admjssion ranged from 1.6% (West Midlands SHA) to 3.5% (North 
West SHA) while admissions following emergency surgery ranged from 52.4% 
(London SHA) to 79.6% (Yorkshire and the Humber SHA). APACHE ll Score was 
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broadly imilar between region (Figure 14). South Ea t Coa t SHA had the lowest 
mean APACHE U APS and full score at 9.9 and 14.4 respectively; however the 
region with the highest mean values in these variable (Northern Ireland) was not 
greatly different at 12.1 and 16.5 respectively. 
Figure 14 Mean APACHE U score by region (error bars denote 95% Cis) 
Mean APACHE 2 Score by Region 
25 
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~~tftl 0 ~~ .~~ <II ~ ~~ f-
20 
15 Mean 
APACHE 2 Score 10 
5 
0 T 
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Table 29 APACHE IT common descriptors for both CMP and SICSAG datasets prior to merging. 
Group Frequency 
No Descriptor • Reason For Admission Rank COMMON APACHE 2 Descriptor CMP SICSAG Total 
GI Surgery for Bleeding Perforation or 
I Neopla.~m 6901 
I Gl Perforation/Obstruction 3322 349 3671 
2 Gastrointestinal 2016 310 2326 
5 GI Bleeding 785 119 904 
2 Surgerv for Neoplasm (inc GI Neoplasm) 2716 
4 Gl Surgery for Neoplasm 2080 124 2204 
12 Renal Surgery for Neoplasm 345 18 363 
18 Neoplasm 86 63 149 
3 Major Vascular SufRery 2302 
Dissecting Thoracic/ Abdominal 
3 Aneurysm 2144 158 2302 
4 Cardiovascular Disease 235 
30 Pulmonary Embolus 22 22 
31 Coronary Artery Disease 14 14 
32 Hypertension 12 12 
20 RhYthm Disrurbance 80 80 
22 Congestive Heart Failure 59 59 
24 Cardiogenic Shock 37 II 48 
s Respiratory Di~ca.~e 663 
ll Respiratory 403 45 448 
19 Respiratory Infection 110 110 
23 Asthma/ Allergy 50 50 
27 COPD 29 29 
29 Pulmonary Edema (Noncardiogenic) 26 26 
6 Pre-Exi~ting Renal Disease 643 
6 Renal vasculitis 643 
i 
643 ! 
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Table 29 (Cont.) 
Group Frequency 
No Descriptor • Reason For Admission Rank COMMON APACHE 2 Descriptor CMP SICSAG Total 
7 Trauma 598 
7 MultiQie Trauma 522 76 598 
9 Sepsis 321 
14 Sepsis 232 89 321 
10 Other 414 
16 Metabolic 220 46 266 
21 Aspiration/Poisoning/Toxic 61 61 
25 Haematologic 45 45 
33 Not documented 4 4 
34 Drug Overdose 2 2 
35 Not mapped I I 
26 Seizure Disorder 34 34 
36 Postrespiratory Arrest I I 
II Missing 294 
15 Missing 294 294 
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Reason for Admission 
Patterns of reason for admission differed between regions. Table 31 outlines these 
differences. Possible reasons for this are: regions with large rural areas e.g. Scotland 
have a more ICUs with fewer admissions. Large urban areas e.g. London have 
proportionally more beds but offer tertiary and quaternary services, hence may e ither 
admit more elective surgery or cases with increased complexity. Emergency 
admission showed marked variation between regions; mean percentage of emergency 
admissions was 68.3%, however this varied from 52.6% (London SHA) to 80.8% 
(Yorkshire and the Humber). Admission following GI bleeding, obstruction and 
perforation formed the largest group across all regions (mean 41 .3%) however there 
was evidence of variation across regions (range 32.9-48.8%). Admission follow ing 
elective surgery for neoplasm and major vascu lar surgery also fo rmed sizeable 
groups with in the cohort. 
JCU Resource Use and Outcome 
Resource use and outcome is summarised in Table 32. Overall median ICU length of 
stay was 2.5 days however IQR was wide (0.8,7.5) (Table 5.8). Acute hospital length 
of stay varied across regions both in survivors and non-survivors. Median acute 
hospital length of stay ranged from 17 to 24 days for survivors; and from 9 to 13 
days for non-survivors. Crude acute hospital morality for the full cohort varied by 
over 10% across regions (Table 32) with a mean of 23.2% and a range of 18.8% 
(London SHA) to 29.1% (North West SHA). 
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Figure 15 Percentage of admissions following emergency surgery by region. 
Total 
London SHA 
South Central SHA 
North East SHA 
South West SHA 
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Table 30 Demographics and casemix. 
Number of Age, mean (sd) Gender, {%) male Prior CPR,{%) [N) Emergency surgery, APACHE II APS, mean APACHE II, mean (sd) 
admissions (%) [N) (sd) [N) [N) 
East Midlands SHA 1,474 61.0 (17.2) 867 {58.8) 38 (2.6) [1,474) 989 {67.1) [1,474) 11.5 (5.5) [1,443) 15.4 {6.2) [1,443) 
East of England SHA 1,108 66.1 (16.4) 581 {52.4) 41 {3.7) [1,107) 784 {70.8) [1,108) 11.3 (4.7) (1,070) 15.9 (5.6) (1,070) 
London SHA 1,757 61.9 {17.4) 997 (56.7) 51 {2.9) [1,757) 920 {52.4) [1,757 10.6 (4.8) (1,722) 14.6 (5.6) (1,722) 
North East SHA 1,024 63.5 (16.0) 585 {57.1) 33 (3.2) (1,024) 663 {64.7) [1,024) 11.4 {4.8) [1,004) 15.9 {5.8) [1,004) 
North West SHA 1,357 62.9 (16.6) 764 (56.3) 48 (3.5) [1,357) 1,004 {74.0) [1,356) 11.2 {4.6) (1,321) 15.5 (5.5) [1,321) 
Northern Ireland 695 63.9 (17.3) 405 {58.3) 13 (1.9) (695) 486 {69.9) (695) 12.1 (4.9) (679) 16.5 (5.7) (679) 
Scotland 1,754 62.0 {16.5) 994 {56.7) 36 (2.1) [1,754) 1,280 {73.8) [1,735) 11.3 {5.3) [1,672) 15.8 {6.1) [1,672) 
South Central SHA 1,048 65.5 (16.5) 598 {57.1) 24 (2.3) [1,048) 628 (59.9) [1,048] 11.4 {5.3) [1019) 15.7 (6.0) [1019) 
South East Coast SHA 947 65.6 {15.8) 552 {58.3) 18 {1.9) [947) 605 {63.9) [947) 9.9 (4.2) (938) 14.4 {5.2) [938) 
South West SHA 1,770 64.7 {16.6) 1,076 {60.8) 46 (2.6) [1,769) 1,123 (63.4) [1,770) 10.5 {4.6) [1,718) 14.9 (5.4) [1,718) 
Wales 797 65.8 {15.4) 452 (56.7) 14 (1.8) [797) 557 (69.9) (797) 10.8 {5.0) (779) 15.2 {5.8) [779) 
West Midlands SHA 1,401 63.2 {16.8) 767 {54.7) 22 (1.6) [1,401) 1,001 {71.4) [1,401) 11.0 (4.6)[1,370) 15.2 (5.5) [1,370) 
Yorksh ire and the Humber 1,316 63.4 {17.5) 716 {54.4) 60 (4.6) [1,316) 1,047 {79.6) [1,315) 11.9 (4.9) [1,267) 16.1 {5.8) [1,267) 
SHA 
16,448 63.5 {16.8) 9,354 {56.9) 444 {2.7) [16,446) 11,087 {67.5) 11.1 {4.9) [16,002) 15.4 (5.8) [16,002) 
Total [16,427) 
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Table 3l Diagnostic categories by region. 
East Midlands East of Enatand london SHA North East SHA North West North em S<otland I" liN) South Central SHA South East South West Wales (")(N) West Midlands Yot1cshlr~ and Tout 
SHA (")(NJ 5HA I")(N) I"IINJ (")(N) 5HA (")(NJ Ireland (")(N) (")(N) Coast 5HA I")(N) SHA (")(N) Hum~r 5HA I"IINI 
5HA("IINI l"MNI 
5uraerv for Gt Bl~ina. Perloration S89 (400) 472 (43.3) 555 (3291 348 (35.1) (9941 S83 (43.0) 2S8 (37.2) 797 (46.7) 42.5 (40.8) )1,043) 657 (37.1) 657 (37.1) 353 (44.4) 576 {444) 630(48.8)J1,292) 6, 670 
or Obstruction )1,4741 (1,090) (1,689) (1,3551 (6941 (1,7081 (947) (1,7701 (7951 (1,2961 (41.3) 
(16, 147) 
Suraerv for Neoplasm (inc Gl 284 (19.3) 132 (12.1) 386 (22.9) 209 (21.0) (9941 159 (11.7) 82 (11.8) 213 (12 5) 191 (18.3) (1,0431 344 (19.4) 344 (19.4) 148 (18.6) 229 (17.7) 128(9.9) (1,2921 2,719 
N~oplasml (1,474) (1,090) (1,6891 (1.3551 (6941 (1,7081 (947) (1.7701 [795) (1.2961 (16.8) 
(16,1471 
Major Vascular Surgery 209 189 (17.3) 221 (13.4) 153 (15.4)(9941 180 (13.3) 100 (14.4) 164 (9.6) 190 (18.2) (1,043) 294 (16.6) 294 (16.6) 110 (13.8) 194 (15.0) 202 (15.6)(1,292) 2,308 
(14.2)(1.4741 (1.0901 (1,689) (1,355) (694} (1,708) (947) [1.770} (795) (1,296) (14.3) 
[16,147} 
Cardiovascular OJsease 52 (3.5) [1,474) 75 {6.9}[1,090) 103 (6.1) 45 {4.5) (994) 86 (6.3)JI.355) 80 (11 .5) 151 (8.4) 56 (5.4) [1,043) 88 (5.0) (947) 88 (5.0) (1,770) 34 (4.3) (795) 52 (4.0) (1.296) 66 (5.1)(1,292) 931 (5.7) 
(1,689) (694) (!.708) (16,147) 
Respiratory Disease 57 (3.9)(1,474) 57 (5.2) (1,090) 70 (4.1) (1,689) 33(3.3) (994) 75 (5.5) (1.355) so 17.21 [694) 46(2.71(1,708) 32 13.101 [1,0431 65 (3.7) (947) 65 (3. 7)(1,770) 32(4.0) (795) 39(3.0) (1,296) 65 (5.0) [1,292) 661 {4.1) 
[16,147) 
Pre-Exfst•nc Renal Disease 94(6.4) [1,474) 45(4.1)(1,090) 79 (4.7) (1,689) 45 (4.5) (994) 51 (3.8) (1,355) 30 (4.3) [694) 0(0) 55 (5.3) (1,043) 58 (3.3)(947) 58(3.3)(1,770) 29 (3.6) (7951 59 (4,6) (1,296) 75 (5.8) (1,292) 664 (4 .1) 
[16.147) 
(1,708) 
Trauma & Orthop~ics 57 (3.9) (1,474) 33 (3.0) (1,090) 100 (5.9) 37 (3.7)(994) 51 (3.8)(1,3SS) 20 (2.9) (694) 85 (5.0)(1,708) 27(2 6) [1,043) so (2.8) (947) so (2.8) (1.770) 37 (4.7) (795) 34 (2.6111.296) 47 (3.6) (1.292) 60S (3.7) I 
(1,689) (16,147) 
N~urological 8S (S.8)(1,474) 20 ( 1.8) (1,090) 60(3.6)(1,689) n (7.8 1 (9941 74 (S.S) (1,3SS} 22 (3.2)(694) 30 (1.8) (1,708) 18 (1.7) (1,043} liS (6.5)(947) liS (6.5) 22 (2.8) (79S) 48 (.7) (1,296) 31 (2.4) (1,292) 620 (3.8) 
(1.770) (16,147) 
Se-psis 3(0.2) (I.A74) 39 (l.6IJ 1,090) 20 (1.2)(1.689) 15 (I 5)(994) 42 (3.1)(1,355) 34 (4.9) (694) 90 (S 3)[1,708) 12 (I 6) (1,043) 16 (1.7)(947) 15(0.8) (1,770) 13 (1.6) (795) 17 (I 3)(1,296) 6 (0.5) (1,292) 322 (2.0) 
[16,147 
Other 35 (2.4) (1,474) 20 (1.8) (1.090) 63 (3.7) (1,689) 20 (2.0) [994) 36 (2.7)[1,355) IS (2.2)(694) 49(2.9) (1,708) 19 (2.0) (1,043) 59 (3.3) [947) S9(3,3)( 1,770) 14 (1.8) [795) 28(2.2) (1,296) 31 (2,4) (1,292) 421 (2.6) 
(16,147) 
Missing 9 (0.6) (1,474) 8 (0.6)(1,090) 26(1.5) (1,689) 12(1.2) [994) 18 (1.3) (1.355) 3(0.4) 83 (4.9)Jl, 708) 3 (0.3) (1,043) 3 (0.3) (947) 25 (1,4) (1,770) 3 (0.4) [795) 20 (1.5)JI.296) II (0.9) (1,292) 226 (1.4) 
(16,147) 
(694) 
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Table 32 Outcomes and resource use. 
Critical care unit mortality, Acute hospital mortality, (%) Critical care length Critical care length of stay · Acute hospital length of Acute hospital length of stay -
(%) [NJ [N] of stay Unit Unit non-survivors, median stay - Survivors, median Non-survivors, median (lQR) 
survivors, median (lQR) (lQR) 
(lQR) 
East Midlands SHA 193 (13.1) (1,474] 291 (19.7) (1,474] 2.6 (1.2, 5.2) 2.9 (1.0, 8.0) 17 (10, 35) 9 (4, 22) 
East of England SHA 196 (17.7) (1,108] 310 (28.0) (1,108] 2.8 (1.52, 5.7) 1.9 (0.7, 6.2) 21 (12,41) 10 (3, 23) 
London SHA 211 (12.0) (1,757] 331 (18.8) [1,757] 2.5 (1.1, 5.4) 3.0 (0.9, 9.9) 19 (11, 35) 13 (4, 30) 
North East SHA 135 (13.2) [1,024] 248 (24.2) [1,024) 2.1 (1.0, 4.9) 2.3 (0.9, 7.3) 21 (11, 41) 12 (5, 36) 
North West SHA 258 (19.0) [1,35 7) 395 (29.1) (1,357] 3.7 (1.9, 8.0) 3.1 (0.9, 9.0) 24 (13, 45) 11 (4, 28) 
Northern Ireland 105 (15.1) [695] 165 (23.7) [695) 2.9 (1.7, 5.7) 3.3 (0.9, 8.6) 20 (12, 36) 10 (4, 24) 
Scotland 216 (12.3) (1,754] 385 (21.9) (1,754] 1.9 (0.9. 3.9) 2.4 (0.8, 6.4) 20 (12, 34) 12 (5, 24) 
South Central SHA 143 (13.6) (l,Q48] 215 (20.5) [1,Q48] 2.2 (1.1, 4.8) 2.1 (0.7, 5.5) 17 {10, 34) 10 (4, 22) 
South East Coast SHA 117 (12.4) [947] 183 (19.3) (947] 3.0 (1.8, 6.0) 2.5 (1.1, 5.3) 17 (10, 32) 10{4.19) 
South West SHA 251 (14.2) (1,770] 398 (22.5) (1,770] 2.7 (1.4, 5.1) 2.2 (0.7, 5.9) 18 (10, 33) 9 (3, 19) 
Wales 130 (16.3) (797] 218 (27.4) [797] 3.0 (1.6, 6.4) 2.2 (0.8, 7.3) 18 (11, 35) 11 (3, 31) 
West Midlands SHA 218 (15.6) (1,401] 321 (22.9) [1,401] 3.1 (1.7, 6.9) 2.6 (0.8, 9.7] 19 (11, 38) 11(4,22) 
Yorkshire and the Humber SHA 240 (18.2) (1,316] 363 (27.6) [1,316] 2.8 (1.4, 6.6) 2.5 (0.8, 7.2) 22 (11. 44) 10 (3, 22) 
Total 2,413 (14.7) [16,448) 3,823 (23.2) [16,448] 2.7 (1.3, 5.7) 2.5 (0.8, 7.5) 19 (11, 37) 11(4,24) 
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6.4 Discussion 
We report successful merging of SICSAG and CMP datasets in order to produce a 
single UK data et of critically ill adults. The mo t challenging aspects of this was the 
receding of categorical data and ensuring that the data used in the APACHE 2 model 
for severity of illness scoring was robust. This was necessary to compare acute 
hospital mortality across regions and allow adjustment for everity of illness, hence 
making the comparisons between groups meaningfu l. Results of summary statistics 
suggest that there is little regional variation in demographic data, i.e. age, sex and 
APACHE 2 scores. However regional vari ation does seem to exist in the proportion 
of patients admitted after emergency surgery, reason for ad mission and length of stay 
and this might suggest regional variations in how ICU beds are utilised and whether 
the avail abil ity of beds influences which patients to admit. Crude hospital mortality 
showed a wide regional variation in acute hospital mortality (more than 10%). This 
does not take account of differences in age, severity of illness, chronic health and 
ad miss ion diagnosis (i.e. casernix) or other potential sources of bias, which I shall 
address below. 
The preliminary findings from this work are consistent with other published work, 
i.e. demonstrated geographic variation in outcome after surgery 1•11 however although 
variation has been demonstrated between nations before, the e new data suggests 
variation within a single country. Differences in age, severity of illness, chronic 
health and admission diagnosis may account for this and the data presented in this 
chapter is unadjusted fo r these factors, although these are avai lable to us. 
Strengths of this analysis are that the data was drawn from two high quality audit 
projects, which are used for national benchmarking. Data are known to be robust and 
extensively checked and validated. 228 Senior analysts and c linical staff with a large 
amount of experience in handling and interpreting the data from both SICSAG and 
ICNARC were available to assist with the analyses. This is the first time merging of 
these to datasets has been attempted successfull y. 
However, there are potentiaUy several sources of systematic error or bias m thjs 
analysis: 
I . Selection Bias 
This occurs when there is a systematic difference in those who are selected for a 
study and tho e who are not. Possible sources of selection bias are: 
a) To ensure that postoperative patients were elected in this analysis, on ly 
patients admitted directly to ICU from theatre or recovery were included. 
Jn reality many patients are admitted to the ward, sub equently deteriorate 
and then are admitted to ICU 15 and in the recent EuSOS study 73% of all 
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those who died were not admitted to Critical Care at any point following 
surgery. 11 Such patients would be excluded from this analysis. 
b) Patients admitted to HDU or other postoperative care faci lities were not 
included in this analysis, as they do not routinely submit data to ICNARC 
or SICSAG. Moreover, in hospitals that send large numbers of patients to 
these faci lities, patients admitted to ICU may be sicker or more complex. 
c) In Scotland SICSAG has I 00% coverage of ICUs but for the years 
stud ied in this analysis, ICNARC only received data 92% of UK ICUs. 
This means 8% of ICUs in England, Wales and Northern Ireland did not 
include patients in this study. 
2. M easu rement Bias 
a) An important difference in recording the APACHE II common descriptor 
for "reason for admission" exists between the two datasets. SICSAG 
allows only one whereas CMP allows two to be entered, hence the 
appearance of some medical codes in the "reason for admission" in the 
CMP dataset. This may have a bearing on the subgroup analysis, as not 
all patients for example with "GI perforation" will be included in the 
group if another diagnosis e.g. "Aspiration" was entered as the primary 
reason for admission. 
b) Minor differences in the collection of some physiological data between 
SICSAG and CMP may have led to measurement bias. However 
APACHE 2 scores appear consistent through regions including Scotland 
where this is most likely to be an issue. Table 5.3 summarises the 
variables where we were concerned about this issue. 
c) There may be some residual "recoding bias", arising from recoding the 
SICSAG variables to match the CMP datafields. Variables where 
recoding was problematic are summarised in Table 27. 
In addition, there are likely to be several sources of confounding i.e. factors 
associated with both the outcome of interest and the exposure, which are not 
measured and may be unequally distributed regionally. Deprivation is one obvious 
example of this. It was hoped at the outset of this study that qu intiles of deprivation 
could be collected in the original analysis plan; however, these are only available for 
Scotland and not for the whole cohort. It is known that regional differences in 
deprivation occur throughout the UK, especially in Scotland. 236 
Other confounding may result from differences in complexity of surgery and ski ll of 
surgeon and other staff: this might be particularly the case in London, which hosts a 
high number of tertiary and quarternary services. Other unmeasured variations in 
practice might include quality of postoperative care, quality o f ICU care, use of HDU 
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or post anaesthesia care units prior to ICU admission, hospital medical emergency 
teams or other differences in the delivery of care. 
The first and most obvious explanation for the observed differences in acute hospital 
morta lity is the effect of case mix and we could adjust for differences using the 
APACHE n model, which we have already calculated. A econd potential reason to 
explain the observed variation would be differences in provi ion of ICU beds within 
the UK. Several commentators have postulated that this is a potential explanation for 
differences seen in international comparisons in ICU outcome 1•11 •115•224 and again 
this hypothesis could be readily tested using data already collected and presented in 
Chapter 4. Adjusti ng for case mix and ICU bed provision would involve multi level 
modell ing (ind ividual ICU nested in region) however there are validated techniques 
avai lable which could assist us to make comparisons in acute hospital mortality in 
surgica l patients admitted to ICU and these are discussed in the next chapter. 
6.5 Conclusion 
Combining of SICSAG and CMP datasets for ICU patients, including data for 
severity of illness scoring was possible and has been undertaken for the year 2009. 
Extraction of patients admitted directly from recovery or the operating theatre shows 
a similar regional profile for age, sex and APACHE n scoring. Prel iminary analysis 
reveal differences in reason for admission, ICU length of stay and crude 
(unadjusted) acute hospital mortality. As with many epidemiological studies using 
data of this type there are several potential sources of bias and confounding. 
Construction of a multilevel model taking account of patient and regional level 
factors might allow comparisons of outcome in surgical patients admitted to ICU 
between regions in the UK. 
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Chapter 7: Geographical Variation in Outcome after High Risk Surgery in the UK 
7.1 Introduction 
Detailed information on surgical activity and ICU proviSlOn within geographical 
regions of the UK is presented in Chapter 4 and in the previous chapter I describe in 
some detail how a database of a large cohort of postoperative patients admitted to an 
intensive care following surgery was constructed. 
I also report (without statistical testing) summary data on patient demographics (e.g. 
age, gender, prior CPR), reason for admission (e.g. nature of surgery, emergency vs. 
elective surgery), severity of illness scoring (constructed from detailed physiological 
data) and outcome (length of hospital and ICU admission, acute hospital morality). 
The cohort was comprised of adult admissions following surgery to ICUs in the UK. 
Patients undergoing cardiac surgery, neurosurgery, transplant surgery and burns were 
excluded from this dataset for the reasons previously outlined. However the cohort 
remains composed of a large and heterogeneous group of postoperative patients 
including patients who had undergone surgery for a variety of indications, 
emergency and elective. 
Preliminary descriptive statistics revealed that, although patient demographics appear 
reasonably consistent throughout the UK, large differences are evident in type and 
urgency of surgery admitted to ICU, length of stay and mortality. This finding was 
surprising and warrants further exploration. However there are several reasons why 
confounding may exist in our data. 
In epidemiology, confounding occurs when another exposure exists within the study 
population and is unequally distributed between the groups. Examples of this are 
given in the previous section. In epidemiological studies confounding can be 
controlled for by matching, stratification or by adjustment. Residual confounding is 
said to exist if there is unmeasured confounding which cannot be controlled. 
Confounding could have a very important influence on outcome of this study. Case 
mix and severity of illness is an important cause of confounding in this patient group. 
Case mix is a term employed to encompass reason for ICU admission, age, co-
morbidities, prior CPR and severity of illness. The outcomes reported in Chapter 5 
are not adjusted for this, although much of the work described in this chapter is 
aimed at providing the data required to adjust for casemix in the cohort. In particular, 
calculation of the APACHE II score allows adjustment for severity of illness, an 
important confounder (i.e. were patients in one region sicker than in another, and 
hence the observed difference in outcome). Data on ICU bed provision and volume 
of surgery is available from Chapter 4 and this could also be used to account for 
observed differences in outcome. 
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Other unmeasured confounding could anse from: social class and deprivation 
(avai lable in SICSAG data but not CMP data), ethnicity, effect of regional centres 
for certain types of surgery, geographical factors (e.g. large urban centres), local care 
pathways and local ICU admission policies. 
Using the data gathered in the previous chapters I attempt to address the following 
research questions: 
1. Does significant regional variation in acute hospital mortality exist in this 
cohort of patients? 
2. D id variation exist within all patient groups? 
3. If significant variation was demonstrated, could it be explained by case mix 
i.e. patient level risk factors: age, sex, surgical urgency, APACHE IT Acute 
Physiology Score (APS), CPR within 24h prior to admission, reason for 
admission (APACHE IT)? 
4. If significanL variation remained, could other associations explain it, for 
example: regional level provision of ICU beds or some measure of ICU bed 
util isation. 
To answer these questions and overcome some of the problems inherent in the data I 
developed the fo llowing analysis plan following detailed discussion with 
collaborators TW, RP, DH and SP. 
7.2 Methods 
Ethical Considerations 
The proposed study protocol was reviewed by the Chairs of South East Scotland 
Research Ethics Committees 01 and 02 (as outlined earlier) and the need for a full 
ethics submission was not deemed necessary. In addition the SICSAG steering group 
forma lly approved the study. 
Study Cohort 
The methodology for constructing the study cohort including inclusion and exclusion 
criteria has been described previously. 
Subgroup Analysis 
Subgroup analysis would allow examination of variation in outcome in patients 
admitted with broadly similar types of surgery. Subgroups chosen for this were those 
which could be grouped together easily from their APACHE ll reason for admission 
as outlined in Chapter 5: patients undergoing emergency GI surgery for perforation, 
obstruction or bleeding; patients undergoing e lective surgery for Gl neoplasm; 
patients undergoing surgery for trauma. Another obvious group, "patients 
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undergoing vascular surgery", was rejected for two reasons. Firstly, vascular surgery 
has become very regionalised over the last decade. Secondly increasing use of 
endovascular and radiological techniques has improved outcome after surgery but 
these techniques are still evolving and not used ubiquitously throughout the UK. 237 
A fourth subgroup was chosen: patients who were admitted to ICU for longer than 
48h. This was chosen because it was postulated that it might contain a more 
homogenous group of ICU patients and exclude patients who were admitted for a 
short period to facilitate extubation postoperatively and al.so patients who were 
moribund at the time of admission. 
Generation of Funnel Plots 
Funnel plots have several uses m epidemiology and involve plotting event rates 
against number of cases or observations, with the addition of confidence limits. 
Funnel plots have been used in meta-analysis (see Chapter 3) to test for publication 
bias. They have been used for comparative audit purposes for example to compare 
differences in acute hospital mortality between hospitals and geographical regions. 
They have also been used to compare mortality rates following surgery 238 and 
compare standardised mortality rates (SMR) between ICUs. 239 When used in this 
context these plots graph an observation (in the case of tills study, acute hospital 
mortality) and its confidence limits against the background population. As the 
background population becomes larger, the confidence limits narrow, making a 
funnel shape. Funnel plots typically have lines displaying 2 and 3 Standard 
Deviations (SD) i.e. 95 and 99.7% confidence intervals (CD. When 13 regions are 
compared there is a possibility that one might lie outside 2SD (5%; 1 in 20) by 
chance, so these regions could be considered as "possibly different". If regions lie 
outside 3 SD there is high probability that these regions "are different" (CI 99.7%). 
240
•
24 1 Examining the data using funnel plots would enable one to account for 
statistical confidence based on size of cohort and hence determine if these 
differences were truly significant. 
In this analysis, funnel plots were constructed by plotting acute hospital mortality 
against number of cases for the full cohort and for pre-defined subgroups. 95% and 
99.7% confidence intervals were added. Individual regions were not identified. 
Multilevel Logistic Regression Analysis 
Multilevel modelling allows quantification of the effect of region on acute hospital 
mortality after correction patient case mix and ICU bed provision. 
Logistic regression examines the effect of a single exposure variable on a binary 
outcome of interest and predicts the probabiLity (P) that an individual will be 
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classified into the outcome of interest, in this case hospital mortality. The logit of this 
probability is the natural logarithm of the "odds" of this outcome. 
log it (p) =In p/1-p 
However because the patients in this study are clu tered both at ICU and 
geographical region level it is necessary to account for thi using a multilevel 
(random effects) model. 242 This type of model considers that individual probability 
is also dependent on the ICU and region of treatment. Thi is used to reduce the 
possibility of residual confounding at regional and rcu level. 
In this analysis, the variance between geographical regions is the outcome of interest 
i.e . is there significant variation in hospital mortality between the regions studied. In 
the null (or empty) model (j), the probability of dying in hospital is the only function 
of geographical region of residence. In subsequent models the effect of patient level 
factors is introduced to reduce the observed variance between regions. In the second 
model (ii) the probability of dying in hospital is a function of area of residence and 
patient level factors i.e. case mix, sex, age, surgical urgency, APACHE ll Acute 
Physiology Score (APS), CPR within 24h prior to admission, reason for admission 
(ba ed on APACHE II). Finally in model (iii) (the fu ll model) the probability of 
dying in hospital is the function of region of treatment, case mix factors and ICU bed 
provision. At each stage it is possible to observe if the variance between regions can 
be explained by casemix factors or provision factors. If significant variance remains 
after adjustment for potential confounders then region of treatment is likely to remain 
an important factor in outcome. 
There are several methods, which can be used to describe variance in clustered data 
and the "median odds ratio" (MOR) was chosen for this analysis. MOR converts the 
variance to an "odds ratio" scale, which is more intuitively understood and uses the 
expression: 
MOR = exp{.Y (2 x VA) x 0.6745}:::: exp (0.95-Y VA) 243 
Hence MOR is a function of the cluster variance and can be conceptualised as two 
individuals with the same covariates chosen from two random clusters. The MOR is 
the median odds ration between the individual in the area of the lowest risk and the 
area of highest risk. If the MOR is 1 there is no variation between clusters. If there is 
considerable between-cluster variation the MOR wi ll be large. 244 
In this analysi , firstly a null model was fined and adjusted for the random effects of 
clustering by geographical region and by ICU. The fol lowing patient-level covariates 
were then included: age; gender; CPR wi thin 24 hours prior to admission; surgical 
urgency; and APACHE II Acute Physiology Score, APAHE n diagnostic category. 
Finally ICU bed provision was added to the model at the regional level. 
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As a sensitivity analysis, the above was then repeated using proportion of surgical 
patients admitted to ICU as a proportion of overall urgica l activity, to give a crude 
e timate of ICU bed utili sation. 
To en ure adequate statistical power, MOR was calculated for the full cohort and for 
the ICU length of stay greater than 48 hours only. 
Data Analysis 
The above statistical analysis plan was agreed a priori, including subgroup analysis. 
Geographical region was defined as SHA or devolved nation. Analyses were 
performed using STAT A SE LO.l (StataCorp, TX, USA). 
The final analysis plan was approved by both ICNARC and SICSAG. For reasons 
outlined earlier, analyses were undertaken on the premise of ICNARC in Holborn, 
London, ei ther by or under the direct supervision of ICNARC analysts. Comparison 
of outcome between region and devolved nation is potentially sensitive. For this 
reason it wa agreed by ICNARC and SICSAG that regions would not be identified 
in thi analysis. Two teleconferences were organised to allow discussion of the 
results with representatives from both SICSAG and ICNARC. 
7.3 Results 
Data from 16, 147 surgical ICU admissions (1 ,708 SICSAG, 14,439 ICNARC) from 
207 ICUs (23 Scotland, 184 England, Wales and Northern Ire land) was analysed. 
Patients were grouped according to country or SHA and numbers of admjssions by 
region plotted against acute hospital mortality. This was done for the full cohort and 
for subgroups (Figure 16, 17). Funnel plots show evidence of significant variation in 
outcome in both the fu ll cohort where 5 regions fall out of 3 standard deviations and 
where length of stay was more than 48 hours, where 4 regions fall out of 3 standard 
deviations. In the other subgroups with the exception of the "Trauma" subgroup 
where the sample is much smaller, the variation is less marked but still present 
(Figure 17). The multilevel logistic regression analysis was undertaken for the whole 
cohort and for admissions to rcu of duration greater than or equal to 48 hours. 
Results of the logistic regression model for the full cohort and for pre-defined 
subgroup are presented in (Tables 33-37). The confidence intervals for the effect of 
geographical region of treatment are very wide in all the subgroups except for 
patient admitted for greater than 48 hours. This is likely to be due to the reduced 
power of these subgroups to demonstrate an effect. Hence median odds ratio for 
geographical region of treatment was only calculated for the full cohort and for the 
subgroup of patients admitted for less than 48h. 
The MOR of regional variation for the full cohort wa 1.42 (95% CI 1.29- 1.62). This 
decreased when the model was adjusted for case mix (MOR: 1.35; 95% CI: 1.22, 
Michael Gillies Doctor of Medicine (2014) 134 
1.58) and slightly further decreased when rcu bed provision was also included in tbe 
model (MOR: 1.33; 95% CI: 1.20, 1.58), although the effect of ICU bed provision 
was not statistically significant (OR: l.04 per J addit ional ICU bed per 100,000 
adults; 95% CI: 0.97, 1.11 ; p=0.25). When repeated for the subgroup of patients 
admitted for greater than or equal to 48 hours, the MOR of regional variation for the 
full cohort was 1 .38 (95% Cl 1.25-1.60) and similarly decreased when the model was 
adjusted for case-mix (MOR: 1.30 95% CI 1.15-1.6 1) and ICU bed provision (MOR: 
1.28 95% CI 1.13- I .63). (Figure 18) 
The model was repeated for the full cohort using surgical ICU admissions per 
I 00,000 surgical procedures, this explained much more of the variation seen within 
regions (MOR: 1.19; 95% CI 1.02, 5.99; OR: 49.91 per 50 addi tional surgical ICU 
admission per 100,000 surgical procedures; 95% CI: 49.84, 49.97; p=O.Ol ). 
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Figure 17 Funnel plot of unadjusted acute ho pital mortality for subgroups 
a. Admi ion greater than or equal to 48h. b. Emergency GI urgery admi s ions. 
\ 




c. E lecti ve Gl urgery admissions. d. Admission with trauma. 
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OR: Odds ratio; C l: Confidence Lmerval APS: Acute Physiology Score* reference category. 
4 ICU beds per 100 000 population 
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Table 34 Logistic regression model for admissions > 48h (n=9515) 
Variable OR (95% CI) 
Age 1.04 ( 1.03, 1.04) 
Gender 0.88 (0.79, 0.97) 
Admission type 
E lective surg ical 0.58 (0.5 1' 0.67) 
Emergency surgical* 1.00 
APACHE IT APS l.09 ( 1.08, l. I 0) 
Prior CPR 2.02 ( 1.49, 2.73) 
Surgery for Abdontinal Neoplasm 0.85 (0. 7 1' 1.02) 
Major Vascular Surgery 0.94 (0.8 1' 1.1 0) 
Cardiovascular Disease 0.82 (0.63, 1.05) 
Re piratory Disease 0.51 (0.37, 0.71) 
Pre-Existing Renal Disease 0. 79 (0.56, 1.08) 
Orthopaedics and Trauma 0.6 (0.43, 0.84) 
Neurological Problem 1.7 ( 1.33, 2.30) 
Other 0.86 (0.59, 1.24) 
Sepsis 1.49 (1.10, 2.02) 
Missing 0.97 (0.57' 1.6 1) 
ICU Bed Provision§ 1.03 (0.98, 1.09) 
OR: Odds ratio; Cl: Confidence Interval APS: Acute Physiology Score 
• reference category. f ICU beds per 100 000 population 



















Table 35 Logistic regression model emergency GI surgery admissions (n=5838). 
Variable OR (9s% en p-value 
Age 1.04 ( 1.04, 1.05) <0.01 
Gender 0.92 (0.82, 0.97) 0.21 
APACHE II APS 1.16 (1J4, 1.16) <0.01 
Prior CPR 2.9 (1.91, 3.01) <0.01 
ICU Bed Provision§ L04 (0.97, 1.11) 0.31 
OR: Odds ratio; CI: Confidence Interval APS: Acute Physiology Score 
§ ICU beds per I 00 000 population 
Table 36 Logistic regression model: surgery for abdominal neoplasm admissions 
(n=1631). 
Variable OR (9s% en p-value 
Age 1.04 (1.02, 1.06) <0.01 
Gender 1.06 (0.73, 1.53) 0.75 
APACHE II APS 1.1] (1.07, 1.16) <0.01 
Prior CPR 3.79 (1.17, 12.2) 0.026 
ICU Bed Provision§ 0.95 (0.80, 1.13) 0.57 
OR: Odds ratio; CI: Confidence loterval APS: Acute Physiology Score 
§ rcu beds per 100 000 population 
Table 37 Logistic regression model: surgery for trauma admissions (n=604). 
Variable OR (95% el) p-value 
Age 1.05 ( L03, 1.06) <0.01 
Gender 1.19 (0.68, 2.06) 0.55 
APACHEUAPS 1.19 (1.13-1.25) <0.01 
Prior CPR 5.9 (2,49, 14. 17) <0.01 
ICU Bed Provision§ J .09 (0.89, I .33) 0.41 
OR: Odds ratio; CJ: Confidence Interval APS: Acute Physiology Score 
reference category. § ICU beds per I 00 000 population 
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Figure 18 Median odds ratio for each model: Null Model, Casemix Adjusted Model, 
Model Adju ted for Critical Care Provision 
a) Full Cohort: IGU Beds per 100 000 Population 
Null Model 
Casemix Adjusted Model • 
Full Model • 
~~ ,.._":> ,.._'} .... ~ .... ~ .... ~ '),":> 
Median Odds Ratio 
b) Admissions greater than 48 hours: ICU beds per 100 000 population 
Null Model • 
Casemlx Adjusted Model I • 
Full Model 
..... ~ ,'Y ..... ~ ....,'? 
Median Odds Ratio 
c) Full Cohort SurgicaiiCU Admissions per 100 000 Surgical Procedures 
Null Model -
casemix Adjusted Model -
Full Model 
Median Odds Ratio 
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7.4 Discussion 
The principal finding of this analysis is that in the UK there is significant regional 
variation in acute hospital mortality for patient recei ving level 3 care in an ICU 
fo llowing urgery. This variation persists after adjustment for casemix and regional 
intensive care bed provis ion. This finding was also observed in predefined 
ubgroups. Thi analysis demonstrated regional variations in practice which may 
partly explain these findings: the proportion of elective vs. emergency surgery 
admitted to ICU (although this is controlled for in the casemix adjusted model); the 
nature of surgical procedures undertaken in patients admitted to ICU and length of 
s tay of surgical patients in ICU. These factors may signal variations in practice 
which may be difficult to fully elucidate in a study such as this or may simply reflect 
unmeasured confounding. 
Despite simi .lar per capita healthcare spend and organisational practices, the 
differences in variation in volume of surgery undertaken and critical care bed 
provis ion within the UK demonstrated in our study were striking. However variation 
in outcome after surgery within the NHS has been demonstrated previously. 
Saunders et al examined outcome after emergency laparotom y in 35 NHS Trusts in 
the UK. In this study, mortality varied between 3.6 and 4 1.7% and in between 0 and 
69% of cases postoperative care was delivered on a normal ward. 8 This variation 
also appears to extend to e lective surgery; Aylin et al showed a " weekday effect" of 
variation in outcome following four out of five higher risk elective surgical 
procedures. 162 In this study, odds of death were 44% and 82% higher if the 
procedure was carried out on a Friday or weekend respecti vely. The authors suggest 
that organisational and staffing factors within hospitals may be implicated. Another 
recently published study suggested "high mortality outlier" hospitals for emergency 
surgery have several differences in the delivery of perioperative care when compared 
to " low m01tality outliers". One such observed difference was s ignifican tly reduced 
provision of ICU beds although this finding did not appear to extend to HDU bed 
provis ion. 17 
The finding in our study that absolute provision of critical care beds did not appear to 
explai n the ob erved regional variation in surgical patients admitted to ICU 
outcomes is at odds with the opinion of many commentators who suggest that 
absence of this is a major factor in the poor outcomes observed after high risk 
surgery in the UK. In reality the answer to this question i likely to be much more 
complex and be more influenced by how these re ources are used. Utilisation of 
criti cal care resources may be more important, as demonstrated in this analysis by the 
observation that surgical ICU admissions as a proportion of overall volume of 
surgery (a crude measure of utilisation) seemed to better explain the variation within 
thi s model. 
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The EuSOS study, which also reported vanatiOn in outcome following surgery 
among European nations, suggested that patient co-morbidities and surgical factors 
have the highest effect on mortality. Several nations included in this study with 
higher per capita provision of critical care beds than the UK had worse surgical 
outcomes and vice ver a. 11 Organisational factors such as "post anaesthesia care 
units", where interventions and monitoring traditionally delivered by critical care are 
provided in the recovery room for the first 24 hour following surgery or 
protocolised care pathways in the ward setting with enhanced monitoring and input 
from specialised teams may also explain this phenomenon. 
Strengths of this analysis are that a large, high quality dataset with good coverage of 
all regions in the UK, low incidence of missing outcome data was utilised 228 and 
robust, well described methodology applied. 243 
Potential sources of bias and confounding remain. Many of the potential systematic 
causes of bias in this data have been addressed ex tensively in previous chapters. The 
most important of these remains that only surgical admissions directly to the ICU 
and from theatre or recovery were considered in this analysis, as it was not possible 
to accurately identify surgical patients admitted to the ward first and then to ICU. 
Several studies have shown that the worst outcome among surgical patients is from 
those admi tted from the ward. 15•114 Moreover in the EuSOS study 73% of all deaths 
were never admitted to ICU at any time after surgery. 11 Patients requiring level 2 
care were also not included in this analysis due to concerns about consistency and 
availability of severity of illness scoring in this group and hence the ability to adjust 
for patient level factors in the model. Increasing use of High Dependency Units, 
"Post Anaesthesia Care Units" or extended recovery periods, where patients are able 
to stay for the first postoperative night and have interventions typica lly delivered in 
an ICU setting in the recovery area may also have confounded these findings as these 
patients may have hi storically been admitted to the ICU. 
Confounding may also exist in regions with higher rates of admiss ion of patients to 
ICU. In these areas less unwell patients may be admitted routinely for postoperative 
care and this may not be completely adj usted for in the APACHE IT model. Other 
confounding factors could include the regional effects of deprivation, ethnicity and 
differences in complexity of surgery and skill of surgical and other staff: this might 
be particularly the case in London, which hosts a high number of tertiary and 
quaternary services. 
Evidence of geographical variation in mortality after high risk surgery within a very 
uniform healthcare system such as the NHS sugge t orne deaths may be 
preventable. The va ri ation observed in this analysis does not seem to be associated 
with JCU bed provision per se but points towards patient selection and resource 
utili sation as being important factors in explaining this phenomenon. Better data 
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linkage and complete coverage of all healthcare providers in England and Wales 
would allow more sophisticated models to be developed whlch could examine all 
surgical admissions. 
7.5 Conclusion 
Significant regional variation in acute hospital mortality for patients admitted to ICU 
following surgery, not explained by casemix or intensive care bed provision is 
reported. Variation in admission practices, nature of surgery and length of stay were 
also observed. ICU resource utilisation as expressed by surgical ICU admissions per 
100 00 procedures seemed to better explain this phenomenon. 
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Chapter 8: Does Goal Directed Haemodynamic Therapy Prevent Perioperative Cardiac 
Injury? 
8.1 Introduction 
As described in previous chapters an estimated 200 million surgical procedures are 
carried out worldwide each year and 1 million patients dje within 30 days of surgery. 
2 Historical data has estimated the incidence of myocardial infarction after general 
surgery as 0.7% in patients over 50 years of age, rising to 3.1% following vascular 
surgery. 174 However observational studies, for example those undertaken by Khuri 
et al using NSQIP data 4'44 have suggested that cardiac complications, in particular 
myocardial infarction although rare are more prevalent in the high risk group 
associated with high perioperative mortality. 4 
Definitions of myocardial infarction were recently revised 245 and are classified as 
follows: 
Type 1: Spontaneous myocardial infarction 
Type 2: Myocardial infarction secondary to an ischemic imbalance 
Type 3: Myocardial infarction resulting in death when biomarker values are 
unavai lable 
Type 4a: Myocardial infarction related to percutaneous coronary intervention (PCI) 
Type 4b: Myocardial infarction related to stent thrombosis 
Type 5: Myocardial infarction related to coronary artery bypass grafting (CABG) 
Cardiac troponins have had an established role in the diagnosis of myocardial 
infarction and prediction of short and long-term outcomes in patients with ischaemic 
heart disease for many years. 80"82•88•246"248 Cardiac troponins are not expressed in 
skeletal muscular and are not detectable in the semm of healthy individuals. The 
prognostic significance is greatest if measured at least six hours after the onset of 
symptoms and serum troponin remains elevated for 7-10 days follow ing a cardiac 
event. Conventionally a serum troponin level of greater than the 99th percentile value 
of the general population has been considered clinically significant and these earlier 
studies demonstrated that peak values of troponin correlate strongly with outcome. 
246 
Increasingly sensitive 41h and 51h generation Troponin assays have been developed 
which can improve the early detection of myocardial necrosis. 86•87 The "Prevention 
of Events using Angiotensin Converting Enzyme Inhibition" (PEACE) Study 
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investigators measured serum troponin T using a highly sensitive, 5th Generation 
assay (Roche Diagnostics) in 3679 patients. 11% of asymptomatic patients with 
ischaemic heart disease had a serum 5th Generation Troponin T (TnT) value that 
exceeded the 99th percentile (2:14 ng/L) and this was strongly predictive of 
cardiovascular death or cardiac failure. 249 A more recent study conducted by Mills et 
al using a 5th generation assay (Abbot, IL, USA) increased the detection of 
myocardial infarction by 29% and predicted the patients with the greatest risk of 
recurrent infarction and death, although the same association with peak serum 
troponin concentration and adverse outcome was not observed. 88 
Serum troponin has also been used to predict outcome following surgery 83•84 and a 
systematic review of fourteen studies (n=3318) by Levy et al found increased 
elevated serum troponin following surgery was an independent predictor of mortality 
(OR 3.4, CI 2.2-5.2) although this study included various manufacturers and 
generations of troponin assay. 85 The more recent "Vascular Events in Non Cardiac 
Surgery Patients Cohort Evaluation" (VISION) Study evaluated major cardiac 
complications in 15 133 patients over the age of 45 undergoing major non-cardiac 
surgery. In this study, there was a high prevalence of cardiac risk factors in the study 
cohort. After adjustment for cardiovascular and respiratory risk factors and also for 
various operative factors logistic regression analysis suggested that elevated 41h 
generation Troponin I assay in the first 72 hours postoperatively was associated with 
mortality. 90 
"Goal Directed Haemodynamic Therapy" seeks to improve outcome by augmenting 
cardiac output, optimising fluid status and hence increasing oxygen delivery to the 
tissues. Although GDHT has been evaluated in many clinical trials, clear evidence 
for widespread implementation is lacking. GDHT may reduce postoperative 
complications, especially infectious complications, 139 however concerns remain that 
the pre-emptive use of inotropic therapy in the absence of traditional indications for 
such treatment may lead to an increased incidence of myocardial ischaemia and 
infarction. The incidence of ischaernic heart disease in patients undergoing major 
surgery is high 174 and use of pharmacological agents which increase myocardial 
work at a time of increased physiological stress (e.g. beta-adrenergic drugs) may 
result in an imbalance of myocardial oxygen supply and demand. 173 Beta adrenergic 
drugs, in particular dopexamine, may also provoke tachyarrhythmia and hypotension. 
141 The absence of data adequately describing the myocardial effects of GDHT is an 
important obstacle to the wider use of this potentially beneficial treatment, and 
increase in Type 2 MI is the primary concern. Two small studies have examined 
troponin release following goal directed haemodynamic therapy (GDHT) in the 
perioperative setting. Pearse et al examined Troponin release over the first two 
postoperative days using a 3rd generation assay in 122 patients randomised to receive 
either GDHT (including administration of dopexamine) or usual care. In this study 
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he found no significant difference in Troponin release between groups. 140 Lee et al 
reported similar findings in 135 patients randomised to a GDHT algorithm (again 
involving dopexamine administration). In this study troponin was measured using 
three different 5th generation highly sensitive assays. 250 
The Optimisation of Peri-operative Cardiovascular Management to Improve Surgical 
Outcome (OPTIMISE) Trial (described in detail in chapter 2) included a biomarker 
sub study in participating s.ites. Trial participants who had agreed to take part in the 
biomarker sub study had samples of blood and urine taken at induction of 
anaesthesia and at 24 and 72 hours postoperatively. 
The biomarker study was led from Edinburgh with support and advice from the 
Centre for Cardiovascular research at the University of Edinburgh. It included a 
planned analysis of troponin release in the perioperative period in both GDHT and 
usual care groups. The following research questions were considered: 
1. Is GDHT associated with increased in myocardial injury as measured by the 
ARCHITECT STAT (Abbot, ll.-, USA) 5th generation highly-sensitive troponin I 
(HST) assay? 
2. Can serum HST accurately predict death, MI or MACE at 7 or 30 days following 
surgery or death at 180 days following surgery? 
8.2 Methods 
Four Hospitals took part in the biomarker sub-study: The Royal Infirmary of 
Edinburgh, The Royal London Hospital, Southampton University Hospitals NHS 
Trust and University College London Hospital. Samples were transported to the 
Queen's Medical Research Institute in Edinburgh at the end of the trial. The sample 
analysis was carried out in the biochemistry department at the Royal Infirmary of 
Edinburgh using reagents provided free of charge by Abbot (Abbot, U-, USA). 
Clinical data for each biomarker study patient was obtained from the main 
OPTIMISE trial dataset. 
Ethics, Sponsorship and Indemnity 
The OPTIMISE trial underwent an independent Ethics Committee review in the UK 
and an interim analysis by a data monitoring and ethics committee in December 
2011. Sample collection and analysis for the biomarker sub-studies were included as 
part of this application. Consent for trial participants to permit collection blood and 
urine samples at 0, 24 and 72 hours were taken at the time of recruitment to the main 
trial. 
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Queen Mary's University, London was the OPTIMISE Trial Sponsor. University of 
Edinburgh was the lead site for the OPTIMISE biomarker analysis. 
Study Population 
Entry criteria for the OPTIMISE trial have been described in more detail in chapter 
2, but in brief were high-risk patients undergoing major abdominal surgery involving 
the gastrointestinal tract, expected to take longer than 90 minutes. High risk patients 
were defined as those aged 65 years and over or those aged 50-64 years with one or 
more of: non-elective surgery, acute or chronic renal impairment, diabetes mellitus 
or presence of a ri sk factor for cardiac or respiratory disease. Patients were then 
randomised to receive either Goal Directed Haemodynamic Therapy (GDHT) or 
Usual Care (UC). Patients receiving GDHT had non-invasive cardiac output 
monitoring and SV optimisation using the LiDCOrapid monjtor and dopexamine at a 
dose of 0.5 meg/kg/min for the duration of surgery and for 6 hours after. A full 
description of the clinical management for patients in the intervention and usual care 
arms can be found in Chapter 2. Participants were centrally allocated to treatment 
groups using a computer generated dynamic procedure (minimisation) with a random 
component. Participants were allocated with an 80% probabil ity to the group that 
minimi ed between group differences in trial site, urgency of surgery and surgical 
procedure category among all participants recruited to the stud y to that date. This is 
applicable to patients recruited into the biomarker substudy. 
Data Collection 
We were permitted access to the full OPTIMISE dataset for patients enrolled in the 
OPTIMISE biomarker sub-study. Demographic data was extracted on: age, sex, 
American Association of Anaesthetists Physical Status (ASA-PS), nature and 
urgency of surgery, anaesthetic technique and baseline risk factors for patients in 
both intervention and control groups and comparison made between intervention and 
control groups to ensure there were no significant differences. 
Outcome data was collected on: clinical diagnosis of myocardial ischaemia or 
infarction, major adverse cardiac events (MACE), death at 30 and 180 days. 
Definitions 
Myocardial Infarction: Definition was that used in Appendix I of the OPTIMISE 
Protocol i.e. ECG changes suggestive of myocardial ischemia or infarction with 
appropri ate clinical findings and a rise or fall in cardiac troponin concentration with 
at least one value above the 99th percentile. 
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Major Adverse Cardiac Events: New diagnosis of arrhythmia, card iogenk 
pulmonary oedema, myocardial infarction or cardiorespiratory arrest as defined in 
Appendix I of the OPTIMISE Protocol. 
Sampling Procedure and Analysis 
Participants had paired blood and urine samples col lected at hour 0 (randomisation), 
hour 24 and hour 72. Blood samples were drawn from arterial or central venous 
catheter or by venepuncture. Samples were inverted five times and left for thirty 
minutes before centrifugation at 3000 rpm for ten minutes. The serum for each 
patient time point was separated into three Eppendorfs and stored at -80°C. 
Prototype 51h generation Troponin I assay (Abbott Diagnostics) was carried out on 
the ARCHITECT STAT platform. This is a two-step assay that offers increased 
precision for measuring very low plasma troponin concentrations and can quantify 
troponin concentrations in 98% of healthy persons with a limit of detection of 1 ng/L 
and I 0% co-efficient of variation <5.5 ng/L. Using thi assay the mean population 
(±SD) concentration of a healthy reference population is I .6±3.1 ng/L with the 99th 
percentile of 26 ng/L for the whole population, 16 ng/L for females and 34ng/l for 
males. 
Statistical Analysis 
Data was analysed using STATA vl2 (Statcorp, TX, USA) and Prism v5.0 
(GraphPad Software Inc, CA, USA). Data are presented as mean [SD] where 
normally distributed and median [IQR] where not normally distributed. Categorical 
variables were analysed using the Chi-Squared Test or Fishers Exact Test and 
continuous data using a 2-sided t-test or ANOV A where appropriate. Significance 
was set at p<0.05. To adjust for skewing and outliers, serum Troponin was 
transformed to natural logarithms, which resu lted in a more normal distribution. Log 
Troponin for each time point and peak value between groups were then compared 
using 2-sided t-test. 
8.3 Results 
Of 734 patients recruited into the OPTIMISE trial, 288 were entered into the 
biomarker sub study; 145 in the GDHT group and 143 in the usual care group. 
Demographic and outcome data for each group are summarised in Table 38 and 
Table 39. 
Patients were randomised to intervention or usual care at time of entry to the 
OPTIMISE trial. In the biomarker sub study cohort there was a greater percentage of 
patients aged over 65 years in the usual care group (87.4% vs 79.3%) although mean 
age was imilar between groups (69.8±8.1 vs 7 1.6±7.5). There wa also a greater 
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proportion of ASA 3 and 4 patients in the usual care group compared with the 
intervention group (52.4% vs. 34.5%) 
There was no significant difference in serum troponin at baseline, 24 hours, 72 hours 
or peak value (Table 39, Figure 19). Troponin release fo llowing surgery was 
estimated by calculating the area under the curve fo r serum troponin for each patient 
at each time point and then comparison was made between groups. There was no 
significant difference in Troponin release in patients receiving GDHT compared with 
usual care as estimated by this method (Figure 20). 
Logistic regress ion showed that, after adjustment fo r age and sex, the preoperative 
5th generation Troponin I assay (i.e. at time point 0) did not predict MI or major 
adverse cardiac events within 30 days of death at 30 or 180 days. Peak seru m 
troponin did predict MI within 30 days (OR 1.5; CI 1.14-2. 11 p=0.005) but did not 
predict death at 30 or 180 days in this population (Table 40). 
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Table 38 Baseline patient characteristics. 
Biomarker Cohort Full Cohort 
Haemodynamic Usual Haemodynamic Usual 
intervention care intervention care 
(n=145) (n=143) (n=368} (n=365) 
Age(years) 69.8 (8.1) 71.6 (7.5) 71·0 (8·4) 72·0 (8·6) 
(mean, SD) 
Age 
50-64 year(%) 30 (20.7) 18 (12.6) 70 (19·0) 59 (16·2) 
~ 65 years(%) 115 (79.3) 125(87.4) 298 (81·0) 306 (83·8) 
Sex 
Male (n,%) 90 (62.1) 93 (65) 237 (64·4) 229 (62·7) 
Female (n,%) 55 (37.9) so (35) 131 (35·6) 136 (37·3) 
Urgency of surgery 
Elective (n,%) 138 (95.2) 137 (95.8) 356 (96·7) 352 (96·4) 
Emergency (n,%) 7 (4.8) 6 (4.2) 12 (3·3) 13 (3·6) 
Baseline risk factors:j: 
Renal impairment (n,%) 8 (5.5) 4 (2.8) 26 (7·1) 12 (3·3) 
Diabetes mellitus (n,%) 23 (15.9) 25 (17.5) 57 (15·5) 65 (17·8) 
Risk factors for cardiac or 45 (31) 54 (37.8) 117 (31·8) 118 (32·3) 
respiratory disease (n,%) 
Planned surgical 
proceduret 
Upper gastrointestinal 53 (36.6) 114 (31·2) 110 (29·9) 114(31·2) 
(n,%) 
Lower gastrointestinal 36 (24.8) 163 (44·7) 167 (45·4) 163 (44·7) 
(n,%) 
Small bowel + j- pancreas 53(36.6) 84 (23·0) 86 (23 ·4) 84 (23·0) 
(n,%) 
Urological or 3(2.1) 4 (1·1) 5 (1·4) 4 (1·1) 
gynaecological surgery 
involving gut (n,%) 
ASA grade 
1 (n,%) 8 (5.5) 5 (3.5) 21 (5·7) 24 (6·6) 
2 (n,%) 87 (60) 63 (44.1) 200 (54·5) 174(48·1) 
3 (n,%) 49 (33.8) 72 (50.3) 143 (39·0) 155 (42 ·8) 
4 (n,%) 1 (0.7) 3 (2.1) 3 (0·8) 9 (2·5) 
:j:Patients may have had more than one risk factor. 
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Myocardial Infarction within 30 Days (n,%) 5 (3.4) 6 (4.2) 0.74 
Major Adverse Cardiac Event Within 30 Days (n,%) 24 (16.6) 32 (22.4) 0.21 
Death Within 30 Days (n,%) 5 (3.4) 5 (3.5) 0.98 
Death Within 180 Days (n,%) 16(11.0) 21 (14.7) 0.36 
Troponin I above 99th Centile (n,%) 67(46.2) 68 (47.6) 0.82 
Troponin Time 0 (ngL·1) (median, JQR) 4.25 (2.75-7.7) 4.3 (2.9-7.4) 0.78 
Troponin Time 24 Hours (ngL·1) (median, JQR) 9.3 (5.1-17.0) 6.9 ( 4.3-17.8) 0.71 
Troponin Time 72 Hours (ngL·l) (median, JQR) 6.35 (4.1-15.85) 6.7 (4.0-13.1) 0.57 
Maximum Troponin (ngL·l) (median, IQR) 10 (5.3-21.5) 7.8 (5-21.8) 0.85 
Troponin Area Under Curve (Mean, SEM) (3.87, 0.21) (3.67, 0.22) 0.5 
Table 40 Logistic regression model of preoperative and maximum troponin within 72 
hours for major clinical outcomes. 
Myocardial Infarction (OR, 95% Cl) 
Major Adverse Cardiac Event (OR, 95% Cl) 
Death Within 30 Days (OR, 95% CI) 







1.01 (0.64-1 .6) 





1.23 (0.84-1. 79) 
1.02 (0.79-1.32) 
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Figure 19 Log serum Troponin I for GDHT and UC group at each timepoint. 
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8.4 Discussion 
The main fi ndi ng from this study was that the goal directed haemodynamic therapy 
intervention delivered in the OPTIMISE trial was not assoc iated with an increase in 
myocardial injury, a measured by 5th generation, highly en itive Troponin I. There 
wa no ob erved difference in postoperative erum troponin concentration at 
ba e line, 24 or 72 hours, in peak serum troponin concentration or in totaJ troponin 
relea e, as measured by area under the troponin concentration/time curve. Peak 
serum troponin levels were associated with increased risk of myocardial infarction 
but not wi th increased incidence of death at 30 or .1 80 days. Also, preoperative serum 
troponin levels were not predictive of myocardia l infarction, major adverse cardiac 
event or death at 30 days, or death at 180 days. 
Clinical data from the main OPTIMISE suggested that although there were increased 
cardiovascular serious adverse events (SAE) in the GDHT group (4, I .6%) compared 
with none in the usual care group rates of card iovascular complications at 30 days 
were similar. This was observed in both the main trial and the biomarker sub-study 
groups. 
The finding from this analysis concur with the systematic review and meta-analysis 
conducted by Grocott and co-workers who, as part of their review, examined the 
association between GDHT and cardiac complications. The investigators in this 
tudy found no association between GDHT and arrhythmia (RR 0.84 (0.67- 1.06); ! 2 
00%; p=0. 14), myocardial infarction (RR 1.0 I (0.71- 1.45); l 00%; p=0.95) and 
congestive cardiac failure/pulmonary oedema (RR I .00 (0.81- 1.24); !2 00%; p=0.98). 
Pearse and co-workers have conducted a similar analysis; they examined patterns of 
Troponin release in 122 patients who had participated in a single centre trial of 
GDHT. This study did not demonstrate increased myocardial troponin release 
associated with the intervention. The results of this study add weight to the assertion 
that GDHT in the perioperative setting is not associated with increased cardiac 
injury. 
The other finding of interest in this s tudy was that preoperative measurement of s'b 
generation highly-sensitive troponin did not predict either death or major adverse 
cardiac event in this cohort of patients; neither did peak serum h Tnl in the fi rst 72 
postoperati ve hour predict mortality at either 30 or 180 day , although was highl y 
predictive of postoperati ve myocardial infarction (p=0.0005). 
Whether the benefits of earlier detection of myocardial necro i u ing so calJed 
"high-sensitivity troponin" assays result in patient benefit is controversial. 88 Lopez-
Jimenez evaluated the incidence and prognostic significance of card iac Troponin T 
(TnT) in 772 patients who had undergone major non-cardiac surgery. 12% of 
patients in thi s cohort had elevated TnT and this was as ociated with increased risk 
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for cardiac events (RR 5.4 (2.2-13.0), p=O.OOJ ). 89 More recently Kavsak and co-
workers reported the incidence of elevated 51h Generation Troponin I assay (i.e. 
greater lhan 99th percentile) to be 45% in a cohort of 325 patients older than 45 years 
of age and undergoing elective or emergent non-cardiac surgery requiring inpatient 
admission. Whether this was associated with mortality was not reported. 91 The 
VISION study investigators measured serum Troponin T using a 4th generation assay 
in a cohort of 15 133 patients over the age of 45 years having inpatient non-cardiac 
surgery. The overall mortality in this cohort was low (1.9%), however the 
investigators found that peak Troponin in the first 72 hours was significantly 
associated with increased mortality at 30 days in thi s group. 
Strengths of th is study are that samples were collected from the largest multicentre 
randomised controlled trial of GDHT undertaken to date and it was reassuring to 
note that the intervention did not seem to be associated with increased myocardial 
necrosis using a highly sensitive troponin assay. Limitations of this study were that 
universal definitions of myocardial infarction as outlined by Thygesen et al were not 
employed in the OPTIMISE trial 251 and access to electrocardiograms (ECGs) for 
individual patients in the trial was not possible. The ability to distinguish "Type 1" 
Myocardial Infarction (i.e. myocardial infarction related to a coronary artery event 
such as plaque rupture) from "Type 2" (i.e. an ischaemic event secondary to 
imbalance of myocardial oxygen supply and demand or related to arrhythmia or 
hypotension) would have been more clinical ly relevant to this study. As the potential 
harm associated with the intervention is like ly to be caused by a combination of 
tachycardia and tachyarrhythmia, increased myocardial oxygen demand and 
hypotension, the incidence of Type 2 MI in these patients would be useful. There 
was also evidence of imbalance between groups in age and ASA-PS score; the 
significance of this is uncertain. The finding that 51h generation highly sensitive 
troponin did not seem to predict short or long term mortality in this group of patients 
was also disappointing and at odds with other published work. 85•90 Possible 
explanations fo r this are: this was a small cohort, patients recruited to this trial were 
higher risk than studied in the VISION study and that findings may have been 
confounded by the trial intervention itself. Peak postoperative hsTni was highly 
predictive of postoperative MI however Troponin rise was a diagnostic criterion for 
this in the study definitions so this finding is perhaps not surprising. 
Absence of evidence of increased cardiac injury associated with this goal directed 
haemodynamic therapy intervention using a highly sensitive marker of cardiac injury 
adds reassu rance that this intervention is unlikely to be associated with significant 
morbidity and may yet be shown to have demonstrable benefits. 
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8.5 Conclusion 
In a sub-study of participants in the OPTIMISE trial, the GDHT intervention did not 
appear to be associated with troponin release in the first 72 hours postoperatively, 
measured as either peak troponin, serum troponin at 24 and 72 hours postoperatively 
or as area under the curve of troponin against time. These findings agree with other 
available data examining this issue. 
After adjustment for age and sex preoperative hsTnllevel was not predictive of death 
at 30 or 180 days or of postoperative cardiac events at 30 days. Peak postoperative 
hsTnl was predictive of postoperative myocardial infarction, but not mortality at 30 
or 180 days in this cohort of patients. Large observational studies of 51h generation 
highly sensitive troponin are required to fully elucidate its role in predicting death or 
adverse outcome when measured preoperatively or in the early postoperative period. 
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Chapter 9 - Conclusions and Directions for Further Research 
9.1 Introduction 
Interventions to improve outcome after high-risk surgery could be associated with 
reduced mortality, morbidity and costs in the surgical population as a whole 2 and as 
highlighted several times in this thesis, there is a demonstrable need to improve 
outcomes in the highest risk groups. 1•15•114 
The OPTIMSE trial demonstrated that the delivery of a goal directed haemodynamic 
therapy algorithm in a group of high-risk surgical patients resulted in a trend towards 
reduction in a composite endpoint of death or major complications at 30 days. This 
effect however did not reach statistical significance (OR 0.84 (CI 0.71-1 .0 I); 
p=0.07). The trial intervention was deliverable in a general NHS hospital setting and 
was unlikely to be associated with early cardiac injury. Despite the overall negative 
outcome of this trial, the results suggested benefit in important pre-specified sub-
group analyses: a trend towards reduction in infectious complications (OR 0.80 (CI 
0.63-1.02); p=0.08); reduction in hospital length of stay (10 v 11 days; p=0.05); a 
statistically significant beneficial effect on the primary outcome was observed in the 
elective only subgroup (OR 0.72 (CI 0.52-0.99); p=0.05), these formed the 
overwhelming majority of patients recruited to the trial and where the first I 0 
patients at each site were excluded (OR 0.59 (CI 0.41-0.84 ); p=0.019). Although 
these findings would not support widespread implementation of this goal directed 
haemodynamic therapy algorithm, they do suggest that the intervention may yet be 
associated with benefit in this group. Hence a further large, multi-centre, randomised 
controlled trial may be warranted to answer this question. 
Investigators conducting such a trial may wish to consider factors in the OPTIMISE 
trial design, del ivery, results as well as some of the research questions considered in 
tbis thesis to better design and deliver another such trial. 
9.2 Conclusions of Research Undertaken in this Thesis 
This thesis set out to inform aspects of the OPTIMISE trial with particular regard to: 
I . Whether choice of fluid therapy influenced the outcome of the triaL 
2. Whether availability or provision of critical care beds could have influenced 
the outcome of the trial. 
3. Whether the trial intervention could have been associated with increased 
cardiac complications. 
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The finding of the research undertaken in this thesis are ummari ed as fo llows: 
Could the choice of colloid used in the perioperative period or trial intervention 
associated with harm or benefit? 
The OPTIMISE trial did not specify which type of colloid should be used for the trial 
intervention and during the study period new evidence emerged which suggested that 
use of Hydroxyeth yl Starch (HES) solutions in critically ill patients was associated 
with inc reased mortality and acute kidney Injury. 169' 172 A post-hoc survey of sites 
followi ng the trial suggested that the vast majori ty of patients received gelofusin for 
the tri al .intervention. Nonetheless if there was an association between perioperative 
HES use and death or renal dysfunction then thi s may have had an effect on the trial 
outcome. There is a genuine paucity of data surrounding the use of 6% HES in the 
su rgical population. 
A deta iled systematic review and meta-analysis of the perioperative use of HES was 
conducted. This rev iew evaluated all types of starch against any comparator fluid, 
but also included a sub-analysis of 6% tetrastarch, a modern RES solution in 
common use in the UK. Using pooled data on 1567 patients no difference in hospital 
mortality, incidence of author-defined AKI or requirement for postoperative RRT 
between groups wa demonstrated. 
No evidence of harm or benefit associated with the perioperative use of HES 
containing solutions was demonstrated in thi s meta-analysis. This provided 
reassurance that the choice of colloid used in the tri al intervention was unlikely to 
have a bearing on the trial outcome. 
A high proportion of patients recruited to the OPTIMISE trial were admitted to 
Critical Care following surgery. Is the use of Critical Care in itself associated with 
improved outcomes after surgery? 
The tri al intervention in the OPTIMISE study involved cardiac output monitoring, 
inotrope use and Ouid optimisation. These intervention are trad itionally delivered in 
an intensive care setting, however for the purposes of the OPTIMISE trial the 
intervention could be delivered in a high dependency unit (HDU) the recovery room 
or even the ward. In the trial approximately 75% of both groups were treated 
postoperatively in an intensive care unit but significant numbers (more than 10% in 
each group) returned to a ward. The remaining patient were treated on an HDU or 
post-anesthesia care unit (PACU). 
The bulk of this thesis explores var1at10n m critical care provtsJon and su rgical 
outcome in the UK and attempts to determine if availability and utilisation of critical 
care beds has any demonstrable effect on outcome. A great many commentators have 
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attributed poor outcomes on lack of cri tical care bed avai lability despite little 
objective evidence of this. 11' 15' 23'113'114 
Marked regional differences within the UK in critical care bed prOVISIOn were 
demonstrated and in an epidemiological study of 16 147 surgical patients admitted to 
ICU, regional variation in acute hospita l mortality which could not be accounted fo r 
by casemix or ICU bed provision. 
In summary, no evidence to support the assertion that availability of ICU beds per se 
improves surgical outcome was found. Other variations in practice, which may be 
difficult to full y elucidate, may be the cause of the observed variation in outcome. It 
is likely that postoperati ve care is a complex interaction of local care pathways, 
increasing use of HDU and PACUs and ICU bed util isation. Alternatively these 
findings may simply reflect unmeasured confounding. Nonetheless, regional 
mortality variation wi thin a very uniform healthcare system suggest some deaths 
may be preventable, as has been highl ighted recently by Aylin et al who 
demonstrated differences in elective surgical outcome dependent on day of the week 
of operation. 162 Further research described later could be undertaken to describe 
patterns of critical care resource use in this population. 
Is GDHT associated with increased myocardial injury as measured by 5'h 
Generation Troponins? 
Administration of beta-agonists outside traditional indications as part of a GDHT 
intervention continues to concern clinicians. Dopexamine is known to cause 
vasodilation and tachycardia 141 and tills combination, in a population known to have 
a high prevalence of ischemic heart disease, 174 could precipitate myocardial 
infa rction (MI). In OPTIMISE, patients receiving the trial intervention had an 
increased incidence of cardiovascular serious adverse events in the first 24 hours of 
the trial compared with the usual care ann (3.9% v 0%) although clinical cardiac 
events at 30 days were similar. In the biomarker study conducted as part of this 
thesis, myocardial injury quantified by 5Lh generation highl y sensitive troponin I 
(HST) assay did not appear to be increased in the intervention group. This findi ng 
provides reassurance that the trial intervention was safe and not associated with 
increa ed risk of myocardial injury. 
Using regression analysis, peak HST in the first 72 hours predicted postoperative 
myocardial infarction but not death at 30 or J 80 days. Preoperative HST was not 
associated with major adverse cardiac events (MACE), MI or death at 30 or L80 
days. This findi ng is not entire ly consistent with other research, notably the recently 
published VISION study, which found that postoperative peak troponin , was highly 
predicti ve of 30-day mortality. 90 Possible explanations for this are: thi was a small 
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cohort, patients recruited to this trial were higher ri sk than studied in the VISION 
study and that findings may have been confounded by the trial intervention itself. 
The re earch que tions regarding fluid therapy and myocardial injury in the context 
of GDHT have been addressed in this thesis. However an association between ICU 
bed provi ion and outcome using a large cohort of surgical ICU admissions was not 
demon trated and the finding of significant regional variation in outcome for surgical 
patients admitted to ICU requires further investigation. 
9.3 Directions for Future Research 
The lack of positive findings of the OPTIMISE trial could be explained by lack of 
statistical power. There are several possible reasons for thi s: 
I. Event rate: OPTIMISE was powered to detect a reduction m the primary 
endpoint of 50% to 37.5% (i.e. 25%) assuming a two sided type I error of 5% 
and a type II error of 10%. In the trial itself the incidence of the primary 
endpoint in the usual care group was 44.4% 
2. Dropouts: I 0 patients withdrew or were lost to follow-up in each arm, this 
may have resulted in the trial being underpowered. Trials in this field have 
historically been hampered by lack of suitable primary endpoints and hence 
sample size. 139 
3. Endpoints: Although complications are common after elective surgery, 
mortality is less so and the composite endpoint of "death or major 
complications within the first 30 days" has obvious attractions, because of a 
higher event rate. Other endpoints e .g. Infectious complications could be 
considered further studies. Data from the OPTIMISE trial suggests that 
infectious complications in particular seemed to be reduced by the trial 
intervention. 
4. Control group care (in particular crossover) also have implications for the 
results of this and other similar studies. 167 In OPTIMISE 8.6% of the usual 
care group received cardiac output monitoring and thi s may also have 
improved outcomes in that group. 
5. Harm associated with the intervention, in particular detrimental effects due to 
excessive or inappropriate fluid administration or myocardial injury are two 
questions, which remain of concern to clin icians using thi therapy and which 
this thesis has sought to address. 
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6. The setting of the trial intervention is another important consideration: might 
admitting trial participants to a critical care in order to deliver the trial 
intervention confer additional benefits? 
7. Biologica l plausibility for the intervention itself is still an area that has not 
yet been full y e lucidated. This could be due to effects of the intervention on 
microcirculatory flow or inflammation. Some commentators have however 
suggested that a fluid restrictive approach in this group ha more biological 
plausibi lity to improve outcomes. 
The development of further research questions arisi ng from the results of the work in 
this thesis may inform further large randomized controlled trials to improve 
outcomes in thi s group. 
Does the choice, timing or other aspects of perioperative fluid therapy influence 
outcomes? 
Choice and timing of perioperative fluid therapy remains a central component of 
perioperative care. 175 Specific questions which remain unanswered in this group are: 
whether use of col loid solutions in the perioperative period confer any benefit, 
whether the timing of fluid administration is important i.e. intra-operative versus 
post-operative and whether a flu id-restrictive strategy is preferable to a fluid-liberal 
one. 
As outlined in Chapter 2 the publication of the CHEST and 6S studies 169•170 and 
several subsequent meta-analyses 182"184 have raised serious safety issues regarding 
the use of hydroxy-ethyl starch solutions in the critically ill , specifically with regard 
to acute kidney injury and mortality. This has led to withdrawal of these solutions in 
the European Union. 252 W hether the results of 6S and CHEST stud ies are applicable 
to the surgical population at all remain contentious. In the 6S study, patients in both 
arms were resuscitated with fluid (which could include HES solutions) to specific 
haemodynamic endpoints prior to randomisation. Patients randomized to the 
crystallo id arm of the CHEST study bad sign ifican tl y worse renal function at 
ba eli ne than those randomized to receive HES. These considerations and also 
whether the results of these studies are applicable to adults having elective surgery at 
all remains an area of ongoing debate. The systemic review and meta-analysis 
pre ented in this thesi along with two others 185•186 suggest that hydroxyl-ethyl 
starch solution neither confer harm or benefit in surgical patients. Many of the 
included trial s are small, single centre, use a variety of starch olutions against a 
variety of comparators and have study populations drawn from diverse surgical 
groups. However a meta-analysis of 1567 patients found essentiall y no difference 
(RD 0.00, 95% CI -0.02, 0.02) between groups. Low study heterogeneity (12 =0%) 
with narrow confidence intervals consistent with a very ti ght level of precision 
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(±2%), suggest these findings are valid. This combined with the low event rates of 
acute kidney injury or death in this group suggest that any rando mised controlled 
trial investigating the safety of starch in the perioperative period would need to very 
large indeed, and are likely to be futile and hence unlikely to be funded. 
In the OPTIMISE trial patients in the intervention arm received approx imately 50% 
more colloid and this was overwhelmingly in the fo rm of gelatin so lutions. Gelatins 
are not widely used outside the UK and have not been submitted to the same degree 
of scrutiny as starch solutions. Therefore their safety profile is largely unknown. 23 
The results of the "Saline versus Albumin for F luid Evaluation" (SAFE) Study and 
the more recent "Effects of Fluid Resuscitation With Collo ids vs. Crystalloids on 
Mortality in Critically DJ Patients Presenting Witb Hypovolemic Shock" 
(CRISTAL) Study have both suggested that the approx imate ratio of crystalloid to 
collo id when used for resusci tation fell far short of the 2: I or 3: I quoted anecdotally. 
253
•
254 With no o bvious benefit associated with collo id use and s imilar volumes of 
crystalloid required for resuscitation (albeit in an intensive care setting) crystalloid 
solutions could feasib ly be used in subsequent GDHT trials. 
Timing of fluid therapy did not appear to be an issue in the OPTIMISE trial. Similar 
amounts of fluid were given to both groups during the operative period and an 
increased amount given to the GDHT group in the first 6 hours. Hence restricting the 
intervention period to the duration of surgery only is unlikely to have any effect. 
Other investigators consider that tissue oedema is implicated in postoperative 
complications and that there is biological plausibility in adopting a more "fluid 
restrictive" strategy. The Restrictive versus Liberal F luid Therapy in Major 
Abdominal Surgery (RELIEF) Study (NCT 01424150) aims to recruit 2800 nigh-risk 
surgical patients and is currently underway in Australi a and New Zealand. This trial 
may reflect a paradigm sh ift in the approach to perioperative fluid management. A 
secondary hypothesis in thi s trial will ascertain if the benefits of fluid restriction are 
seen whether or not a goal directed strategy is employed. 
In conclusion, fu rther trials evaluating either the safety or benefits o f starch or any 
other solution in surgical patients are unlikely to be feasible or provide a definitive 
answer to the question of whether these solutio ns confer any advantage in the 
perioperative etting. Further studies investigating goa l directed fluid therapy could 
conceivably use balanced crystalloid solutions such as Hartmann's Solution or 
Plasmalyte: other studies will investigate whether a " Ouid restrictive approach" is 
bette r and the results of these are awaited with interest. 
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Does use of dopexamine in GDHT confer any additional benefit over fluid therapy 
alone? 
Dopcxamine was included as part of the GDHT algorithm because the results of a 
meta-regression suggested reduction in 28 day mortality and reduced length of 
hospital stay associated with it's use at low doses, 142 although another meta-analysis 
employing different methodology was published around the arne time with 
connicting re ult . 143 A European multi -centre trial showed a tendency towards 
improved survi val and reduced complications in patients treated with low dose 
dopexamine, however at higher doses it was associated with increased rates of 
cardiova cular complications. 141 Possible adverse effects o f dopexamine include 
vasodilation and tachycardia and the combination of these effects in the presence of 
ischacmic heart disease remain of concern to clinicians, begging the question "is 
dopexamine necessary as part of a GDHT trial at all"? 
Although there was an increased incidence of cardiovascular SAEs in the 
intervention group of the OPTIMISE trial the re was no difference in the incidence of 
cardiac complications at 30 days and in the sub-group of patients taking part in the 
biomarker sub-study, there was no difference in early myocardial injury as measured 
by 51h Generation Troponin I release. This is the largest pro pective randomised trial 
of goal directed therapy using dopexamine to date and the absence of a demonstrable 
increase in myocard ial injury in the intervention group is reassuring. However, what 
is the possible mechanism for benefit associated with its use? 
Investigators have postulated that the benefits from dopexamine administration in 
this setting are as a result of improvements in splanchnic microvascular flow and 
there are experimental studies to support thi s. 255•256 Moreover, a more recent clinkal 
investigation using a GDHT protocol involving dopexamine reported improved 
gastrointestinal function and reduced ileus in the postoperative period in the 
. . 145 
tnterventton group. 
New evidence is emerging that dopexamine may have immunomodulatory properties 
which could affect inflammation and immune function fo llowing surgery. In a recent 
study, Bangash et al used a rodent model of laparotomy and endotoxemia to 
investigate the effect of three doses of dopexamine on infla mmatory markers: tumour 
necrosis factor (TNF) a, interleukin (IL) 1-P, IL-6 and IL- l 0; leukocyte cell adhesion 
molecule CD I l b; pulmonary myeloperoxidase (a marker of pulmonary lymphocyte 
infiltration). He also collected data on organ dy function: pia ma urea, creatin ine, 
aspartate and alanine aminotransferase (AST and ALT), plas ma base excess (BE) 
and emm lactate. Results of this study suggested a dose-dependent reduction in 
inflammation associated with dopexamine administration and also reduction in end 
organ damage. 120 Hence, the beneficial effects of dopexamine may be explained by 
Michael Gillies Doctor of Medicine (2014) 162 
attenuation of the inflammatory response to surgery and endotoxemia. This may 
explain the particular reduction in infectious complications seen in the intervention 
group of the OPTIMISE triaL 
Using the OPTIMISE biomarker sub-study sample bio-bank it would be possible to 
investigate the effects of the trial intervention and in particular the ad ministration of 
dopexamine on the same markers of inflammation and this could be correlated to 
clinical complications and other markers of end organ damage such as serum 
creatin ine, urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) and 
transaminases. A subsequent GDHT trial could include arms with o r without 
dopexamine to investigate whether the immunomodulatory effects of dopexamine 
are clinica11 y significant. 
Can the use of perioperative critical care improve outcomes; how can patterns of 
surgical critical care utilization be further investigated and refined? 
Although in Chapter 6 we attempt to use modeling techniques to ascertain if critical 
care provision or utilization can explain variability in outcome after high-risk 
surgery, a major drawback of this work is that the analysi only includes patients 
admi tted directly to ICU following surgery. It is known that a large group of surgical 
patients are initiall y admitted to the ward before admission to ICU and in the work 
undertaken by Pearse et al this group had the worst outcomes. 15 High qual ity data 
on the numbers of high-risk patients presenting for surgery and their requirements for 
Intensive Care in the UK remain sparse. 
In England, Wales and Northern Ireland there is no linkage between the hospi tal, 
intensive care and death databases (Health Episode Statistics, Intensive Care 
National Audit and Research Centre (ICNARC), Register of Deaths) and therefore it 
is not possible for investigators to link inpatient surgical admissions to intens ive care 
admission or to adjust for social deprivation or preceding co-morbidities. Moreover 
ICNARC only capture data on 92% of Intensive Care Units in England, Wales and 
Northern Ireland. Therefore it has not been possible to obtain a clear picture of the 
epidemiology of the high-risk surgical population and the ir utilisation of intensive 
care resources.5 
Information Services Division (ISD) Scotland holds data on all acute hospital 
discharges in Scotland through the Scottish Morbidity Record (SMR) databases. 
Through linkage, data can be extracted relating to diagnostic information, detailed 
physiological data from ICU admission (the Scottish Intensive Care Society Audit 
Group (SJCSAG) database is also hosted by lSD), long-term outcomes (deaths 
registry), data on hospital readmissions (SMRO I), and other relevant data such as 
social deprivation. The SMROJ database is subject to regular va lidation checks, and 
the most recent quali ty assurance report indicated good levels of accuracy (>90%) 
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for the fields used in this study. Up to four surgical procedure codes can be recorded 
on each SMRO I episode along with the date of procedure. These fields have an 
accuracy of more than 95%. 228 Diagnostic information field , which could be used to 
derive co-morbidities, are recorded using the International Clas ification of Diseases 
version I 0 (I CD-I 0). There are up to six fields that can be used to record diagnoses, 
with one allocated as the main reason for admission. Information Services Division 
links SMRO I routinely to the Scottish death register using patient characteristics in a 
probabilistic matching algorithm with a high degree of accuracy. 257 
As described earlier the Scottish Intensive Care Society Audit Group (SICSAG) 
holds data on to all admissions to general ICUs in Scotland and data are collected 
prospectively at the time of admission by clinical staff in the ICU. The database 
contains information relating to patient demographics, physiological measures of 
illness severity, number of days of organ support, diagnostic in formation including 
surgical status, and patient outcome. Quality assessment reports are produced on a 
regular basis, which demonstrate high levels of data quality. 228 
Using data available from lSD it would be possible to determine proportion of 
patients admitted to ICU directly after high-risk surgery and those admitted to the 
ward first. Because all hospital and ICU admissions are captured a very accurate and 
detailed picture of pattern of critical care utilization as well a outcomes in the short, 
medium and long term (i.e. 1-3 years) could be constructed. Hospital re-admission 
could be used to look at hospital resource use in the year following high-risk surgery 
and whether critical care use mitigated this. It would also be possible to construct a 
detailed model identifying patient, surgical, hospital and socioeconomic factors 
associated with morbidity and mortality following high-risk su rgery. 
Accurate, complete data at national level on critical care utilisation and outcomes 
after high-risk surgery would enable identification of the patients at highest risk of 
dying or developing major complications in the postoperative period. This could 
inform strategies to reduce morbidity and mortality. Data of this nature is highly 
re levant to clinicians, healthcare funders and patients, as well as those designing 
large clinical trials. 
Can other biomarkers of organ dysfunction or inflammation predict those at risk of 
complications when measured either pre-operatively or in the early post-operative 
period? 
There is a great deal of interest in the role of using novel biomarkers either pre-
operatively or in the early postoperative period to predict tho e at risk of death or 
com pi ications. 
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In this thesis one such biomarker, highly sensitive troponin I is used, not only to 
quantify myocardial injury between groups but also to ascertain if preoperative 
values or peak value in the first 72 hours postoperatively can predict death or major 
adver e cardiac events at 30 or 180 days. The urine and pia rna amples collected for 
the OPTIMISE biomarker sub study could be used to study the predictive value of 
other novel and established biomarkers. 
Candidates for this would be: 
1. Brain Natriuretic Peptide (BNP) or N-Terminal Pro-Brain Natriuretic Peptide 
(NT-proBNP). 
BNP can only be measured in plasma; therefore NT-proBNP measurement would 
need to be used on these samples. Such an analysis could answer two important 
questions. Firstly the ability of NT pro-BNP concentration to accurately predict 
patients suffering death, MI or MACE at 7 or 30 following surgery or death at 180 
days fo llowing surgery in the entire cohort and each group could be assessed. 
Secondly, because BNP and NT-proBNP are released in response to volume 
overload, this could assess whether the intervention was associated with fluid 
overload in the early postoperati ve period. Excessive fluid administration has been a 
concern in previous GDHT studies. 220 
2. Biomarkers of Renal Dysfunction 
Post-operative Acute Kidney Injury (AKI) is associated with significantly increased 
morbidity, mortality and cost. 258 The incidence of peri-operative AKI may be as high 
as 7.5% dependi ng on the definitions used. 259 Current classifications (AKIN, 
RIFLE) use "fold-change" in serum creatinine (SCr) and urine output to define 
different stage. 260 Many authors consider SCr changes to be a poor early marker of 
kidney injury. 261 
Novel biomarkers have been recently described that enable the early prediction and 
detection of AKI prior to changes in serum creatinine. The most commonly studied 
of these, NGAL, is described in a previous chapter, however other renal biomarkers 
are emerging. Pia rna Cystatin C (plasma CyC) is a produced by all nucleated cells, 
excreted through glomerular filtration and metabolised by the proximal tubules 
without any evidence of tubular secretion. Plasma CyC is therefore a good marker of 
GFR and di criminates small changes in GFR more accurately than SCr. 
Using the OPTIMISE bio-bank, the effect of GDHT on biomarkers of renal 
dysfunction and the ability of these novel biomarkers to predict post operative renal 
dysfunction in major non-cardiac surgery could be assessed. 
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3. Biomarkers of Inflammation 
C-reacti ve protein (CRP) is an acute phase protein and levels ri e in response to 
inflammation. As described earlier it has been used to predict postoperative 
complications including myocardial infarction, anastomotic leak and death. Other 
inflammatory cytokines have been investigated in the postoperative period but 
whether they can be used to make prognostic decisions is largely unknown. The 
effect of GDHT (and in particular dopexamine) on markers of inflammation has been 
proposed above. Logistic regression could be used to test for association between 
serum levels of inflammatory biomarkers and if this was found, standard 
methodology using receiver-operated curves (ROC) could be used to determine 
optimal diagnostic points . 
In summary, further research utilising the OPTIMISE trial bio-bank could be used to 
determjne the effects of GDHT on inflammation and organ dysfunction following 
high-risk surgery. It could also be used to develop the role of biomarkers to predict 
those most at risk of developing complications. 
What refinements could be made to a large trial of GDHT to successfully answer this 
question? 
Although the OPTIMISE trial demonstrated no significant reduction in 30-day 
complication rates, findings of pre-specified secondary and subgroup analyses and 
the non-s ignificant reduction in mortality at 180 days were all consistent with a 
beneficial effect of the intervention. A larger clinical trial would be required to 
resolve thi s. Were the trial to be repeated, investigators may consider several changes 
to trial des ign in order to answer the question definitely . 
Firstly, detai led and accurate epidemiological data on mortality and complication 
rates will be vital to ensure any subsequent study is adequately powered. In 
OPTIMISE the estimated incidence of the primary endpoint was overestimated (50% 
vs. 44.4.%) and this may have resulted in the trial being underpowered once patients 
who withdrew consent or were lost to follow-up were considered. 
Suitable endpoints should also be considered. Infectious complications seem to have 
been reduced mo L in the intervention group of OPTIMISE although overall thi s did 
not reach significance (p=0.08). A longer mortality period may also be worth 
considering; as noted earlier in the thesis 45, 60 and 90-day mortality have all been 
proposed a tudy endpoints for surgical patients. 11' 21 The RELIEF study (described 
above) has similar endpoints to OPTIMISE and intends to recruit 2800 patients. 
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Another question for subsequent GDHT trials is the intervention itself. It would seem 
from considerations discussed above that dopexamine should be investigated as part 
of the trial intervention. However to better separate the effects of dopexamine from 
the goal directed fluid therapy it might be desirable to randomi e patients to receive 
either goal directed fluid therapy or usual care and either low-dose dopexamine or 
placebo. Thi would effectively create four groups but would allow better study of 
the trial intervention. Final.ly consideration must be given to the control group care. 
8.6% of patients in the usual care arm received cardiac output monitoring of some 
description and almost 30% received an infusion of vasoactive drugs. Like recent 
ARDS trials, 262·263protocolisation of the usual care arm to reflect best current 
practice may also reduce the effect of the intervention. 
9.4 Summary 
The research undertaken in this thesis was to inform the interpretation of OPTIMISE, 
a randomised controlled trial of goal directed haemodynamic therapy versus usual 
care in high-risk patients undergoing gastrointestinal surgery. The work done in this 
thesis may guide future studies. 
The principal findings of this thesis are: 
• In a meta-analysis of 1567 patients comparing perioperative 6% hydroxyl-
ethyl tarch solutions versus any comparator no difference in 30-day 
mortal ity or acute kidney injury was observed. 
• Significant regional variation exists in ICU bed provision within the UK. 
• In an epidemiological study of 16 147 patients admitted to ICU fo llowing 
surgery in the UK significant variation in acute hospital mortality was 
observed. This did not appear to be accounted for by casemix or ICU bed 
provision. 
• Using 51h Generation highly sensitive Troponin I no difference difference in 
myocardial injury or infarction between GDHT and usual care groups was 
detected. 
Future research should concentrate on: refining the GDHT intervention and this may 
include further investigation of its biological mechanism; high quality 
epidemiological data to inform future studies and predict tho e patients at the highest 
risk; more detailed epidemiological investigation of critical care re ource util ization 
and its effects on outcome; perioperative measurement of biomarkers to identify 
patient at high risk of specific complications and death. 
Michael Gillies Doctor of Medicine (2014) 167 
References 
1. Bennett-Guerrero E, Hyam JA, Shaefi S, et al. Comparison of P-POSSUM risk-
adjusted mortality rates after surgery between patients in the USA and the UK. Br J 
Surg. 2003;90(12): 1593-1598. 
2. Weiser TG, Regenbogen SE, Thompson KD, et al. An estimation of the global 
volume of surgery: A modelling strategy based on available data. Lancet. 
2008;372(9633): 139-144. 
3. Findlay GP, Goodwin APL, Protopapa K. Knowing the risk - A review of tbe 
perioperative care of surgical patients .. 2011 . 
4. Khuri SF, Henderson WG, DePalma RG, et al. Determinants of long-term survival 
after major surgery and the adverse effect of postoperative complications. Ann Surg. 
2005;242(3):326-41; discussion 341-3. 
5. Sweetland S, Green J, Liu B, et al. Duration and magnitude of the postoperative 
risk of venous thromboembolism in middle aged women: Prospective cohort study. 
BMJ. 2009;339:b4583. 
6. Head SJ, Howell NJ, Osnabrugge RLJ, et al. The european association for cardia-
thoracic surgery (EACTS) database: An introduction. European Journal of Cardia-
Thoracic Surgery. 2013. 
7. Bridgewater B, Gummert J, Kinsman R. Fourth EACTS adult cardiac surgical 
database: Individual country report for england 2010 . . 2010. 
8. Saunders DI, Murray D, Piche! AC, Varley S, Peden CJ, on behalf of the members 
of the UK Emergency Laparotomy Network. Variations in mortality after emergency 
laparotomy: The first report of the UK emergency laparotomy network. British 
Journal of Anaesthesia. 2012;109(3):368-375. 
9. Gawande AA, Thomas EJ, Zinner MJ, Brennan TA. The incidence and nature of 
surgical adverse events in colorado and utah in 1992. Surgery. 1999; 126(1 ):66-75. 
10. KABLE AK, GIBBERD RW, SPIGELMAN AD. Adverse events in surgical 
patients in australia. International Journal for Quality in Health Care. 
2002;] 4( 4):269-276. 
11. Pearse RM, Moreno RP, Bauer P, et al. Mortality after surgery in europe: A 7 
day cohort study. Lancet. 2012;380(9847):1059-1065. 
Michael Gillies Doctor of Medicine (2014) 168 
12. Karthikesalingam A, Holt PJ, Vidai-Diez A, et aJ. Mortality from ruptured 
abdominal aortic aneurysms: Clinical lessons from a comparison of outcomes in 
england and the USA. Lancet. 20 14;383(9921 ):963-969. 
13. NHS Executive. Quality and performance in the NHS: NHS performance 
indicator .. 2000. 
14. Head J, Ferrie JE, Alexanderson K, Westerlund H, Vahtera J, Kivimaki M. 
Diagnosis-specific sickness absence as a predictor of mortality: The whitehall II 
prospective cohort study. BMJ. 2008;337. 
15. Pearse RM, Harrison DA, James P, et aJ. Identification and characterisation of 
the high-risk surgical population in the united kingdom. Crit Care. 2006;1 0(3 ):R8 J. 
16. Anderson Id, Eddleson J, Grocott M et al. The higher risk surgical patient: 
Towards improved care in a forgotten group . . 2011. 
17. Symons NR, Moorthy K, Almoudaris AM, et al. Mortality in high-risk 
emergency general surgical admissions . Br J Surg. 2013;100(10):1318-1325. 
18. Ghaferi AA, Birkmeyer JD, Dimick JB. Variation in hospital mortality associated 
with inpatient surgery. N Engl J Med. 2009;361 (14): 1368-1375. 
19. Peter Craig, Paul Dieppe, Sally Macintyre, Susan Michie, Irwin Nazareth, Mark 
Petticrew. Developing and evaluating complex interventions: The new medical 
research counci l guidance. BMJ. 2008;337. doi: 10.1136/bmj.a1655. 
20. Pearse RM. Another inconvenient truth: Meeting the challenge of preventing 
poor surgical outcomes. Curr Opin Crit Care. 2010;16(4):337-338. 
21. Visser BC, Keegan H, Martin M,Wren SM. Death after colectomy: It's later than 
we think. Archives of Surgery. 2009;144(11):1021- l 027. 
22. Ghaferi AA, Birkmeyer JD, Dimick JB. Variation in hospital mortality associated 
with inpatient surgery. N Engl J Med. 2009;361(14):1368-1375. 
23. Bennett-Guerrero E, Welsby I, Dunn TJ , et al . The use of a postoperative 
morbidity survey to evaluate patients with prolonged hospitalization after routine, 
moderate-risk, elective surgery. Anesthesia & Analgesia. 1999;89(2):514-514. 
24. Davies S, Francis J, Dilley J, Wilson RJ , Howell S, Allgar V. Measuring 
outcomes after major abdominal surgery during hospitalization: Reliability and 
validity of the postoperative morbidity survey. Perioperati ve Medicine. 2013 ;2( 1 ): l. 
Michael Gillies Doctor of Medicine (2014) 169 
25. Grocott MP, Browne JP, Van der Meulen J, et al. The postoperative morbidity 
survey was validated and used to describe morbidity after major surgery. J Clin 
Epidemiol. 2007;60(9):919-928. 
26. Papazian L, Forel J , Gacouin A, et al. Neuromuscular blockers in early acute 
respiratory distress syndrome. N Engl J Med. 201 0;363(12): 1107-1116. 
27. Mercat A, Richard JM, VieJle B,et al. Positive end-expiratory pressure setting in 
adults with acute lung injury and acute respiratory distress syndrome: A randomized 
controlled trial. JAMA. 2008;299(6):646-655. 
28. Brown SR, Mathew R, Keding A, MarshaJI HC, Brown JM, Jayne DG. The 
impact of postoperative complications on long-tem1 quality of life after curative 
colorectal cancer surgery. Ann Surg. 2013. 
29. Rausei S, Mangano A, Galli F, et al. Quality of life after gastrectomy for cancer 
evaluated via the EORTC QLQ-C30 and QLQ-ST022 questionnaires: Surgical 
considerations from the analysis of 103 patients. Int J Surg. 2013; 11 SuppJ 1 :S 104-9. 
30. Biring GS, Masri BA, Greidanus NV, Duncan CP, Garbuz DS. Predictors of 
quality of life outcomes after revision total hip replacement. J Bone Joint Surg Br. 
2007;89(1 1):1446-1451. 
31. Essving P, Axelsson K, Aberg E, Spannar H, Gupta A, Lundin A. Local 
infiltration analgesia versus intrathecal morphine for postoperative pain management 
after total knee arthroplasty: A randomized controlled trial. Anesth Analg. 2011 . 
32. Black NA, Jenkinson C, Hayes JA, et al. Review of outcome measures used in 
adult critical care. Crit Care Med. 2001;29(11 ):2119-2124. 
33. The National Insti tute for Clinical Excellence. Measuring effectiveness and cost 
effectiveness: The QALY. 
http://www. nice. or g. uk/newsroorn/features/measuringeffecti venessandcosteffecti ven 
esstheqaly.jsp. Updated 2013. Accessed 01106, 2014. 
34. Devlin N, Parkin D. Does NICE have a cost-effectiveness threshold and what 
other factors influence its decisions? A binary choice analysis. Health Econ. 
2004; 13(5):437 -452. 
35. Appleby J, Devlin N, Parkin D, Buxton M, Chalkidou K. Searching for cost 
effectiveness thresholds in the NHS. Health Policy. 2009;91 (3):239-245. 
36. Cuthbertson B, Campbell M, StottS, et al. A pragmatic multi-centre randomised 
controlled trial of fluid loading in high-risk surgical patients undergoing major 
elective surgery - the FOCCUS study. Critical Care. 2011 ;15(6):R296. 
Michael Gillies Doctor of Medicine (2014) 170 
37. Saklad M. Grading of patients for surgical procedure . Anesthesiology. 
1941 ;2:28 1. 
38. Dripp RD. New classification of physical status. Anesthes io l. 1963;24: 111. 
39. Owen WD. American society of anesthesiologists physical status classification 
system in not a risk class ification system. Anesthesiology. 200 I ;94(2):378. 
40. Mak PH, Campbell RC, Irwin MG, American Society of Ane thesiologists. The 
ASA physica l status classification: Inter-observer consistency. american society of 
anesthesiologists. Anaesth Intensive Care. 2002;30(5):633-640. 
41. Haynes SR, Lawler PG. An assessment of the consistency of ASA physical status 
classification allocation. Anaesthesia. 1995;50(3): 195-199. 
42. Owens WD, Felts JA, Spitznagel EL,Jr. ASA physical status classifications: A 
study of consistency of ratings. Anesthesiology. 1978;49( 4):239-243. 
43. Wolter U, Wolf T , Stutzer H, Schroder T. ASA classification and perioperative 
variables as predictors of postoperative outcome. Br J Anaesth. 1996;77(2):217 -222. 
44. Davenport DL, Bowe EA, Henderson WG, Khuri SF, Mentzer RM,J r. National 
surgical quality improvement program (NSQIP) risk factor can be used to validate 
american soc iety of anesthesiologists physical status classification (ASA PS) levels. 
Ann Surg. 2006;243(5):636-41; discussion 641-4. 
45. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying 
prognostic comorbidity in longitudinal studies: Development and validation. J 
Chronic Dis. 1987;40(5):373-383. 
46. Charlson M , Szatrowski TP, Peterson J, Gold J . Validation of a combined 
comorbidity index. J Clin Epidemiol. 1994;47(11 ): 1245-1251. 
47. Deyo RA, Cherkin DC, Ciol MA. Adapting a cjjnical comorbidity index for use 
with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613-619. 
48. Ghali WA, Hall RE, Rosen AK, Ash AS, Moskowitz MA. Searching for an 
improved clinical comorbidity index for use with ICD-9-CM administrati ve data. J 
Clin Epide miol. 1996;49(3):273-278. 
49. Copeland GP, Jones D, Walters M. POSSUM: A coring ystem for surgical 
audit. Br J Surg. 199 J ;78(3):355-360. 
50. Prytherch DR, Whiteley MS, Higgins B, Weaver PC, Prout WG, Powell SJ. 
POSSUM and portsmouth POSSUM for predicting mortality. physiological and 
Michael Gillies Doctor of Medicine (2014) 171 
operative severity score for the enUmeration of mortality and morbidity. Br J Surg. 
1998;85(9): 12 17- 1220. 
51. Shuhaiber JH, Hankins M, Robless P, Whitehead SM. Comparison of POSSUM 
with P-POSSUM for prediction of mortality in infrarenal abdominal aortic aneurysm 
repair. Ann Vase Surg. 2002; 16(6):736-741. 
52. Mohamed K, Copeland GP, Boot DA, et al. An assessment of the POSSUM 
system in orthopaedic surgery. J Bone Joint Surg Br. 2002;84(5):735-739. 
53. Ramesh VJ, Rao GS, Guha A, Tbennarasu K. Evaluation of POSSUM and P-
POSSUM scoring systems for predicting the mortality in elective neurosurgical 
patients. Br J Neurosurg. 2008;22(2):275-278. 
54. Sutton R, Bann S, Brooks M, Sarin S. The surgical ri sk scale as an improved tool 
for ri sk-adjusted analysis in comparative surgica l audit. Br J Surg. 2002;89(6):763-
768. 
55. Brooks MJ, Sutton R, Sarin S. Comparison of surgical risk score, POSSUM and 
p-POSSUM in higher-risk surgical patients. Br J Surg. 2005;92( I 0): 1288-1292. 
56. Knaus WA, Zimmerman JE, Wagner DP, Draper EA, Lawrence DE. APACHE-
acute physiology and chronic health evaluation: A physiologically based 
classification system. Crit Care Med. 1981 ;9(8):59 1-597. 
57. Knaus WA, Wagner DP, Draper EA, et aJ. THe apache ii i prognostic system. risk 
prediction of hospital mortality for critically ill hospitalized adults. CHEST Journal. 
1991 ; 1 00(6): 1619-1636. 
58. Zimmerman JE, Kramer AA, McNair DS, Malila FM. Acute physiology and 
chronic health evaluation (APACHE) IV: Hospital mortality assessment for today's 
criti cally ill patients. Crit Care Med. 2006;34(5): 1297-13 10. 
59. Rowan KM, Kerr JH, Major E, McPherson K, Short A, Vessey MP. Intensive 
care society's APACHE II study in britain and ireland--IT: Outcome comparisons of 
intensive care units after adjustment for case mix by the american APACHE II 
method. BMJ. 1993;307(6910):977-981. 
60. Kulkarni SV, Naik AS, Subramanian N,Jr. APACHE-II scoring system m 
perforative peritonitis. Am J Surg. 2007;194(4):549-552. 
61. Ohtake H, Kimura K, Sanada J, Matsui 0 , Watanabe G. Risk factor analysis of 
thoracic endovascular repair using the matsui -kitamura stent graft for acute aortic 
emergencies in the descending thoracic aorta. J Vase Surg. 20 I 0;52(6): 1464-1470. 
Michael Gillies Doctor of Medicine (2014) 172 
62. Leung E, McArdle K, Wong LS. Risk-adjusted scoring systems in colorectal 
surgery. Int J Surg. 2011 ;9(2): 130-135. 
63. Goldman L, Caldera DL, Nussbaum SR, et al. Multifactorial index of cardiac ri sk 
in noncardiac surgical procedures. N Eng! 1 Med. 1977;297( 16):845-850. 
64. Eagle KA, Coley CM, Newell JB, et al. Combini ng clinical and thallium data 
optimizes preoperative assessment of cardiac risk before major vascular surgery. 
Ann Intern Med. 1989;110(11):859-866. 
65. Detsky AS, Abrams HB, Forbath N, Scott JG, Hilliard JR. Cardiac assessment 
for patients undergoing noncardiac surgery A mul tifactorial c linical risk index. Arch 
Intern Med. 1986; 146( 11 ):2 131-2134. 
66. Gilbert K, Larocque BJ, Patrick LT. Prospecti ve eva luation of cardiac ri sk 
indices fo r patients undergoing noncardiac surgery. Annals of Internal Medicine. 
2000; 133(5):356-359. 
67. Lee TH, Marcantonio ER, Mangione CM, et al. Derivation and prospective 
val idation of a simple index for prediction of cardiac risk of major noncardiac 
surgery. Circulation. 1999; 1 00( I 0): I 043-J 049. 
68. Boersma E, Kertai MD, Schouten 0 , et al. Perioperative cardiovascular mortality 
in noncardiac surgery: VaJjdation of the lee cardiac risk index. Am 1 Med. 
2005; 11 8(1 0):1134-1141. 
69. Commi ttee Members, Eagle KA, Berger PB, et al. ACC/AHA guideline update 
for perioperative cardiovascular evaluation for noncardiac Surgery- Executive 
summary A report of the american coJJege of cardiology/american heart association 
task force on practice guidelines (committee to update the J 996 guidelines on 
perioperative cardiovascular evaluation for noncardiac surgery). Circulation. 
2002; 1 05( I 0): 1257-1267. 
70. Reilly DF, McNeely MJ, Doerner D, et al. Self-reported exercise tolerance and 
the risk of serious perioperative complications. Arch Intern Med. 
1999; 159( 18):2185-2192. 
71. Biccard BM. Relationship between the inability to climb two flights of stairs and 
outcome after major non-cardiac surgery: Implication for the pre-operative 
assessment of functional capacity. Anaesthesia. 2005;60(6):588-593. 
72. Older P, Smith R, Courtney P, Hone R. Preoperative evaluation of cardiac failure 
and ischemia in elderly patients by cardiopulmonary exercise testing. Chest. 
1993; I 04(3):701-704. 
Michael Gillies Doctor of Medicine (2014) 173 
73. American Thoracic Society, American College of Chest Physicians. ATS/ACCP 
statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med. 
2003;167(2):211-277. 
74. Beaver WL, Wasserman K, Whipp BJ. A new method for detecting anaerobic 
threshold by gas exchange. J AppJ Physiol. 1986;60(6):2020-2027. 
75. Snowden CP, Prentis JM, Anderson Ill.., et al. Submaxirnal cardiopulmonary 
exercise testing predicts complications and hospital length of stay in patients 
undergoing major elective surgery. Ann Surg. 2010;251(3):535-541. 
76. Wilson RJT, Davies S, Yates D , Redman J, Stone M. Impaired functional 
capacity is associated with all-cause mortality after major elective intra-abdominal 
surgery. British Journal of Anaesthesia. 2010;105(3):297-303. 
77. Nugent AM, Riley M, Megarry J, O'Reilly MJ , MacMahon J , Lowry R. 
Cardiopulmonary exercise testing in the pre-operative assessment of patients for 
repair of abdominal aortic aneurysm. Ir J Med Sci. 1998;167(4):238-241. 
78. Gerson MC, Hurst JM, Hertzberg VS, Baughman R, Rouan GW, Ellis K. 
Prediction of cardiac and pulmonary complications related to elective abdominal and 
noncardiac thoracic surgery in geriatric patients. Am J Med. 1990;88(2): 101-107. 
79. Nagamatsu Y, Shima I, Yamana H, Fujita H, Shirouzu K, Ishitake T. 
Preoperative evaluation of cardiopulmonary reserve w ith the use of expired gas 
analysis during exercise testing in patients with squamous cell carcinoma of the 
thoracic esophagus. J Thorac Cardiovasc Sur g. 2001; 121 (6): 1064-1068. 
80. Hamm CW, Ravkilde J, Gerhardt W, et al. The prognostic value of serum 
troponin Tin unstable angina. N Engl J Med. 1992;327(3):146-150. 
81. Ohman EM, Armstrong PW, Christenson RH, et al. Cardiac troponin T levels for 
risk stratification in acute myocardial ischemia. N Engl J Med. 1 996;335(18): 1333-
1342. 
82. Hsieh BP, Rogers AM, Na B, Wu AH, Schiller NB, Whooley MA. Prevalence 
and prognostic significance of incidental cardiac troponin T elevation in ambulatory 
patients with stable coronary artery disease: Data from the heart and soul study. Am 
Herut J. 2009; 158(4):673-679. 
83. Landesberg G, Shatz V, Akopnik I, et al. Association of cardiac troponin, CK-
MB, and postoperative myocardial ischemia with long-term survivaJ after major 
vascular surgery . .TAm Coli Cardiel. 2003;42(9):1547-1554. 
Michael Gillies Doctor of Medicine (2014) 174 
84. Tambyraja A.L., Dawson A.R.W., Murie J.A. , Chalmers R.T.A. Cardiac troponin 
I predicts outcome after ruptured abdominal aortic aneurysm repair. British Journal 
of Surgery. 2005~92(7):824-827. http://sheJcat.org/sfxJcl3/menu?issn=0007-
1323&isbn=&volume=92&issue= 7 &pages=824-827 &date=2005&title=British 
Journal of Surgery&doi=. 
85. Levy M, Heels-Ansdell D, Hiralal R, et al. Prognostic value of troponin and 
creatine kinase muscle and brain isoenzyme measurement after noncardiac surgery: 
A systematic review and meta-analysis. Anesthesiology. 2011 ;114(4):796-806. 
86. Keller T, Zeller T, Peetz D, et al. Sensitive troponin I assay in early diagnosis of 
acute myocardial infarction. N Engl J Med. 2009;361(9):868-877. 
87. Reichlin T, Hochholzer W, Bassetti S, et al. Early diagnosis of myocardial 
infarction with sensitive cardiac troponin assays. N Eng! J Med. 2009;361 (9):858-
867. 
88. Mills NL, Churchhouse AM, Lee KK, et al. Implementation of a sensitive 
troponin I assay and risk of recurrent myocardial infarction and death in patients with 
suspected acute coronary syndrome. JAMA. 2011;305(12):1210-1216. 
89. Lopez-Jimenez F, Goldman L, Sacks DB, et al. Prognostic value of cardiac 
troponin T after noncardiac surgery: 6-month follow-up data. J Am Coli Cardiel. 
1997;29(6): 1241-1245. 
90. Vascular Events In Noncardiac Surgery Patients Cohort Evaluation (VISION) 
Study Investigators, Devereaux PJ, Chan MT, et al. Association between 
postoperative troponin levels and 30-day mortality among patients undergoing 
noncardiac surgery. JAMA. 2012;307(21):2295-2304. 
91. Kavsak PA, Walsh M, Srinathan S, et al. High sensitivity troponin T 
concentrations in patients undergoing noncardiac surgery: A prospective cohort 
study. Clin Biochem. 2011;44(12):1021-1024. 
92. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type 
natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 
2002;347(3): 161-167. 
93. Rodseth RN, Lurati Buse GA, Bolliger D, et al. The predictive ability of pre-
operative B-type natriuretic peptide in vascular patients for major adverse cardiac 
events: An individual patient data meta-analysis. JAm Coli Cardiel. 2011 ;58(5):522-
529. 
94. Karthikeyan G, Moncur RA, Levine 0 , et al. Is a pre-operative brain natriuretic 
peptide or N-terminal pro-B-type natriuretic peptide measurement an independent 
Michael Gillies Doctor of Medicine (2014) 175 
predictor of adverse cardiovascular outcomes within 30 days of noncardiac surgery? 
A systematic review and meta-analysis of observational studies. J Am Coli Cardiel. 
2009;54( 17): 1599-1606. 
95. Parikh CR, Devarajan P, Zappitelli M, et al. Postoperative biomarkers predict 
acute kidney injury and poor outcomes after adult cardiac surgery. J Am Soc 
Nephrol. 20 II ;22(9): 1748-1757. 
96. Haase M, Bellomo R, Devarajan P, et al. Novel biomarker early predict the 
severity of acute kidney injury after cardiac surgery in adults. Ann Thorac Surg. 
2009;88(1 ): 124- 130. 
97. Haase M, Bellomo R, Devarajan P, Schlattrnann P, Haase-Fielitz A, NGAL 
Meta-analysis Investigator Group. Accuracy of neutrophil gelatinase-associated 
1ipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: A systematic 
rev iew and meta-analysis. Am J Kidney Dis. 2009;54(6): 1012- 1024. 
98. Cruz DN, de Cal M, Garzotto F, et al. Plasma neutrophi l gelatinase-associated 
lipocalin is an early biomarker for acute kidney injury in an adult ICU population. 
Intensive Care Med. 2010;36(3):444-451. 
99. Shavit L, Dolgoker I, Ivgi IL Assous M, Slotki I. Neutrophil gelatinase-
associated lipocalin as a predictor of complications and mortality in patients 
undergoing non-cardiac major surgery. Kidney Blood Press Res. 20 I I ;34(2): 116-
124. 
100. Ridker PM. Clinical application of C-reactive protein for cardiovascular disease 
detection and prevention. Circulation. 2003;107(3):363-369. 
101. Kullo IJ, Khaleghi M, Hensrud DD. Markers of inflammation are inversely 
associated with V02 max in asymptomatic men. Journal of Appl ied Physiology. 
2007; I 02(4): 1374- 1379. 
102. Almeida AB, Faria G, Moreira H, Pinto-de-Sousa J, Correia-da-Silva P, Maia 
JC. Elevated serum C-reactive protein as a predictive factor for anastomotic leakage 
in colorectal surgery. Int J Surg. 201 1. 
103. Warschkow R, Tarantino I, Torzewski M, Naf F, Lange J, Steffen T. Diagnostic 
accuracy of C-reactive protein and white blood cell counts in the early detection of 
inflammatory complications after open resection of colorectal cancer: A 
retrospective study of I , 187 patients. lnt J Colorectal Dis. 20 II ;26( I I): 1405-141 3. 
104. Goransson J, Jonsson S, Lasson A. Screening of concentrations of C-reactive 
protein and various plasma protease inhibitors preoperatively for the prediction of 
postoperative complications. Eur J Surg. 1998;164(2):89-10 1. 
Michael Gillies Doctor of Medicine (2014) 176 
105. Ackland GL, Scollay JM, Parks RW, De Beaux I, M ythen MG. Pre-operative 
high sensitivity C-reactive protein and postoperative outcome in patients undergoing 
elective orthopaedic surgery. Anaesthesia. 2007;62(9):888-894. 
I 06. Desborough JP. The stress response to trauma and surgery. British Journal of 
Anaesthesia. 2000;85( I ) : 109- I 17. 
107. Kvarnstrom AL, Sarbinowski RT, Bengtson JP, Jacobsson LM, Bengtsson AL. 
Complement activation and interleukin response in majo r abdominal surgery. Scand 
J lmmunol. 2012. 
108. Pal N, Axisa B, Yusof S, et al. Volume and outcome fo r major upper GI surgery 
in england. J Gastrointest Surg. 2008;12(2):353-357. 
I 09. Dudley RA, Johansen KL, Brand R, Rennie DJ, Mi lstein A. Selective referral to 
high-volume hospitals. JAMA: The Journal of the American Medical Association. 
2000;283(9):1 159-1166. 
I I 0. Birkmeyer JD, Siewers AE, Finlayson EVA, et al. Hospital volume and surgical 
mortality in the united states. N Engl J Med. 2002;346(15): 11 28- 11 37. 
11 1. Finks JF, Osborne NH, Birkmeyer JD. Trends in hospital volume and operative 
mortality for h igh-ri sk surgery. N Engl J Med. 201 1 ;364(22):2128-21 37. 
1 I 2. Chowdhury MM, Dagash H, Pierro A. A systematic review of the impact of 
volume of surgery and specialization on patient outcome. Br J Surg. 2007;94(2): 145-
16 1. 
I 13. Wunsch H, Angus DC, Harrison DA, et al. Variation in critical care serv ices 
across north america and western europe. Crit Care Med. 2008;36(10):2787-93, e l -9. 
I 14. Jhanji S, Thomas B, Ely A, Watson D , Hinds CJ, Pearse RM. Mortality and 
utili sation of critical care resources amongst high-risk surgical patients in a large 
NHS trust*. Anaesthes ia. 2008;63(7):695-700. 
115. Wunsch H, Angus DC, Harri son DA, Linde-Zwirble WT, Rowan KM. 
Comparison o f medical admissions to intensive care units in the united states and 
united kingdom. Am J Respir Crit Care Med. 2011; 183( 12): 1666- 1673. 
11 6. Shoemaker WC, Montgomery ES, Kaplan E, Elwyn DH. Phys io logic patterns in 
surviving and nonsurviving shock patients. use of sequential cardiorespiratory 
variables in defi ning criteria for therapeutic goals and earl y warn ing of death. Arch 
Surg. 1973; I 06(5):630-636. 
Michael Gillies Doctor of Medicine (2014) 177 
117. Shoemaker WC, Appel PL, Kram HB, Waxman K, Lee TS. Prospective trial of 
supranormal values of survivors as therapeutic goals in high-risk surgical patients. 
Chest. 1988;94(6): 1176-1186. 
118. Pearse R, Dawson D, Fawcett J, Rhodes A, Grounds RM, Bennett ED. Changes 
in central venous saturation after major surgery, and association with outcome. Crit 
Care. 2005;9(6):R694-9. 
119. Jhanji S, Vivian-Smith A, Lucena-Amaro S, Watson D, Hinds CJ, Pearse RM. 
Haemodynamic optimisation improves tissue microvascular flow and oxygenation 
after major surgery: A randomised controlled trial. Crit Care. 201 0; 14( 4) :R 151. 
120. Bangash MN, Patel NS, Benetti E, et al. Dopexamine can attenuate the 
inflammatory response and protect against organ injury in the absence of significant 
effects on hemodynamics or regional microvascular flow. Crit Care. 2013;17(2):R57. 
121. Boyd 0, Grounds RM, Bennett ED. A randomized clinical trial of the effect of 
deliberate perioperative increase of oxygen delivery on mortality in high-risk 
surgical patients. JAMA. 1993;270(22):2699-2707. 
122. Bender JS, Smith-Meek MA, Jones CE. Routine pulmonary artery 
catheterization does not reduce morbidity and mortality of elective vascular surgery: 
Results of a prospective, randomized trial. Ann Surg. 1997;226(3):229-36; 
discussion 236-7. 
123. Fleming A, Bishop M, Shoemaker W, et al. Prospective trial of supranormal 
values as goals of resuscitation in severe trauma. Arch Surg. 1992;127(10):1175-
1181. 
124. Velmahos GC, Demetriades D, Shoemaker WC, et al. Endpoints of resuscitation 
of critically injured patients: Normal or supranormal? A prospective randomized 
trial. Ann Surg. 2000;232(3):409-418. 
125. Wilson J, Woods I, Fawcett J, et al. Reducing the risk of major elective surgery: 
Randornised controlled trial of preoperative optimisation of oxygen delivery. BMJ. 
1999;318(7191): 1099-1103. 
126. Lobo SM, Salgado PF, Castillo VG, et al. Effects of maximizing oxygen 
delivery on morbidity and mortality in high-risk surgical patients. Crit Care Med. 
2000;28( I 0):3396-3404. 
127. Gan TJ, Soppitt A, Maroof M, et al. Goal-directed intraoperative fluid 
administration reduces length of hospital stay after major surgery. Anesthesiology. 
2002;97(4):820-826. 
Michael Gillies Doctor of Medicine (2014) 178 
128. Conway DH, Mayall R, Abdul-Latif MS, Gilligan S, Tackaberry C. 
Randomised controlled trial investigating the influence of intravenous fluid titration 
using oesophageal doppler monitoring during bowel urgery. Anaesthesia. 
2002;57 (9): 845-849. 
129. Sandham JD, Hull RD, Brant RF, et al. A randomized, controlled trial of the use 
of pulmonary-artery catheters in high-risk surgical patients. N Engl J Med. 
2003;348(1 ):5-14. 
130. Chytra 1, Pradl R, Bosman R, Pelnar P, Kasal E, Zidkova A. Esophageal 
doppler-guided fluid management decreases blood lactate levels in multiple-trauma 
patients: A randomized controlled trial. Crit Care. 2007; 11 (1 ):R24. 
13 1. Pearse R, Dawson D, Fawcett J, Rhodes A, Grounds RM, Bennett ED. Early 
goal-directed therapy after major surgery reduces complications and duration of 
hospital stay. A randomised, controlled trial [ISRCTN38797445. Crit Care. 
2005;9(6):R687-93. 
132. Wakeling HG, McFall MR, Jenkins CS, et al. Intraoperative oesophageal 
doppler gu ided fluid management shortens postoperative hospi tal stay after major 
bowel surgery. British Journal of Anaesthesia. November 2005;95(5):634-642. 
133. Noblett SE, Snowden CP, Shenton BK, Horgan AF. Randomized cl inical trial 
assessing the effect of doppler-optimized flu id management on outcome after 
elective colorectal resection. Br J Surg. 2006;93(9): 1069- 1076. 
134. Lopes MR, Oliveira MA, Pereira VO, Lemos IP, Aule r JO,Jr, Michard F. Goal -
directed fluid management based on pulse pressure variation monitoring duri ng high-
risk surgery: A pi lot randomized controlled trial. Crit Care. 2007; II (5):RI 00. 
135. Chall and C, Struthers R, Sneyd JR, et al. Randomized controlled trial of 
intraoperative goal-directed fluid therapy in aerobicaJly fit and unfit patients having 
major colorectal surgery. British Journal of Anaesthesia. 20 12; I 08( I ):53-62. 
136. Giglio MT, Marucci M, Testini M, Brienza N. Goal -directed haemodynamic 
therapy and gastrointestinal complications in major surgery: A meta-analysis of 
randomized controlled trials. British Journal of Anaesthesia. 2009; I 03(5):637-646. 
137. Brienza N, Giglio MT, Marucci M, Fio re T. Doe perioperative hemodynamic 
optimization pro tect renal function in surgical patients? A meta-analytic study. Crit 
Care Med. 2009;37(6):2079-2090. 
138. Dalfino L, Giglio MT, Puntillo F, Marucci M, Brienza N. Haemodynamic goal-
directed therapy and postoperative infections: Earlier is better. A systematic review 
and meta-ana lysis. Crit Care. 2011;15(3):Rl54. 
Michael Gillies Doctor of Medicine (2014) 179 
139. Grocott MPW, Dushianthan A, Hamilton MA, et al. Pcrioperative increase in 
global blood fl ow to explicit defined goals and outcomes after surgery: A cochrane 
systematic review. British Journal of Anaesthesia. 2013 ; I ll (4):535-548. 
140. Pear e RM, Dawson D, Fawcett J, Rhodes A, Ground RM, Bennett D . The 
incidence of myocardial injury fo llowing post-operative goal directed therapy. BMC 
Cardiova c Disord. 2007;7: 10. 
141. Takala J, Meier-Hellmann A, Eddleston J, Hulstaert P, Sramek V. Effect of 
dopexaminc on outcome after major abdominal surgery: A prospective, randomjzed, 
controlled multicenter stud y. european multicenter study group on dopexamjne in 
major abdominal surgery. Crit Care Med. 2000;28(10):3417-3423. 
142. Pearse RM, BeJsey JD, Cole JN, Bennett ED. Effect of dopcxamine in fusion on 
mortality following major surgery: Individual patient data meta-regression analysis 
of published clinical trial s. Crit Care Med. 2008;36(4): 1323-1329. 
143. Gopal S, Jayakumar D , Nelson PN. Meta-analysis on the effect of dopexamjne 
on in-hospital mortality. Anaesthesia. 2009;64(6):589-594. 
144. Pandit JJ. Meta-analyses of the effects of dopexamine in major surgery: Do all 
roads lead to rome? Anaesthesia. 2009;64(6):585-588. 
145. Davies SJ, Yates D, Wilson RJ. Dopexamine has no additional benefit in high-
risk patient receiving goal-directed fluid therapy undergoing major abdominal 
surgery. Anesth Analg. 2011;112(1):130-138. 
146. Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality 
and cardiovascular morbidity after noncardiac surgery. N Engl J Med. 
1996;335(23): 1713-172 I . 
147. Wallace A, Layug B, Tateo I, et al. Prophylactic atenoJol reduces postoperative 
myocardial ischemia. McSPI research group. Anesthesiology. 1998;88( I ):7 -17. 
148. Brady AR, Gibbs JS, Greenhalgh RM, Powell JT, Sydes MR, POBBLE trial 
investigator . Perioperati ve beta-blockade (POBBLE) for patients undergoing 
infrarenaJ vascular surgery: Results of a randomized double-blind controlled trial. J 
Vase Surg. 2005;41 (4):602-609. 
149. Scar JW, Giles JW, Howard-Aipe G, Foex P. Pe riopcrative beta-blockade, 
2008: What does POISE tell us, and was our earlier caution justified? British Journal 
of Anaesthesia. 2008; 101 (2): 135- 138. 
Michael Gillies Doctor of Medicine (2014) 180 
150. Bouri S, Shun-Shin MJ, Cole GD, Mayet J, Francis DP. Meta-analysis of secure 
randontised controlled trials of B-blockade to prevent perioperative death in non-
cardiac surgery. Heart. 2013. 
151. Grass JA. The role of epidural anesthesia and analgesia in postoperative 
outcome. Anesthesiol Clin North America. 2000;18(2):407-28, viii . 
152. Ballantyne JC, Carr DB, deFerranti S, et al. The comparative effects of 
postoperative analgesic therapies on pulmonary outcome: Cumulative meta-analyses 
of randontized, controlled trials. Anesth Analg. 1998;86(3):598-6 12. 
153. Anthony Rodgers, Nata)je Walker, S Schug, et al. Reduction of postoperative 
mortality and morbidity with epidural or spinal anaesthesia: Results from overview 
of randontised trials. BMJ. 2000;321 (7275): 1493. doi: 1 0.11361bmj.321.7275.1 493. 
154. Beattie WS, Badner NH, Choi P. Epidural analgesia reduces postoperative 
myocardial infarction: A meta-analysis. Anesth Analg. 2001 ;93(4):853-858. 
155. Beattie WS, Badner NH, Choi PT. Meta-analysis demonstrates statistically 
significant reduction in postoperative myocardial infarction with the use of thoracic 
epidural analgesia. Anesth Analg. 2003;97(3):919-920. 
156. Werawatganon T, Charulux.anun S. Patient controlled intravenous opioid 
analgesia versus continuous epidural analgesia for pain after intra-abdominal 
surgery. Cochrane Database Syst Rev. 2005;(1 )(l):CD004088. 
157. Liu SS, Wu CL. Effect of postoperative analgesia on major postoperative 
complications: A systematic update of the evidence. Anesth Analg. 2007; 1 04(3):689-
702. 
158. Park WY, Thompson JS, Lee KK. Effect of epidural anesthesia and analgesia 
on perioperative outcome: A randomized, controlled veterans affairs cooperative 
study. Ann Surg. 2001 ;234( 4):560-9; discussion 569-71. 
159. - Epidural anaesthesia and analgesia and outcome of major surgery: A 
randomised trial. - The Lancet.(- 9314):- 1276. 
160. Choi PT, Beattie WS, Bryson GL, Paul JE, Yang H. Effects of neuraxial 
blockade may be difficult to study using large randomized controlled trials: The 
PeriOperative epidural trial (POET) pilot study. PLoS One. 2009;4(2):e4644. 
161. Futier E, Constantin J, Paugam-Burtz C, et al. A trial of intraoperative low-
tidal-volume ventilation in abdominal surgery. N Eng! J Med. 2013;369(5):428-437. 
Michael Gillies Doctor of Medicine {2014) 181 
I 62. P Aylin, R Alexandrescu, M H Jen, E K Mayer, A Bottle. Day of week of 
procedure and 30 day mortality for elective surgery: Retrospective analysis of 
hospital episode statistics. BMJ. 2013;346. doi: 1 0.1136/bmj.f2424. 
163. Hamilton MA, Cecconi M, Rhodes A. A systematic review and meta-analysis 
on the use of preemptive hemodynamic intervention to improve postoperative 
outcomes in moderate and high-risk surgical patients. Anesthesia & Analgesia. 
2011 ;112(6): 1392-1402. 
164. Eddleston J, Goldhill D, Morris J . Levels of critical care for adult patients .. 
2009. 
165. Cuzick J, Edwards R, Segnan N. Adjusting for non-compliance and 
contamination in randomized clinical trials. Stat Med. 1997; 16(9): 1017-1029. 
166. Campbell M, Fitzpatrick R, Haines A, et a l. Framework for design and 
evaluation of complex interventions to improve health. BMJ. 2000;321(7262):694-
696. 
167. MacDonald N, Pearse RM. Peri-operative hemodynamic therapy: Only large 
clinical trials can resolve our uncertainty. Crit Care. 20 11 ; 15(3): 122. 
168. Deans KJ, Minneci PC, Suffredini AF, et al. Randomization in cl inical trials of 
titrated therapies: Unintended consequences of using fixed treatment protocols. Crit 
Care Med. 2007;35(6):1509-1516. 
169. Perner A, Haase N, Guttormsen AB, et al. Hydroxyethyl starch 130/0.42 versus 
ringer's acetate in severe sepsis. N Engl J Med. 20 12;367(2): 124-134. 
170. Myburgh JA, Finfer S, Bellomo R, et al. Hydroxyethyl starch or sal ine fo r fluid 
resusc itation in intensive care. N Eng! J Med. 2012;367(20): 1901 - 1911. 
17 1. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P, CONSORT Group. 
Methods and processes of the CONSORT group: Example of an extension for trials 
assessing nonpharmacologic treatments. Ann Intern Med. 2008; 148(4):W60-6. 
172. Myburgh JA, Finfer S, Bellomo R, et al. Hydroxyethyl starch or saline for fluid 
resuscitation in intensive care. N Engl J Med. 20 12;367(20): 1901-1911. 
173. Haye MA, T immins AC, Yau E, Palazzo M , Hinds CJ, Watson D. Elevation of 
ystemic oxygen de livery in the treatment of critically ill patients. N Engl J Med. 
1994;330(24): 1717-1722. 
174. Chassot P- , Delabays A, Spahn DR. Preoperative evaluation of patients wi th, 
or at risk of, coronary artery disease undergoing non- cardiac surgery. British 
Journal of Anaesthesia. 2002;89(5):747-759. 
Michael Gillies Doctor of Medicine (2014) 182 
175. Pear e RM, Ackland GL. Peri operative fluid therapy. BMJ. 20 12;344:e2865. 
176. Finfer S, Liu B, Taylor C, et al. Resuscitation fluid use in critically ill adults: 
An international cross-sectional study in 391 intensive care units. Crit Care. 
2010; 14(5):R 185. 
177. Ertmer C, Kampmeier T , Van Aken H. Fluid therapy in critical illness: A 
special focus on indication, the use of hydroxyethyl starch and its different raw 
materials. Curr Opin Anaesthesiol. 2013. 
178. Brunkhorst FM, Engel C, Bloos F, et al. Intensive insulin therapy and 
pentastarch resuscitation in severe sepsis. N E ng! J Med. 2008;358(2): 125-1 39. 
179. Hecht-Dolnik M , Barkan H, Taharka A, Loftus J . Hetastarch increases the risk 
of bleeding complications in patients after off-pump coronary bypass surgery: A 
randomized clinical trial. J Thorac Cardiovasc Surg. 2009; 138(3):703-7 11 . 
180. European Medicines Agency. Hydroxyethyl-starch solutions (HES) no longer to 
be used in patients with sepsis or burn injuries or in criticall y ill patients 
http://www.ema.europa.eu/docs/en_GB/document_li brary/Referrals_document/Solut 
ions_for_ infusion_containing_hydroxyethyl_starch/European_Commission_final_de 
cision/WC50016236J.pdf. Updated 2013. Accessed 05/06, 20 14. 
181. Reilly C. Retraction. notice of formal retraction of articles by dr. joachim boldt. 
British journal of anaesthesia JID - 0372541. 0823. 
182. Dart AB, Mutter TC, Ruth CA, Taback SP. Hydroxyethyl starch (HES) versus 
other fluid therapies: Effects on kidney function. Cochrane Database Syst Rev. 
2010;(1 ):CD007594. doi( l):CD007594. 
183. Gattas DJ , Dan A, Myburgh J, et al. Fluid resusc.itation with 6 % hydroxyethyl 
starch ( 130/0.4 and 130/0.42) in acutely ill patients: Systematic rev iew of effects on 
mortality and treatment with renal replacement therapy. Intensive Care Med. 
20 13;39(4):558-568. 
184. Pate l A, Waheed U, Brett SJ. Randomised trials of 6 % tetrastarch 
(hydroxyethyl starch 130/0.4 or 0.42) for severe sepsis reporting mortality: 
Systematic rev iew and meta-analysis. Intensive Care Med. 20 13;39(5):8 11 -822. 
185. Martin C, Jacob M , Vicaut E, Guidet B, Van Aken H, Kurz A. Effect of waxy 
maize-derived hydroxyethyl starch 130/0.4 on renal function in surgical patients. 
Anesthesio logy. 201 3;118(2):387-394. 
J 86. Van Der Linden P, James M, Mythen M, Weiskopf RB. Safety of modern 
starches used during surgery. Anesth Analg. 20 13; 11 6( I ):35-48. 
Michael Gillies Doctor of Medicine (2014) 183 
187. Gillies MA, Habicher M , Jhanji S, et at. Incidence of postoperative death and 
acute kidney injury associated with i.v. 6% hydroxyethyl tarch use: Systematic 
review and meta-analysis. British Journal of Anaesthesia. 20 13. 
188. Moher D, Liberati A, Tetzlaff J , Altman DG, PRISMA Group. Preferred 
reporting items for systematic reviews and meta-analyses: The PRISMA statement. 
PLoS Med. 2009;6(7):e l 000097. 
189. Olivo SA, Macedo LG, Gadotti IC, Fuentes J, Stanton T, Magee DJ. Scales to 
assess the quality of randomized controlled trials: A systematic review. Phys Ther. 
2008;88(2): 156- 175. 
190. Alavi SM, Ahmadi BB, Baharestani B, Babaei T. Comparison of the effects of 
gelatin, ringer's solution and a modern hydroxyl ethyl starch solution after coronary 
artery bypass graft surgery. Cardiovasc J Afr. 2012;23(8):428-43 1. 
191. Dehne MG, Muhling J, Sablotzki A, Dehne K, Sucke N, Hempelmann G. 
Hydroxyethyl starch (HES) does not directl y affect renal function in patients with no 
prior renal impairment. J Clio Anesth. 2001 ; 13(2): l 03-1 11 . 
192. Feldheiser A, Pavlova V, Bonomo T, et at. Balanced c rysta lloid compared with 
balanced colloid solution using a goal-directed haemodynamic algorithm. Br J 
Anaesth. 20 13; 1 10(2):231-240. 
193. Godet G, Lehot JJ, Janvier G, Steib A, De Castro V, Coriat P. Safety of HES 
130/0.4 (voluven(R)) in patients with preoperative renal dysfunction undergoing 
abdominal aortic surgery: A prospective, randomized, controlled, parallel-group 
multicentre trial. Eur J Anaesthesiol. 2008;25(12):986-994. 
194. Gondos T, Marjanek Z, Ulakcsai Z, et al. Short-term effectiveness of different 
volume replacement therapies in postoperative hypovolaemic patients. Eur J 
Anaesthesiol. 201 0;27(9):794-800. 
195. Guo X, Xu Z, Ren H, Luo A, Huang Y, YeT. Effect of volume replacement 
with hydroxyethyl starch solution on splanchnic oxygenation in patients undergoing 
cytoreducti ve surgery for ovarian cancer. Chin Med J (Engl). 2003; 1 16(7):996-1 000. 
196. Hung M, Zou C, Lin F, Lin C, Chan K, Chen Y. New 6% hydroxyethyl starch 
130/0.4 doe not increase blood loss during major abdominal surgerya€"A 
randomized, controlled trial. J Formos Med Assoc. 2012. 
197. Kuitunen AH, Hynynen MJ, Yahtera E, Salmenpera MT. Hydroxyethyl starch 
as a priming solution for cardiopulmonary bypass impairs hemostasis after cardiac 
surgery. Anesth Analg. 2004;98(2):291-7, table of contents. 
Michael Gillies Doctor of Medicine (2014) 184 
198. Lee JS, Ahn SW, Song JW, Shim JK, Yoo KJ, Kwak YL. Effect of 
hydroxyethyl starch 130/0.4 on blood loss and coagulation in patients with recent 
exposure to dual antiplatelet therapy undergoing off-pump coronary artery bypass 
graft surgery. Circ J. 20 11 ;75(10):2397-2402. 
199. Mahmood A, Gosling P, Barclay R, Kilvington F, Vohra R. Splanchnic 
microcirculation protection by hydroxyethyl starches during abdominal aortic 
aneurysm surgery. Eur J Vase Endovasc Surg. 2009;37(3):3 19-325. 
200. Marik PE, Iglesias J, Maini B. Gastric intramucosal pH changes after volume 
replacement with hydroxyethyl starch or crystalloid in patients undergoing elective 
abdominal aortic aneurysm repair. J Crit Care. 1997; 12(2):51-55. 
201. Munsch CM, Maci ntyre E, Machin SJ, Mackie IJ, Treasure T. Hydroxyethyl 
starch: An alternative to plasma for postoperative volume expansion after cardiac 
surgery. Br J Surg. 1988;75(7):675-678. 
202. Ooi JS, Ramzisham AR, Zamrin MD. Is 6% hydroxyethyl starch 130/0.4 safe in 
coronary artery bypass graft surgery? Asian Cardiovasc Thorac Ann. 
2009; 17(4):368-372. 
203. Sirvinskas E, Sneider E, Svagzdiene M, et al. Hypertonic hydroxyethyl starch 
solution for hypovolaemia correction following heart surgery. Perfusion. 
2007 ;22(2): 121-127. 
204. Vander Linden PJ, De Hert SG, Daper A, et al. 3.5% urea-linked gelatin is as 
effective as 6% HES 200/0.5 for volume management in cardiac surgery patients. 
Can J Anaesth. 2004;5 1(3):236-241. 
205. Vander Linden PJ, De Hert SG, Deraedt D, et al. Hydroxyethyl starch 130/0.4 
versus modified flu id gelatin for volume expansion in cardiac surgery patients: The 
effects on perioperative bleeding and transfusion needs. Anesth Analg. 
2005;101(3):629-34, table of contents. 
206. Yerheij J, Lingen A, Beishuizen A, et a l. Cardiac response is greater for colloid 
than saline fluid loading after cardiac or vascular surgery. Intensive Care Med. 
2006;32(7): I 030-1038. 
207. Matthias Egger, George Davey Smith, Andrew N Phill ips. Meta-analysis: 
Principles and procedures. BMJ. 1997;315(7 121):1533-1537. doi: 
10.1 136/bmj.315.712l. I533. 
208. Ando Y, Terao Y, Fukusaki M, et al. Influence of low-molecular-weight 
hydroxyethyl starch on microvascular permeability in patients undergoing abdominal 
surgery: Comparison with crystalloid. Journal of Anesthesia. 2008;22(4):391-396. 
Michael Gillies Doctor of Medicine (2014) 185 
209. Belcher P, Lennox SC. Avoidance of blood transfusion in coronary artery 
surgery: A trial of hydroxyethyl starch. Ann Thorac Surg. 1984;37(5):365-370. 
210. Hruten J, Crozier JE, McCreath B, et a]. Effect of intraoperative fluid 
optimisation on renal function in patients undergoing emergency abdominal surgery: 
A randomised controlled pilot study (ISRCTN 11799696). Int J Surg. 2008;6(3): 197-
204. 
211. Senagore AJ, Emery T, Luchtefeld M, Kim D, Dujovny N, Hoedema R. Fluid 
management for laparoscopic colectomy: A prospective, randomized assessment of 
goal -directed admjnistration of balanced salt solution or hetastarch coupled with an 
enhanced recovery program. Dis Colon Rectum. 2009;52(12): 1935-1940. 
212. Shabazi S, Zeighami D, Allahyary E, Alipour A, Esmaeeli MJ, Ghaneie M. Iran 
Cardiovascular Research Journal. 2011 ;5(1 ):24-31. 
213. Tiryakioglu 0, Yildiz G, Vural H, Goncu T, Ozyazicioglu A, Yavuz S. 
Hydroxyethyl starch versus ringer solution in cardiopulmonary bypass prime 
solutions (a randomized controlJed trial). J Cardiothorac Surg. 2008;3:45-8090-3-45. 
214. Honkonen EL, Jarvela K, Huhtala H, Holm P, Lindgren L. Hyper osmolality 
does not modulate natriuretic peptide concentration in patients after coronary artery 
surgery. Acta Anaesthesia! Scand. 2009;53(5):565-572. 
215. Kasper SM, Walter M, Grune F, Bischoff A, Erasmi H, Buzello W. Effects of a 
hemoglobin-based oxygen carrier (HBOC-201) on hemodynamics and oxygen 
transport in patients undergoing preoperative hemodilution for elective abdominal 
aortic surgery. Anesth Anal g. 1996;83(5):921-927. 
216. Magder S, Potter BJ, Varennes BD, Doucette S, Fergusson D, Canadian Critical 
Care Trials Group. Fluids after cardjac surgery: A pilot study of the use of colloids 
versus crystalloids. Crit Care Med. 2010;38(11):2117-2124. 
217. Olofsson CI, Gorecki AZ, Dirksen R, et al. Evaluation of MP40X for 
prevention of perioperative hypotension in patients undergoing primary hip 
arthroplasty with spinal anesthesia: A randomized, double-blind, multicenter study. 
Anesthesiology. 2011 ;114(5): 1048-1063. 
218. Sirieix D, Hongnat JM, Delayance S, et al. Comparison of the acute 
hemodynamic effects of hypertonic or colloid infusions immediately after mitral 
valve repair. Crit Care Med. 1999;27(10):2159-2165. 
219. Standi T, Burmeister MA, Horn EP, WilhelmS, Knoefel WT, Schulte am Esch 
J. Bovine haemoglobin-based oxygen carrier for patients undergoing haemodilution 
before liver resection. Br J Anaesth. 1998;80(2): 189-194. 
Michael Gillies Doctor of Medicine (2014) 186 
220. ChaiJand C, Struthers R, Sneyd JR, et al. Randomized controlled trial of 
intraoperative goal-directed fluid therapy in aerobically fit and unfit patients having 
major colorectal surgery. Br J Anaesth. 2012;108(1):53-62. 
221 . Mukhtar A, Aboulfetouh F, Obayah G, et al. The safety of modern hydroxyethyJ 
starch in living donor liver transplantation: A comparison with human albumin. 
Anesth Analg. 2009;109(3):924-930. 
222. Bellomo R, Ronco C, Kellum JA, Mehta RL, PaJevsky P, Acute Dialysis 
Quality Initiative workgroup. Acute renal failure - definition, outcome measures, 
animal models, fluid therapy and information technology needs: The second 
international consensus conference of the acute dialysis quality initiative (ADQI) 
group. Crit Care. 2004;8(4):R204-12. 
223. Murray GF, Solanke T, Thompson WL, Ballinger WF. Hydroxyethyl starch as a 
plasma expander in hemorrhagic shock. Surg Forum. 1965;16:34-35. 
224. Wunsch H, Angus DC, Harrison DA, et al. Variation in critical care services 
across north america and western europe. Crit Care Med. 2008;36(10):2787-93, e l -9. 
225. HES Data Quality Team. The HES processing cycle and data quality. 
http://www .hscic.gov. uk/media/1366/The-RES-processing -cycle-and-HES-data-
quality/pdf/The_HES_Processing_Cycle_and_RES_Data_Quality.pdf. Updated 
2014. Accessed 03/01, 2014. 
226. RES Data Quality Team. Data quality checks performed on SUS and RES data. 
http://www.hscic.gov.uk/media/13655/Data-quality-checks-performed-on-SUS-and-
RES-datalpdf/Data_quality_checks_performed_on_SUS_and_HES_data.pdf. 
Updated 2014. Accessed 03/01, 2014. 
227. Sharp J. The quality of health and social care data, england, annual report 2013. 
http://www. bscic.gov. uk/catalogue/PUB I 1 530/second-annu-data-qual-rep-2013. pdf. 
Updated 2013. Accessed 03/01, 2014. 
228. Information Services Division. NHS hospital data quality: Towards better data 
from scottish hospitals .. 2007. 
229. Health and Social Care Information System. OPCS classification of 
interventions and Procedures<br 1>. 
http://www.datadictionary.nhs.uk/web_site_content/supporting_information/clinical_ 
coding/opcs_cJassification_of_interventions_and_procedures.asp. Updated 2013. 
Accessed 03/01, 2014. 
230. Auditor General. Healthcare across the UK: A comparison of the NHS in 
england, scotland, wales and northern ireland .. 2012. 
Michael Gillies Doctor of Medicine (2014) 187 
231. Office of National Statistics. Implications of the 2001 census results. 
http://www. ons.gov. uk/ons/ guide-method/census/census-200 1 /data-and-
product /quality-of-the-census-data/data-quaJity-notes-and-reports/implications-of-
the-2001-census-results/index.html. Updated 2013. Accessed 03/01,2014. 
232. Harri on DA, Brady AR, Parry GJ, Carpenter JR, Rowan K. Recalibration of 
ri k prediction models in a large multicenter cohort of admissions to adu lt, general 
critical care units in the united kingdom. Crit Care Med. 2006;34(5): J 378- 1388. 
233. Harrison DA, Parry GJ, Carpenter JR, Short A, Rowan K. A new risk prediction 
model for critical care: The intensive care national audit & research centre 
(ICNARC) model. Crit Care Med. 2007;35(4):1091 -1098. 
234. JCNARC. ICNARC casemic programme resources. 
https://www. icnarc.org/Our-Audit/ Audits/Cmp/Resources. Updated 2014. Accessed 
05109, 2014. 
235. Scotti sh Intensive Care Society Audit Group. Wardwatcher user manuals. 
http://www .sicsag.scot.nhs. uk!Data/W ardWatcher.htrnJ. Updated 2009. Accessed 
05109,20 14. 
236. Hanlon P, Lawder RS, Buchanan D, et al. Why is mortality higher in scotland 
than in england and wales? decreasing influence of ocioeconomic deprivation 
between 198 I and 200 I supports the existence of a 'Scottish effect'. Journal of 
Public Health. June 2005;27(2): 199-204. 
237. Goode SO, Keltie K, Burn J , et al. Effect of procedure vo lume on outcomes 
after iliac artery angioplasty and stenting. Br J Surg. 20 13; 100(9): 1189-1196. 
238. Stark J, Gall ivan S, Lovegrove J, et al. Mortality rates after surgery for 
congenital heart defects in children and surgeons' performance. Lancet. 
2000;355(9208): I 004-1 007. 
239. Scottish Intensive Care Society Audit Group. SICSAG, scottish intensive care 
society audit group annual report: Audit of intensive care units in scotland 20 11 
reporting on 20 I 0 .. 20 11 . 
240. Spiegelhalter D. Funnel plots for institutional comparison. Qual Saf Health 
Care. 2002; 11 (4):390-391. 
24 1. Spiegelhalter OJ. Funnel plots for comparing in titut ional performance. Stat 
Med. 2005;24(8): 1185-1202. 
242. Kirkwood BR, Sterne JAC. Essential medical statistics. 2nd ed. Oxford: 
Blackwell; 2003. 
Michael Gillies Doctor of Medicine (2014) 188 
243. Merlo J, Chaix B, Yang M, Lynch J, Rastam L. A brief conceptual tutorial of 
multilevel analys is in social epidemiology: Linking the tati stical concept of 
clustering to the idea of contextual phenomenon. Journal of Epidemiology and 
Community Health. 2005;59(6):443-449. 
244. Lar en K, Merlo J. Appropriate assessment of neighborhood effects on 
individua l health: Integrating random and fixed effects in mul tilevel logistic 
regres ion. American Journal of Epidemiology. 2005; 16 1 (1 ):8 1-88. 
245. Thygesen K, Alpert JS, Jaffe AS, et al. Third universal definition of myocardial 
infarction. JAm Coli Cardiol. 2012;60(16): 1581 - 1598. 
246. Antman EM, Tanasijevic MJ, Thompson B, et al. Cardiac-specific troponin I 
levels to predict the risk of mortality in patients with acute coronary syndromes. N 
Engl J Med. 1996;335( 18): 1342-1349. 
247. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L. Markers of myocardial 
damage and inflammation in relation to long-term mortality in unstable coronary 
artery di ease. N Engl J Med. 2000;343(16):1139-1147. 
248. Bonaca M , Scirica B, Sabatine M, et al. Prospecti ve evaluation of the prognostic 
implications of improved assay performance with a sensitive assay for cardiac 
troponin I. J Am Coli Cardiel. 201 0;55(19):2118-2124. 
249. Omland T, de Lemos JA, Sabatine MS, et al. A sensitive cardiac troponin T 
assay in stable coronary artery disease. N Engl J Med. 2009;361 (26):2538-2547. 
250. Lee GR, Jhanji S, Tarrant H , James S, Pearse RM, Fitzgibbon M. Peri -operative 
troponin monitoring using a prototype high-sensitivity cardiac troponin I (hs-cTni) 
assay: Comparisons with hs-cTnT and contemporary cTni assays. Ann Clin 
Biochem. 2014;5 1 (Pt 2):258-268. 
25 1. Thygesen K, Alpert JS, White HD, et al. Universal definition of myocardial 
infarct ion: Kri stian thygesen, joseph S. alpert and harvey D. white on behalf of the 
joint ESC/ACCF/AHA/WHF task force for the redefinition of myocardial infarction. 
European Heart Journal. 2007;28(20):2525-2538. 
252. EMA. As essment report for solutions for infusion comaining hydroxyethyl 
starch. procedure under article 31 of directive 200 1/83/EC resulting from 
pharmacovigilance data .. 20 13(Procedure number: EMEAIH/ A-31/1348.). 
253. A comparison of albumin and saline for fluid resu citation in the intensive care 
unit. N Eng! J Med. 2004;350(22):2247-2256. 
Michael Gillies Doctor of Medicine (2014) 189 
254. Annane D, Siami S, Jaber S, et al. Effects of fluid resusc itation with colloids vs 
crystalloid on mortality in critically ill patients presenting wi th hypovolemic shock: 
The CRISTAL randomized triaL JAMA. 2013;31 0(17): 1809- 1817. 
255. Maynard ND, Mason RC, Bihari DJ, Smithies MN, Dalton RN. INcreasing 
splanchnic blood flow in the critically iii. CHEST Journal. 1995; I 08(6): 1648-1654. 
256. Sack F-, Reidenbach B, Schledt A , et aJ. Dopexamine attenuates microvascular 
perfu ion injury of the small bowel in pigs induced by extracorporeal circulation. 
British Jou rnal of Anaesthesia. 2002;88(6):841-847. 
257. Kendrick S, Clarke J. The scottish record linkage system. Health Bull (Edinb). 
1993;5 1 (2):72-79. 
258. Uchino S, Kellum JA, Bellomo R,et al. Acute renal failure in criticall y ill 
patients: A multinational, multicenter study. JAMA. 2005;294(7):813-818. 
259. Abelha F, Botelho M, Fernandes V, Barros H. Determinants of postoperative 
acute kidney injury. Critical Care. 2009; 13(3):R79. 
260. Kellum J, Lameire N, for the KDIGO AKI Guideline,Work Group. Diagnosis, 
evaluation, and management of acute kidney injury: A KDIGO summary (part 1). 
Critical Care. 2013;17(1):204. 
26 1. Waikar SS, Betensky RA, Bonventre JV. Creatinine as the gold standard for 
kidney InJUry biomarker studies? Nephrology Dialysis Transplantation. 
2009;24(11 ):3263-3265. 
262. Young D, Lamb SE, Shah S, et al. High-frequency oscillation fo r acute 
respiratory distress syndrome. N Engl J Med. 2013;368(9):806-813. 
263. Ferguson ND, Cook DJ, Guyatt GH, et al. High-frequency osc illation in early 
acute respiratory distress syndrome. N Engl J Med. 20 13;368(9):795-805. 
Michael Gillies Doctor of Medicine (2014) 190 
Appendix 1 - Publications Aris ing from this Thesis 
To date, the following papers have been published arisi ng from research described in 
thi s the is (with weblinks): 
I . Pearse RM, Harrison DA, MacDonald N, Gillies MA, Blunt M, Ackland 
G, Grocott MP, Ahem A, Griggs K, Scott R, Hinds C, Rowan K. Effect of a 
perioperative, cardiac output-guided hemodynamic therapy algorithm on outcomes 
fo llowing major gastrointestinal surgery: a randomized clinical tri al and systematic 
rev iew. JAMA. 2014 Jun 4; 311(21):2181-90. 
URL: http://j ama.jamanetwork.com/article.aspx?articleid=l873985 
2. Gillies, MA, Habkher M, Jhanji S, Sander M, Mythen M, Hamilton M, Pearse 
RM. Incidence of post-operative death and acu te kidney injury associated with 
intravenous 6% hydroxyethyl starch use: systematic review and meta-analysis. Br J 
Anaesth 2013 112 (1) 25-34. 
URL: http://bja.oxfordjournals.org/content/112/l/25.1ong 
Michael Gillies Doctor of Medicine (2014) 191 
